Methods
in
Molecular Biology™
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For other titles published in this series, go to www.springer.com/series/7651
Immunotoxicity Testing Methods and Protocols
Edited by
Rodney R. Dietert Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
Editor Rodney R. Dietert Department of Microbiology and Immunology College of Veterinary Medicine Cornell University Ithaca, NY 14853 USA
[email protected]
ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-60761-400-5 e-ISBN 978-1-60761-401-2 DOI 10.1007/978-1-60761-401-2 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2009936794 © Humana Press, a part of Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface Immunotoxicology as an interdisciplinary area of research, assessment, and instruction has been formally recognized since at least the 1970s. The science supporting immunotoxicology has driven both mechanistic research defining the interactions between xenobiotics and the immune system as well as safety testing for chemicals, drugs, and medical devices. During that time, there have emerged societies, specialty sections, and entire journals devoted solely to Immunotoxicology. While several important books have been prepared on this and related topics, Immunotoxicity Testing is among the first to meld consideration of immunotoxicity testing approaches and strategies with a comprehensive presentation of detailed laboratory protocols. The goal of the book is to utilize the expertise of scientists actually engaged in immunotoxocity testing to provide the reader with lab-ready procedures and the background information needed to identify effective testing approaches. The book includes an introduction to the topic with a description of the evolution of immunotoxicity testing and ideas concerning its future direction. Additionally, the importance of immunotoxicity testing for health risk reduction is presented by categories of disease. Given this scope, the book is appropriate for a broad audience reaching beyond immunotoxicology itself. Chapters are designed to be accessible by students, technicians, lab and safety office personnel as well as biology- and chemistry-oriented researchers. Above all, the book provides a one-stop reference resource for the most important and commonly used laboratory protocols in immunotoxicology. As an editor, I thank the expert authors for the time and effort they devoted to each chapter and hope that this novel reference work will aid the continued evolution and the application of immunotoxicity testing. Dr. Rodney R. Dietert Ithaca, NY March 2009
v
Contents Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
v ix
Part I Introduction 1 Immunotoxicology Testing: Past and Future . . . . . . . . . . . . . . . . . . . . . . . . . . . . Michael I. Luster and G. Frank Gerberick
3
Part II Overview and Health-Risk Considerations 2 Developmental Immunotoxicity (DIT): The Why, When, and How of DIT Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Rodney R. Dietert and Jamie DeWitt 3 An In Vivo Tiered Approach to Test Immunosensitization by Low Molecular Weight Compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Irene S. Ludwig, Lydia M. Kwast, Daniëlle Fiechter, and Raymond H.H. Pieters 4 Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing . . . . . . . . . Rodney R. Dietert, Janice M. Dietert, and Jerrie Gavalchin 5 Markers of Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dori R. Germolec, Rachel P. Frawley, and Ellen Evans 6 Evaluating Macrophages in Immunotoxicity Testing . . . . . . . . . . . . . . . . . . . . . . John B. Barnett and Kathleen M. Brundage
17
27
39 53 75
Part III Immunotoxicity and Host Resistance Models 7 Host Resistance Assays Including Bacterial Challenge Models . . . . . . . . . . . . . . . 97 Florence G. Burleson and Gary R. Burleson 8 Viral Host Resistance Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109 Wendy Jo Freebern 9 Parasite Challenge as Host Resistance Models for Immunotoxicity Testing . . . . . . 119 Robert W. Luebke 10 Tumor Challenges in Immunotoxicity Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . 143 Sheung Ng, Kotaro Yoshida, and Judith T. Zelikoff
Part IV Testing Protocols in Rodents and Other Laboratory Animals 11 The T-Dependent Antibody Response to Keyhole Limpet Hemocyanin in Rodents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 Lisa M. Plitnick and Danuta J. Herzyk 12 The Sheep Erythrocyte T-Dependent Antibody Response (TDAR) . . . . . . . . . . . 173 Kimber L. White, Deborah L. Musgrove, and Ronnetta D. Brown
vii
viii
Contents
13 The Delayed Type Hypersensitivity Assay Using Protein and Xenogeneic Cell Antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Rodney R. Dietert, Terry L. Bunn, and Ji-Eun Lee 14 The Cytotoxic T Lymphocyte Assay for Evaluating Cell-Mediated Immune Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gary R. Burleson, Florence G. Burleson, and Rodney R. Dietert 15 NK Cell Assays in Immunotoxicity Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Qing Li 16 The Local Lymph Node Assay and Skin Sensitization Testing . . . . . . . . . . . . . . . Ian Kimber and Rebecca J. Dearman 17 Use of Contact Hypersensitivity in Immunotoxicity Testing . . . . . . . . . . . . . . . . . Jacques Descotes 18 Evaluation of Apoptosis in Immunotoxicity Testing . . . . . . . . . . . . . . . . . . . . . . . Mitzi Nagarkatti, Sadiye Amcaoglu Rieder, Dilip Vakharia, and Prakash S. Nagarkatti 19 Dendritic Cells in Immunotoxicity Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Donghong Gao and David A. Lawrence 20 Evaluating Cytokines in Immunotoxicity Testing . . . . . . . . . . . . . . . . . . . . . . . . . Emanuela Corsini and Robert V. House 21 Flow Cytometry in Preclinical Drug Development . . . . . . . . . . . . . . . . . . . . . . . . Patrick B. Lappin 22 Enhanced Histopathology Evaluation of Lymphoid Organs . . . . . . . . . . . . . . . . . Susan A. Elmore 23 Immunotoxicity Testing in Nonhuman Primates . . . . . . . . . . . . . . . . . . . . . . . . . Stephanie Grote-Wessels, Werner Frings, Clifford A. Smith, and Gerhard F. Weinbauer
185
195 207 221 233 241
259 283 303 323 341
Part V Evaluation in Humans 24 Fundamentals of Clinical Immunotoxicology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363 Robert V. House
Part VI Wildlife Testing 25 In Vivo Functional Tests for Assessing Immunotoxicity in Birds . . . . . . . . . . . . . . 387 Keith A. Grasman
Part VII In Vitro Alternatives 26 In Vitro Testing for Direct Immunotoxicity: State of the Art . . . . . . . . . . . . . . . . 401 D.P.K. Lankveld, H. Van Loveren, K.A. Baken, and R.J. Vandebriel Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425
Contributors K. A. Baken • Laboratory for Health Protection Research, National Institute for Public Health & the Environment, Bilthoven, The Netherlands John B Barnett • Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, USA Ronnetta D. Brown • Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA Kathleen M. Brundage • Department of Microbiology, Immunology and Cell Biology West Virginia University, Morgantown, WV, USA Terry L. Bunn • Department of Preventive Medicine and Environmental Health, University of Kentucky, Lexington, KY, USA Florence G. Burleson • Burleson Research Technologies, Morrisville, NC, USA Gary R. Burleson • Burleson Research Techologies, Morrisville, NC, USA Emanuela Corsini • Department of Pharmacological Sciences, University of Milan, Milan, Italy Rebecca Dearman • Faculty of Life Sciences, University of Manchester, Manchester, UK Jacques Descotes • Poison Center and Claude Bernard University, Lyon, France Jamie DeWitt • Department of Phamacology and Toxicology, East Carolina University, Greenville, NC, USA Janice M. Dietert • Performance Plus Consulting, Lansing, NY, USA Rodney R. Dietert • Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA Susan A. Elmore • Cellular and Molecular Pathology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA Ellen Evans • Clinical Pathology and Immunotoxicology, Schering Plough Research Institute, Lafayette, NJ, USA Rachel P. Frawley • Toxicology Branch, National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA Wendy J. Freebern • Department of Immunotoxicology, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Co., Syracuse, NY, USA Danielle Fiechter • Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands Werner Frings • Covance Laboratories, Muenster, Germany Donghong Gao • Wadsworth Center, Albany, NY, USA Jerri Gavalchin • Department of Animal Science, Cornell University, Ithaca, NY Department of Medicine, SUNY Upstate Medical University, Syracuse, NY G. Frank Gerberick • Miami Valley Innovation Center, Proctor & Gamble, Cincinnati, OH, USA Dori R. Germolec • Toxicology Branch, National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA Keith A. Grasman • Department of Biology, Calvin College, Grand Rapids, MI, USA Stephanie Grote-Wessels • Covance Laboratories, Muenster, Germany ix
x
Contributors
Danuta J. Herzyk • Department of Safety Assessment, Merck Research Laboratories, West Point, PA, USA Robert V. House • DynPort Vaccine Company LLC, Frederick, MD, USA Ian Kimber • Faculty of Life Sciences, University of Manchester, Manchester, UK Lydia M. Kwast • Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands D. P. K. Lankveld • Laboratory for Health Protection Research, National Institute for Public Health & the Environment, Bilthoven, The Netherlands Patrick B. Lappin • Investigative Pathology, Pfizer, Inc. San Diego, CA, USA David A. Lawrence • Wadsworth Center, Albany, NY, USA Ji-Eun Lee • Product Safety, Colgate-Palmolive Company, Piscataway, NJ, USA Qing Li • Department of Hygiene and Public Health, Nippon Medical School, Japan Irene S. Ludwig • Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands Robert W. Luebke • Immunotoxicology Branch, Division of National Health and Environmental Effects, United State Environmental Protection Agency, Research Triangle Park, NC, USA Michael I. Luster • Luster Associates, Morgantown, WV, USA Deborah L. Musgrove • Department of Pharmacology and Toxicology School of Medicine,Virginia Commonwealth University, Richmond, VA, USA Mitzi Nagarkatti • Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA Prakash S. Nagarkatti • Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA Sheung Ng • Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY, USA Raymond H. H. Pieters • Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands Research Centre for Innovative Testing, Institute for Life Sciences and Chemistry, Utrecht University of Applied Sciences, Utrecht, The Netherlands Lisa M. Plinick • Department of Safety Assessment, Merck Research Laboratories, West Point, PA, USA Sadiye Amcaoglu Rieder • Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA Clifford A. Smith • Covance, Harrogate, UK Dilip Vakharia • Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA Rob J. Vandebriel • Laboratory for Health Protection Research, National Institute for Public Health & the Environment, Bilthoven, The Netherlands Henk van Loveren • Laboratory for Health Protection Research, National Institute for Public Health & the Environment, Bilthoven, The Netherlands Gerhard F. Weinbauer • Covance Laboratories, Muenster, Germany Kimber L. White Jr. • Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA Kotaro Yoshida • Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY, USA Judith T. Zelikoff • Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY, USA
Part I Introduction
Chapter 1 Immunotoxicology Testing: Past and Future Michael I. Luster and G. Frank Gerberick Abstract A brief historical perspective of immunotoxicology is presented describing the early development of predictive screening tests to identify xenobiotics that may cause immunosuppression or skin sensitization. This includes a discussion of the evolution of the discipline to support a better understanding of basic science and improvement of human risk assessment. The last section describes the need for additional validated screening tests and recent efforts to address this gap in the other areas of immunotoxicology including food and respiratory allergy, autoimmunity and immunostimulation. Key words: Testing, Guidelines, Immunosuppression, Hypersensitivity, Risk assessment
1. Introduction The identification and regulation of xenobiotic agents that inadvertently alter the immune system and affect human health have been of concern to the chemical/agricultural, pharmaceutical and consumer product industries, as well as to the federal regulatory agencies for over 40 years. Initial interest originated in the area of sensitization from the observations made by Landsteiner and Jacobs (1) that low molecular weight chemicals or drugs can be antigenic and capable of producing organ-specific (i.e., skin, lung or gastrointestinal tract) allergic responses. Subsequently, other studies reported that certain xenobiotics, such as halogenated aromatic hydrocarbons, could suppress, or in rare instances stimulate, the immune system resulting in an increased risk of infectious or neoplastic diseases, or in the latter case, exacerbate autoimmune disease. Of particular concern have been the xenobiotic effects in the neonate as increasing evidence suggests that the developing immune system is particularly sensitive to damage. Other materials, particularly certain pharmaceuticals, cause autoimmune-like syndromes R.R. Dietert (ed.), Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, vol. 598 DOI 10.1007/978-1-60761-401-2_1, © Humana Press, a part of Springer Science + Business Media, LLC 2010
3
4
Luster and Gerberick
in which the disease dissipates following cessation of exposure while other chemicals appear to exacerbate existing autoimmune disease. The development and adoption of appropriate experimental methods to assess the influence of xenobiotics to cause these various toxicities were for many years the major focus of immunotoxicology, and for some effects such as autoimmunity, respiratory allergy and the so-called systemic allergies still remain an issue. The following provides a brief historical review on the development of immunotoxicity testing and a perspective of what testing strategies are needed in the future.
2. Immunosuppression As it is relatively difficult to determine the contribution of chronic low-level immunosuppression or the cumulative effects of modest changes in immune function to the background incidence of disease in the human population, efforts have been made to examine the relationships between laboratory measures of immune response and disease resistance in experimental animal models. Although the experimental methods initially adopted by immunotoxicologists to assess immune function were those common to immunology laboratories, the tests that were commonly performed and the experimental design by which they were conducted were performed ad hoc. Even the experimental species that have been selected varied with the earliest studies using rabbits and guinea pigs and later studies conducted using rats and mice. While rodents became the test species of choice, debate occurred on species selection with those trained in toxicology usually preferring the rat to allow comparison with other toxicology studies, and those trained in immunology preferring the mouse as the mouse immune system was well studied. The lack of standardized testing made it difficult to compare the chemical-specific effects and led Dean et al. (2), to suggest a “Tier” approach with the idea that each subsequent tier provided identification of a more defined effect on the immune system. Subsequently, the National Toxicology Program (NTP) organized a series of workshops composed of experts in immunotoxicology, basic immunology, toxicology, risk assessment, epidemiology and clinical medicine to help identify the most appropriate tests for immunotoxicology testing (3). Two major points were agreed upon from these workshops: First, since the immune system is not fully operational until it is challenged, the most appropriate tests would be those that incorporate an antigen challenge. Second, since it may be construed that an inadequate response to antigenic challenge does not represent an “adverse effect,” tests should also be added that could be readily identified with disease.
Immunotoxicology Testing: Past and Future
5
The former recommendation highlighted several common assays including measurement of an antibody response following antigen challenge as a measure of humoral immunity and quantification of delayed hypersensitive response (DHR) or cytotoxic T lymphocyte response (CTL) as a measure for cell-mediated immunity. These assays were based upon the measurement of a primary immune response rather than secondary since it is generally thought that memory responses are less sensitive to inhibition than primary responses. To address the need to identify a clear adverse effect, a set of tests, usually referred to as “host resistance assays,” was suggested. These tests would also be used to validate the usefulness of other methods and extrapolate the potential for environmental agents to alter host susceptibility in the human population. In these assays, groups of experimental animals are challenged with either an infectious agent or transplantable tumor at a challenge level sufficient to produce disease in control animals and increased incidence is examined in the treated groups. As the endpoints in these tests have evolved from relatively non-specific (e.g., animal morbidity and mortality) to quantitative, such as tumor numbers, viral titers or bacterial cell counts, the sensitivity of these models has significantly increased. However, they are still somewhat limited by the need to use relatively large numbers of animals. Eventually, a three tier approach emerged in which Tier 1 included screening assays that would likely detect immunotoxic xenobiotics, Tier 2 allowed for defining the immune component(s) effected as well as establish effects on host resistance and Tier 3 provided, in very general terms, approaches that could be used to identify the mode of action. An interlaboratory validation effort involving four laboratories1 and sponsored by the NTP was conducted using Tier 1 and 2 tests (4). In addition to the demonstration of interlaboratory reproducibility, this effort helped identifying the relative sensitivity of the various immune tests and the degree to which they agreed with the commonly employed host susceptibility tests. This effort was followed several years later in which the concordance between various histological, hematological and immune function tests to identify immunotoxicity and host susceptibility changes were determined in a large dataset (5, 6). These latter studies were important, not only as a validation exercise for tier testing, but for providing a basis for moving immunotoxicology assessment forward. The analyses indicated that inclusion of a functional test, most notably the T-dependent antibody response (TDAR) to
The four participating laboratories were the National Institute of Environmental Health Sciences (Research Triangle Park, NC), Chemical Industry Institute of Toxicology (Research Triangle Park, NC), Virginia Commonwealth University (Richmond, VA) and IIT Research Institute (Chicago, IL).
1
6
Luster and Gerberick
sheep red blood cells, along with a non-functional test, such as thymus weights, allowed achieving concordance, with respect to identifying potential immunotoxic agents, of well over 90%, although a number of other immune test groupings provided excellent levels of accuracy. These studies also provided evidence of a linear relationship between many of the immune tests and host resistance assays. In the Unites States, the preferred species for testing was the mouse, but subsequent validation studies were conducted in rats (7–9) and results from either rodent species are now equally accepted. Tiered screening panels have been the basis for several risk assessment guidelines and most regulatory agencies in the United States, European Union and Japan have established or are developing requirements or guidelines (reviewed by (10)). However, the Office of Prevention, Pesticides and Toxic Substances (OPPTS), US Environmental Protection Agency (EPA) was responsible for developing the first immunotoxicology test guideline (11) and over the years has taken the lead in their development. It should be noted that the configurations of these testing panels vary depending upon the agency/ organization/program under which they are conducted. The most notable difference is whether a functional immune test (i.e., incorporates antigen challenge) is included in Tier 1 or Tier 2. Although, as indicated earlier, it is generally agreed that functional testing provides the greatest sensitivity for identifying immunosuppression, it has been argued that a careful histological and hematological evaluation, particularly inclusion of extended histopathology endpoints, would identify a large proportion of potential immunotoxic agents (12–14). This is reflected in published and proposed immunotoxicity testing guidelines by the Committee for Proprietary Medicinal Products (CPMP), Organization of Economic Cooperation and Development (OECD) and International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Humans Use (ICH) (reviewed by (10)). While testing for potential immunotoxicty in experimental animals has gained increased acceptance, few systematic epidemiological immunotoxicological studies had been undertaken. This is due to a number of difficulties in working with human populations (15): (a) Lack of validated immunological assays of sufficient sensitivity (b) Difficulty in accurately determining infectious disease incidence (c) Large cost and difficulty of sample acquisition at sites geographically distant from the investigator
Immunotoxicology Testing: Past and Future
7
Table 1.1 Tier 1 immunotoxicty testing recommendations for human studies NRC recommendations
WHO recommendations
Serum IgG, IgM, IgA and IgE levels
Hematological profile
Natural antibody levels to ubiquitous antigens
Antibody mediated immunity
Secondary antibody response to proteins and polysaccharides
Immunophenotyping
Immunophenotyping
Delayed hypersensitivity response
Secondary DTH response
C-Reactive protein
Autoantibody titers (DNA, mitochondria)
Autoantibody titers (DNA, mitochondria) IgE to common allergens NK cells activity or numbers Phagocytosis Clinical chemistry
The US National Academy of Sciences (NAS) in understanding these challenges, proposed a three tier testing scheme to be used for study of populations known or suspected to have been exposed to an immunotoxicant (16). As with experimental animals, it was proposed that tests be conducted from the first Tier and the results used to consider proceeding to the next Tier. The tests included in the first Tier are shown in Table 1.1. The International Programme on Chemical Safety of the World Health Organization (IPCS/ WHO) issued a report on principles and methods for assessing direct immunotoxicity associated with exposure to chemicals (17). Although many assays overlapped, that report recommended a larger number of assays that can be used to evaluate possible immunotoxicity than the NRC tier system (Table 1.1). A symposium on Epidemiology of Immunotoxicity remarked on the need for welldesigned studies of immunotoxicity in humans and supported the application of the NRC three Tier approach (18). Over the years, a number of immunotoxicology population studies were conducted based on a selection of immune biomarkers from both the WHO and NRC Tier 1 recommendations (e.g., 19–21).
3. Skin Sensitization Testing
For many decades, the guinea pig has been the animal of choice for predictive studies of skin sensitization potential. This arose largely as
8
Luster and Gerberick
a result of the use of the guinea pig in the pioneering investigations into mechanisms of skin sensitization to chemicals (1, 22). The first definition of a real predictive test came from the work of Draize more than 60 years ago (23). Since that time, numerous protocols have been described whose aims have been, in one way or another, to make improvements to the sensitivity and predictivity of the guinea pig as a surrogate for man. In essence, all the test protocols follow similar principles. Typically, a combination of intradermal and/or epicutaneous treatments is administered to 10–20 guinea pigs, with or without adjuvant, over a 2–3 week period in an attempt to induce skin sensitization, then a 1–2 week rest period to allow any immune response to mature, followed finally by a topical challenge to assess the extent to which the skin sensitization might have been induced. A set of 5–10 sham treated controls is also challenged. Evaluation of the skin reactions is usually by subjective visual assessments 24–48 h after the challenge application, the main reaction element being erythema. The protocol of Magnusson and Kligman (24) and that of Buehler (25, 26) are the two most studied and accepted guinea pig methods used for regulatory purposes worldwide (27). The Local Lymph Node Assay (LLNA) is a validated alternative approach to the traditional guinea pig test methods for skin sensitization testing that provides important animal welfare benefits (28, 29). In this method, skin sensitizing potential is measured as a function of lymph node cell proliferative responses induced in mice following repeated topical exposure to the test chemical (30, 31). Not least due to the improved animal welfare benefits, the LLNA has become the preferred method for assessing skin sensitization hazard by various regulatory authorities (32, 33). The OECD test guideline 429 for the LLNA indicates that a minimum of 3 test concentrations and a vehicle control group with a minimum of 4 animals per group are needed (27). A chemical is classified as a skin sensitizer if, at one or more test concentrations, it induces a three-fold or greater increase in draining lymph node cell proliferation compared with concurrent vehicletreated controls (Stimulation Index [SI] ≥3). In the standard LLNA, lymph nodes are pooled and processed on an experimental group basis using 4 mice per group. Alternatively, using 5 mice per group, lymph nodes are pooled on an individual animal basis providing the opportunity to employ statistical analyses and appropriate power (34). The LLNA has been evaluated extensively in both national and international inter-laboratory collaborative trials and has been the subject of comparisons with guinea pig predictive test methods and human sensitization data. An important point is that the LLNA was subjected to rigorous independent scrutiny and validated by the International Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (29). There soon
Immunotoxicology Testing: Past and Future
9
followed a similar endorsement by the European Centre for the Validation of Alternative Methods (ECVAM) (28). Thus, the tests traditionally used for the identification of chemicals possessing the intrinsic ability to cause skin sensitization are the guinea pig maximization test, the Buehler occluded patch test and the LLNA. The capacity of these methods to identify skin sensitization hazard has only been formally validated for the LLNA. However, both within this validation and via the publication of other datasets, the guinea pig methods are also recognized to be of sufficient sensitivity and specificity.
4. Needs in Immunotoxicity Screening Testing
As described above, the most attention to development of validated methods for immuntoxicity testing thus far has been devoted to identify xenobiotics that have the potential to produce skin sensitization or immunosuppression. Although not validated, opportunities exist to improve the current testing schemes in terms of improved sensitivity, less reliance on experimental animals and cost reduction, such as cytokine and gene expression profiling (35–37). These procedures offer the additional opportunity to make direct comparisons with humans using samples from serum or isolated leuokocytes. The use of in vitro systems, such as dendritic cell activation, peptide reactivity and T-cell activation are also being applied to hypersensitivty testing (38, 39). Unfortunately, these traditional testing paradigms are inadequate for many issues relevant to immunotoxicity testing that are of signi ficant current importance. For example, food allergies, which are often life-threatening, are common and affect 6–8% of children under the age of 4 and 1–4% of adults (40). While considerable attention has been given to the types of food products that can produce an allergic response, few studies have addressed development of appropriate test methods for identifying sensitizers in food. Rodent models employed for the evaluation of food allergy have utilized strains inherently skewed towards a Th2 allergic phenotype and high IgE production such as the Brown Norway rat or BALB/c and C3H/ HeJ mouse (41). Rodent models tend to replicate the IgE response to food allergens seen in humans but often fail to present similar clinical symptoms. Other animal models, including dogs and pigs, demonstrate many clinical characteristics of human food allergy including respiratory involvement, digestive problems and even anaphylaxis (41). However, lack of standardization due to variable use of adjuvant, varying routes of exposure, not to mention most appropriate test model, make assessing chemical-induced modulation of responses to protein allergens difficult. Importantly, however, dialog on standardized testing protocols for food allergens is continuing (42).
10
Luster and Gerberick
Respiratory sensitizers can be identified in inhalation studies using the guinea pig (43). However, the technical difficulty, particularly as it relates to conducting inhalation, does not lend this procedure to a routine screening test. Most of the issues related to screening tests for food sensitizers, particularly as it relates to the Th2 phenotype, also apply for respiratory sensitizers. A number of studies have and still continue to address screening tests for respiratory sensitizers. These include among others, monitoring IgE or IgG1 levels in various test species and employing bronchial associated lymphoid tissues for immunophenotyping, cytokine profiling, gene expression and a modified LLNA (43). The observation that many drugs produce autoimmune-like syndromes and environmental chemicals induce onset and modulate autoimmune disease severity, has led the efforts to identify reliable screening tests for xenobiotic-induced autoimmunity. Animal models of autoimmunity have been used to explore both molecular mechanisms and therapeutic interventions for a variety of autoimmune diseases (44). However, while a number of syndromes that are similar to those clinically observed in humans can be mimicked in animal models, the diversity of autoimmune diseases limits the utility of any single model as a screening tool. The popliteal lymph node assay, which measures non-specific stimulation and proliferation in the lymph nodes draining chemically exposed tissues, has been used in conjunction with reporter antigens as a tool to screen for immunostimulating compounds (45). However, this assay falls short of measuring the potential to produce disease. Finally, an ongoing need in immunotoxicology testing is to develop screening tests to identify adverse health consequences from xenobiotics that produce immunostimulation or modulate inflammatory responses. Although these may include some industrial chemicals, they primarily represent therapeutics designed to treat immune-mediated diseases, such as asthma, autoimmunity, or chronic inflammatory diseases. Some general examples include Toll-like receptor (TLR) agonists, cytokine agonists or antagonists, modulators of adhesion molecules, angiogenic therapies, novel vaccine adjuvants and arachidonic acid modulators. Since the immune system represents a vast network of regulatory loops, altering the production or expression of one regulatory immune mediator to treat a disease would likely influence other mediators, the consequences of which may have adverse effects that outweigh the benefits of its intended use.
5. Conclusion In this survey, we have provided the reader with a brief historical perspective of immunotoxicology conveying that its foundation was in the development of predictive screening tests to identify
Immunotoxicology Testing: Past and Future
11
xenobiotics that may cause immunosuppression or skin sensitization. The discipline, however, continues to evolve to include contributions to basic science as well as in improving human risk assessment. It is essential, however, that we understand the fact that immunotoxicology represents the study of a number of distinct diseases associated with perturbances of the immune system, and that there is a critical need to develop standardized and validated screening tests for all these immunotoxicities.
References 1. Landsteiner K, Jacobs J (1935) Studies on the sensitization of animals with simple chemical compounds I. J Exp Med 61:643–657 2. Dean JH, Padarathsingh ML, Jerrells TR (1979) Assessment of immunobiological effects induced by chemicals, drugs or food additives. I Tier testing and screening approach. Drug Chem Toxicol 2:5–16 3. Dean JH, Luster MI, Boorman GA, Lauer LD (1982) Procedures available to examine the immunotoxicity of chemicals and drugs. Pharmacol Rev 34:137–148 4. Luster MI, Munson AE, Thomas P, Holsapple MP, Fenters J, White K, Lauer LD, Dean JH (1988) Development of a testing battery to assess chemical-induced immunotoxicity. Fund Appl Toxicol 10:2–19 5. Luster MI, Portier C, Pait DG, White KL, Gennings C, Munson AE, Rosenthal GJ (1992) Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fund Apppl Toxicol 18:200–210 6. Luster MI, Portier C, Pait DG, Rosenthal GJ, Germolec DR, Corsini E, Blaylock BL, Pollock P, Kouchi Y, Craig W, White KL, Munson AE, Comment CC (1993) Risk assessment in immunotoxicology. II. Relationship between immune and host resistance tests. Fund Appl Toxicol 21:71–82 7. van Loveren H, Vos J (1989) Immunotoxicological considerations: a practical approach to immunotoxicity testing in the rat. In: Dayan A, Paine A (eds) Advances in applied toxicology. Taylor & Francis, New York, NY, pp 143–164 8. White K, Jennings P, Murray P, Dean J (1994) International validation study carried out in 9 laboratories on the immunological assessment of cyclosporin A in the Fisher 344 rat. Toxicol In Vitro 8:957–962 9. Ladics GS, Smith CE, Elliott GS, Slone TW, Loveless SE (1998) Further evaluation of the incorporation of an immunotoxicological functional asay for assessing humoral
10.
11. 12.
13.
14.
15.
16.
17.
immunity for hazard identification purposes in rats in a standard toxicology study. Toxicology 126:137–152 House RV, Luebke RW (2007) Immunotoxicology: thirty years and counting. In: Luebke R, House R, Kimber I (eds) Immunotoxicology and immunopharmacology, 3rd edn. CRC, Boca Raton, FL, pp 3–20 EPA, Biochemical Test Guidelines (1996) OPPTS 880.3550 immunotoxicity. US/EPA, Washington DC Kuper CF, Harleman JH, Richter-Reichelm HB, Vos JG (2000) Histopathologic approaches to detect changes indicative of immunotoxicity. Toxicol Pathol 2:454–466 Germolec DR, Nyska A, Kashon M, Kuper CF, Portier C, Kommineni C, Johnson KA, Luster MI (2004) The accuracy of extended histopathology to detect immunotoxic chemicals. Toxicol Sci 82:504–514 Haley P, Perry R, Ennulat D, Frame S, Johnson C, Lapointe JM, Nyska A, Snyder P, Walker D, Walter G (2005) STP Immunotoxicology Working Group. Best practice guideline for the routine patholgy evaluation of the immune system. Toxicol Pathol 33:404–408 Descotes J, Nicolas B, Pham E (1997) Sentinel screening for human immunotoxicity. In: Environment and immunity. Proceedings of a Workshop held in Brussels on 20–21 May 1996. Air Pollution Epidemiology Reports Series. S. R NRC (1992) Biologic markers in immunotoxicology. A report by the US National Research Council. National Academy Press, Washington DC WHO (1996) Principles and methods for assessing direct immunotoxicity associated with exposure to chemicals. A report of the International Programme on Chemical Safety (Environmental Health Criteria 180). World Health Organization, Geneva
12
Luster and Gerberick
18. van Loveren H, Germolec DR, Koren HS, Luster MI, Nolan C, Repetto R, Smith E, Vos JG, Vogt RF (1999) Report of the Bilthoven Symposium: advancement of epidemiological studies in assessing the human health effects of immunotoxic agents in the environment and the workplace. Biomarkers 4:135–157 19. Weisglas-Kuperus N, Patandin S, Berbers GAM, Sas TCJ, Mulder PGH, Sauer PJJ, Hooijkaas H (2000) Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children. Environ Health Perspect 108:1203–1207 20. Leonardi GS, Houthuijs D, Steerenberg PA, Fletcher T, Armstrong B, Antova T, Lochman I, Lochmanova A, Rudnai P, Erdei E, Musial J, Jazwiec-Kanyion B, Niciu EM, Durbaca S, Fabianova E, Koppova K, Lebret E, Brunekreef B, van Loveren H (2000) Immune biomarkers in relation to exposure to particulate matter: a cross-sectional survey in 17 cities of Central Europe. Inhalation Toxicol 12(Supp 4):1–14 21. Pinkerton L, Biagini R, Ward EM, Hull RD, Deddens JA, Boeniger MF, Schnoor TM, Luster MI (1998) Immunologic findings among lead-exposed workers. Am J Indus Med 33:400–408 22. Landsteiner K, Jacobs J (1936) Studies on the sensitization of animals with simple chemical compounds II. J Exp Med 64:625–639 23. Draize JH, Woodard G, Calvery HO (1944) Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 8:377–390 24. Magnusson B, Kligman AM (1970) Allergic contact dermatitis in the guinea pig. Identification of contact allergens. Charles C. Thomas, Springfield IL 25. Buehler EV (1965) Delayed contact hypersensitivity in the guinea pig. Arch Dermatol 91:171–177 26. Robinson MK, Nusair TL, Fletcher ER, Ritz HL (1990) A review of the Buehler guinea pig skin sensitization test and its use in a risk assessment process for human skin sensitization. Toxicology 61:91–107 27. Organisation for Economic Cooperation and Development (2002) Test Guideline 429: The local Lymph Node Assay. OECD, Paris 28. Balls M, Hellsten E (2000) Statement on the validity of the local lymph node assay for skin sensitization testing. ECVAM Joint Research Centre, European Commission, Ispra. Altern Lab Anim 28:366–367 29. Dean JH, Twerdock LE, Tice RR, Sailstad DM, Hattan DG, Stokes WS (2001) ICCVAM evaluation of the murine local lymph node
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
assay. II. Conclusions and recommendations of an independent scientific review panel. Regul Toxicol Pharmacol 34:258–273 Kimber I, Mitchell JA, Griffin AC (1986) Development of a murine local lymph node assay for the determination of sensitizing potential. Fd Chem Toxic 24:585–596 Kimber I, Hilton J, Weisenberger C (1989) The murine local lymph node assay for identification of contact allergens: a preliminary evaluation of in situ measurement of lymphocyte proliferation. Contact Derm 21:215–220 United States Environmental Protection Agency Health Effects Test Guidelines (2003) OPPTS 870.2600 Skin sensitization. US/ EPA, Washington, DC Cockshott A, Evans P, Ryan CA, Gerberick GF, Betts CJ, Dearman RJ, Kimber I, Basketter DA (2006) The local lymph node assay in practice: a current regulatory perspective. Hum Exp Toxicol 25:387–394 Gerberick GF, Ryan CA, Dearman RJ, Kimber I (2007) Local lymph node assay (LLNA) for detection of sensitizing capacity of chemicals. Methods 41:54–60 Loveless SE, Ladics GS, Smith C, Holsapple MP, Woolhiser MR, White KL, Musgrove DL, Smialowicz RJ, Williams W (2007) Interlaboratory study of the primary antibody response to sheep red blood cells in outbred rodents following exposure to cyclophosphamide or dexamethasone. J Immunotoxicol 4:233–238 Luebke R, Holsapple M, Ladics G, Luster MI, Selgrade M-J, Woolhiser M, Germolec DR (2006) Immunotoxicogenomics: the potential of genomics technology in the immunotoxicity risk assessment process. Toxicol Sci 94:22–27 Boverhof DR, Gollapudi BB, Hotchkiss JA, Osterioh-Quiroz M, Woolhiser MR (2008) Evaluation of a toxicogenomic approach to the local lymph node assay (LLNA). Toxicol Sci 107(2):427–439 Ryan CA, Hulette BC, Gerberick GF (2001) Review: approaches for the development of cell based in vitro methods for contact sensitization. Toxicol In Vitro 15:43–55 Ryan CA, Gerberick GF, Gildea LA, Hulette BC, Betts CJ, Cumberbatch M, Dearman RJ (2005) Interactions of chemicals with dendritic cells – a novel approach for identification of potential allergens. Toxicol Sci 88:4–11 Teufel M, Biedermann T, Rapps N, Hausteiner C, Henningsen P, Enck P, Zipfel S (2007) Psychological burden of food allergy. World J Gastroenterol 3:3456–3465 McClain S, Bannon GA (2006) Animal models of food allergy: opportunities and barriers. Curr Allergy Asthma Rep 2:141–144
Immunotoxicology Testing: Past and Future 42. Ladics GS, Selgrade MK (2008) Identifying food proteins with allergenic potential: evolution of approaches to safety assessment and research to provide additional tools. Regul Toxicol Pharmacol 54(3 Suppl): S2–S6 43. Holsapple MP, Jones D, Kawabata TT, Kimber I, Sarlo K, Selgrade MK, Shah J, Woolhiser MR
13
(2006) Assessing the potential to induce respiratory hypersensitivity. Toxicol Sci 91:4–13 44. Germolec DR (2005) Autoimmune diseases, animal models. In: Vohr H-W (ed) Encyclopedic reference of immunotoxicology. Springer, Berlin, pp 75–79 45. Pieters R (2007) Detection of autoimmunity by pharmaceuticals. Methods 41:112–117
Part II Overview and Health-Risk Considerations
Chapter 2 Developmental Immunotoxicity (DIT): The Why, When, and How of DIT Testing Rodney R. Dietert and Jamie DeWitt Abstract Developmental immunotoxicity (DIT) has emerged as a serious health consideration given the increases in the prevalence of many immune-based childhood diseases and conditions, including allergic diseases and asthma, recurrent otitis media, pediatric celiac disease, and type 1 diabetes. As a result, the use of DIT testing to identify potential environmental risk factors contributing to these and other diseases has become a higher priority. This introductory chapter considers: (1) the basis for an increased and earlier use of DIT testing in safety evaluations and (2) the general features of DIT testing strategies designed to reduce health risks. Key words: Developmental immunotoxicity, DIT, Developmental immunotoxicology, Pediatric health risks, Safety testing, Autoimmunity, Allergic hypersensitivity, Inflammation, Immuno suppression, Host resistance
1. Introduction Developmental immunotoxicity (DIT) testing is a significant consideration under the larger umbrella of immunotoxicity testing covered in this book. DIT received only occasional research consideration before the mid-1990s (1–3). However, it has grown sufficiently in scope and impact to be the subject of a stand-alone book by Holladay (4) and has been an integral part of virtually every book on immunotoxicology to appear since that time (5–10). Luster et al. (10) recently defined developmental immunotoxicology as “the effects on the immune system resulting from pre- and/or postnatal exposure to physical factors (e.g., ionizing and ultraviolet radiation), chemicals (including drugs), biological materials, medical devices, and in certain instances, physiological factors, collectively referred to as agents.” DIT increases the risk R.R. Dietert (ed.), Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, vol. 598 DOI 10.1007/978-1-60761-401-2_2, © Humana Press, a part of Springer Science + Business Media, LLC 2010
17
18
Dietert and DeWitt
of autoimmunity, allergic hypersensitivity, susceptibility to infectious diseases and cancer, and inflammatory diseases in humans as well as in wildlife. The increased risk exists because the immune system is central not only to host defense but also to physiological homeostasis. Since environmentally induced immune dysfunction encompasses both suppression and inappropriate enhancement of immune responses, DIT testing should be capable of detecting both types of changes. This introductory chapter on DIT considers three key topics that significantly impact DIT testing. These are: (1) the “why” of DIT testing or the scientific basis for early-life vulnerability that has led DIT testing to become a central issue within safety testing, (2) the “when” of DIT testing or the circumstances that would be expected to result in DIT testing, and (3) the “how” of DIT testing or the key considerations that can guide an effective testing strategy for health-risk reduction.
2. The “Why” of DIT Testing Epidemiological studies and animal studies have consistently demonstrated the adverse effects of exogenous agents on the developing immune system that last longer or that occur at lower doses than effects of the same agents on adults. Therefore, assessing immunotoxicity in adult animals may not adequately reflect the severity or the persistence of the adverse effects following developmental exposure. From a risk assessment perspective, if early-life exposure to toxicants poses the greatest environmental risk for the immune system, then it poses the greatest effect on human health (11). Epidemiological studies of humans environmentally exposed to exogenous agents provide concrete examples of how developmental exposure to toxicants alters immunocompetence and subsequent susceptibility to infections (12–17). Populations in Canada, China, the Netherlands, and Japan accidentally exposed to polychlorinated biphenyls (PCBs) and their associated breakdown products are well-documented examples of DIT. In each of these populations, rates of recurrent otitis media (inflammation of the inner ear), recurrent respiratory infections, and other types of immune dysfunction were higher in developmentally exposed children than in matched controls. Myriad animal studies with PCBs and other chlorinated compounds corroborate these epidemiological data that developmental exposure increases the risk of infections later in life. Numerous other exogenous agents have been implicated as developmental immunotoxicants in animal models, exposed human populations, or both. These include therapeutic agents
Developmental Immunotoxicity (DIT): The Why, When, and How of DIT Testing
19
(diazepam, diethylstilbestrol, and dexamethazone), additional environmental chemicals such as pesticides (chlordane, heptachlor, and hexa-chlorobenzene), and metals (lead, mercury, and organotin compounds). Luebke et al. (18) compared the immunotoxicity of five different compounds (diethylstilbestrol, diazepam, lead, TCDD, and tributyltin oxide) following adult or developmental exposure and concluded that until information to the contrary is available, the developing immune system is more sensitive to toxicant exposure than the adult immune system. One important consideration is that the timing of exposure determines the immuno-toxicological outcome, which means that DIT produces a myriad of effects. For example, if lead exposure occurs throughout gestation, the juvenile and adult delayed-type hypersensitivity (DTH) response (a functional measure of cell-mediated immunity) is decreased; if exposure is restricted to the first half of gestation, macrophage function is impaired but later-life DTH response is unaffected (19). Therefore, the evaluation of DIT requires: (1) the understanding of immune system development, (2) the utilization of relevant age-based exposure regimes, and (3) the selection of appropriate immunological outcomes for assessment. These considerations are discussed in the subsequent section.
3. The “When” of DIT Testing As discussed in the prior section, the developing immune system is generally accepted as a more sensitive toxicological target compared with the immune system of an adult. In fact, even the nature of adverse immune outcomes resulting from early-life exposures is not reliably predictable, based on adult-exposure immunotoxicity results (11). This disconnection between adult-exposure immunotoxicity data and early-life immunotoxic risk raises two key questions in immunotoxicity testing: (1) Are age-relevant immunotoxicity data needed to ensure adequate protection of the nonadult from exposure to a chemical or drug? and (2) When should DIT studies be conducted in safety testing? In recent years, there has been an increased concern over the protection of children’s health that has been reflected in new government and international agency-sponsored activities (20–25). Not surprisingly, this has extended to an increased interest in DIT. Since many of the significant chronic diseases of childhood feature immune dysfunction (26), this increased interest appears warranted. A comparison of DIT publications from the years 1982– 1994 vs.1996–2008 makes it clear that the number of DIT studies, workshops, conference symposia, and reviews has
Additional host resistance testing may be requested
Developmental immune testing after most adultexposure testing
DIT testing may be triggered with adverse adult outcome
Secondary tier immune testing of adult exposed animals: may or may not include secondary immunizations
Pediatric-relevant immune data: are highly drug-specific and usually entail histopathology on unchallenged animals
Adult exposure immune data requested on challenged animals
Cause of concern requirement before proceeding to functional testing
Histopathology on unchallenged animals: routinely adult-exposure
Drugs
Adult exposure immune functional testing
DIT functional immune testing on primary and secondarily challenged animals exposed across all non-adult windows
Any additional narrow age-based or gender-specific testing
Chemicals and Drugs*
Histopathology and associated immune and/or host resistance parameters evaluated on adult-exposed animals
DIT histopathology and associated immune and/or host resistance parameters evaluated
*DIT testing would not be expected for a drug never consumed by a pregnant woman or a child
Sample Immunotoxicity Testing Flow Chart Based on Disease Risk Potential
Fig. 2.1. The flow diagrams on the left half of the figure illustrate the placement of DIT safety testing for chemicals and drugs based on recent regulatory expectations. In contrast, the flow chart on the right half of the figure illustrates a potential placement of DIT testing driven by its potential for disease risk reduction.
LEVEL 3
LEVEL 2
LEVEL 1
First tier immune testing of adult exposed animals: usually primary immunization only
Chemicals
Placement of DIT Testing in Recent Regulatory Requirements
20 Dietert and DeWitt
Developmental Immunotoxicity (DIT): The Why, When, and How of DIT Testing
21
increased significantly in recent years (10, 11, 18, 26–36). As a result, more information is now available on age-based immune safety for selected chemicals and drugs. However, this increase appears to be largely a result of increased government- and industry-funded research into DIT as well as recent National Toxicology Program (NTP) contracts for early-life exposure studies. In contrast, regulatory expectations for DIT testing have remained relatively unchanged across the years with limited exceptions (e.g., pesticide safety). As illustrated in Fig. 2.1, current immunotoxicity testing of drugs and chemicals expected by regulatory agencies is focused on adult-exposure assessment. Additionally, the collection of specific immune data from adult exposures is often predicated on a “cause for concern” triggered by initial, more general data. DIT exposure assessment is not routinely expected and would usually be triggered only by evidence of clear immunotoxicity from the adult-exposure data. The problem with this priority of testing is that adverse immune outcomes from an insensitive toxicological response system (the fully matured adult immune system) are used as a prerequisite for pursuing DIT testing. The strategy of evaluating risk to the developing immune system only if and when the fully matured immune system (i.e., the adult trigger) is altered should produce two types of errors. The first is essentially a quantitative error. In this case, the adultexposure immunotoxicity data would not provide an indication of the dose–response sensitivity, persistence of adverse effects, or range of adverse effects that the same chemical or drug might produce with early-life exposure (11, 18). If direct DIT testing is pursued, this information is then available. But in the absence of additional DIT testing, addition of safety factors may be applied to reduce age-based risk for some immunotoxicants. Because age-based sensitivities vary widely (18), these may or may not be sufficient. The second type of error is more qualitative and of greater concern. If a chemical or drug is not identified as an immunotoxicant (based on adult-exposure results), then it may never be tested for DIT. Yet, the chemical or drug may be capable of producing an adverse immunotoxic outcome in early life at relevant exposures. While it is not clear if examples of this second type of error do exist, it is also likely that adult-defined “non-immunotoxicants” will never be tested for early-life risk of facilitating allergy, autoimmunity, or targeted immunosuppression. Therefore, the data may not exist to address the likelihood of overlooking developmental immunotoxicants. One advantage of using DIT testing earlier in the safety testing regime (shown in Fig. 2.1) is the benefit of having evaluated the most sensitive age-group for potential immunotoxicity. A negative finding in a comprehensive DIT assessment should
22
Dietert and DeWitt
provide safety information that extends to the adult immune system as well. However, the reverse is not true in that negative adult immune exposure results provide little assurance for earlylife immune safety.
4. The “How” of DIT Testing The specific protocols described in the assay-specific chapters within this book are directly relevant not only to adult-exposure assessment but also to DIT testing. Therefore, they should be considered as having direct relevance across age groups. Hence, there is no need to repeat details of these same assays in this background chapter on DIT. Most of the scientific discussions surrounding the use of specific assays and immune parameters in DIT testing concern: (1) the most informative version of each assay to use, (2) the optimum (or minimum) combination of assays needed for an informative DIT assessment, and (3) the timing of applying these assays in DIT assessment. There is general agreement that a routine screen of DIT would normally include exposure to the environmental agent over the entire developmental period of the nonadult (prenatal, neonatal, juvenile) with immune assessment occurring during the juvenile and/or young adult periods (8). More restricted or specialized exposure regimes could be applied as needed to address specific age-based concerns or the most relevant human exposure (e.g., proposed use of a drug in the pediatric population). DIT assessment should be performed on a challenged immune system (immunized or exposed to an infectious agent) to provide the opportunity to detect potential immune dysfunction (32). Beyond those basic suggestions, the optimum combination of assays and parameters to be employed in the assessment is the subject of considerable discussion. However, given that DIT testing is unlikely to be structured into a multiple tier approach, as are some adult immunotoxicity testing regimes, the probable one-time assessment needs to include a sufficient range of immune measures to address health concerns. Like adult-exposure immunotoxicity assessment, DIT testing is designed to identify potentially problematic exposures and to reduce immune-associated health risks. To accomplish the latter, it is useful to identify target diseases that could be impacted by a reduction of childhood and adult adverse immune outcomes and would serve as the justification for DIT testing. Dietert (26) started with eight of the most significant diseases or conditions of children and young adults having environmental risk factors and featuring immune dysfunction. Most of these diseases are chronic in nature, have increased in prevalence in recent decades and
Developmental Immunotoxicity (DIT): The Why, When, and How of DIT Testing
23
include: allergies (including asthma), autism, childhood leukemia, late-onset sepsis, multiple sclerosis, otitis media, pediatric myalgic encephalomyelitis, and type 1 diabetes. A reverse engineering approach was taken toward the goal of optimizing DIT testing for human health-risk reduction. The author asked how one might identify the earliest signs of the immune problems found with the eight childhood diseases and then progressed backwards to the immune parameters that were most useful for this identification. The results from this exercise led to a series of generalized priorities that may prove helpful in guiding effective DIT testing. These are presented here as a series of nine questions that should be useful in a consideration of specific DIT testing regimes and the desired combination of immune parameters to be included in DIT assessments. 1. Was the immune system adequately challenged to permit detection of immune dysfunction, including those parameters prominent during the secondary immune responses? 2. Did the measures permit a sensitive detection of changes in T helper (Th) balance (Th1, Th2, Th17)? 3. Was there an adequate assessment of cell-mediated immunity? 4. Was the potential risk of autoimmunity determined (involving changes in T regulatory cells and/or T cell receptor diversity)? 5. Was innate immune maturation adequately evaluated? 6. Was the status of marginal zone B lymphocytes and the potential responsiveness to T-independent antigens determined? 7. Was the status of resident macrophage populations such as microglia evaluated? 8. Did the assessment parameters evaluate immune cell recruitment and trafficking? 9. Was mucosal immune status determined [including the status of the bronchus-associated lymphoid tissue (BALT) and the gastrointestinal-associated lymphoid tissue (GALT)]?
5. Summary Numerous immunotoxicity testing protocols are detailed in the subsequent chapters of this book and virtually all of these are directly applicable to use in DIT testing. A broader issue concerns the conditions under which these protocols would be applied to DIT testing within a safety testing regime. In the past, DIT testing has been a relatively rare regulatory requirement. However,
24
Dietert and DeWitt
the increasing prevalence of immune-based childhood diseases coupled with the uncertainties inherent in applying adult-exposure immunotoxicity data to predict early-life health risks should increase the role of DIT testing in safety evaluation. With this in mind, it is important that DIT testing designs optimize detection of those adverse immune outcomes that contribute to the most significant health risks of the at-risk population (prenatal, neonatal, juvenile). This introductory chapter has provided disease-pertinent immune information that should prove useful in designing DIT testing strategies.
Acknowledgments The authors thank Janice Dietert for her editorial assistance.
References 1. Luster MI, Faith RE, Kimmel CA (1978) Depression of humoral immunity in rats following chronic developmental lead exposure. J Toxicol Environ Pathol 1:397–402 2. Barnett JB, Holcomb D, Menna JH, Soderberg LS (1985) The effect of prenatal chlordane exposure on specific anti-influenza cell-mediated immunity. Toxicol Lett 25:229–238 3. Dietert RR, Qureshi MA, Nanna UC, Bloom SE (1985) Embryonic exposure to aflatoxin-B1: mutagenicity and influence on development and immunity. Environ Mutagen 7:715–725 4. Holladay SD (2005) Developmental immunotoxicology. CRC Press, Boca Raton, FL 5. Barnett JB (1996) Developmental immunotoxicology. In: Smialowicz RJ, Holsapple MP (eds) Experimental Immunotoxicology. CRC Press, Boca Raton, FL, pp 47–62 6. Smialowicz RJ, Brundage KB, Barnett JB (2007) Immune system ontogeny and developmental immunotoxicology. In: Luebke R, House R, Kimber I (eds) Immunotoxicology and Immunopharmacology, 3rd edn. CRC Press, Boca Raton, FL, pp 327–346 7. Dietert RR (2009) Developmental immunotoxicology. In: Ballantyne B, Marrs T, Syversen T (eds) General and applied toxicology, 3rd edn. Wiley, Chichester, UK, pp 1977–1991 8. Dietert RR, Burns-Naas LA (2008) Develop mental immunotoxicity in rodents. In: Herzyk DJ, Bussiere JL (eds) Immunotoxicology strategies for pharmaceutical safety assessment. Wiley, Hoboken, NJ, pp 273–297
9. Holsapple MP, van der Laan JW, van Loveren H (2008) Development of a framework for developmental immunotoxicity (DIT) testing. In: Luebke R, House R, Kimber I (eds) Immunotoxicology and Immunopharma cology, 3rd edn. CRC Press, Boca Raton, FL, pp 327–346 10. Luster MI, Dietert RR, Germolec DR, Luebke RW, Makris SL (2008) Developmental immunotoxicology. In: Sonawane B, Brown R (eds) Encyclopedia of environmental health. Elsevier, Oxford 11. Dietert RR, Piepenbrink MS (2006) Perinatal immunotoxicity: why adult exposure assessment fails to predict risk. Environ Health Perspect 114:477–483 12. Lu YC, Wu YC (1985) Clinical findings and immunological abnormalities in Yu-Cheng patients. Environ Health Perspect 59:17–29 13. Nakanishi Y, Shigematsu N, Kurita Y, Matsuba K, Kanegae H, Ishimaru S, Kawazoe Y (1985) Respiratory involvement and immune status in Yusho patients. Environ Health Perspect 59:31–36 14. Yu ML, Hsin JW, Hsu CC, Chan WC, Guo YL (1998) The immunologic evaluation of the Yucheng children. Chemosphere 37: 1855–1865 15. Dewailly E, Ayotte P, Bruneau S, Gingras S, Belles-Isles M, Roy R (2001) Susceptibility to infections and immune status in Inuit infants exposed to organochlorines. Environ Health Perspect 108:205–211
Developmental Immunotoxicity (DIT): The Why, When, and How of DIT Testing 16. Weisglas-Kuperus N, Patandin S, Berbers GA, Sas TC, Mulder PG, Sauer PJ, Hooijkaas H (2000) Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children. Environ Health Perspect 108:1203–1207 17. Karmaus W, Kuehr J, Kruse H (2001) Infections and atopic disorders in childhood and organochlorine exposure. Arch Environ Health 56:485–492 18. Luebke RW, Chen DH, Dietert R, Yang Y, King M, Luster MI (2006) The comparative immunotoxicity of five selected compounds following developmental or adult exposure. J Toxicol Environ Health B Crit Rev 9:1–26 19. Dietert RR, Lee JE, Bunn TL (2002) Developmental immunotoxicology: emerging issues. Hum Exp Toxicol 21:479–485 20. Selevan SG, Kinnel CA, Mendola P (2000) Identifying critical windows of exposure for children’s health. Environ Health Perspect 108(Suppl. 3):451–455 21. Daston G, Faustman E, Ginsberg G, FennerCrisp P, Olin S, Sonanwane B, Bruckner J, Breslin W, McLaughlin TJ (2004) A framework for assessing risks to children from exposure to environmental agents. Environ Health Perspect 112:238–256 22. Landrigan PJ, Kimmel CA, Correa A, Eskenazi B (2004) Children’s health and the environment: public health issues and challenges for risk assessment. Environ Health Perspect 112:257–265 23. Kimmel CA, Collman GW, Fields N, Eskenzi B (2005) Lessons learned for the National Children’s Study from the National Institute of Environmental Health Sciences/U.S. Environmental Protection Agency Centers for Children’s Environmental Health and Disease Prevention Research. Environ Health Perspect 113:1414–1418 24. Landrigan PJ, Trasande L, Thorpe LE, Gwynee C, Lioy PJ, D’Alton ME, Lipkind HS, Swanson J, Wadhwa PD, Clark EB, Rauh VA, Perera FP, Susser E (2006) The National Children’s Study: a 21-year prospective study of 100, 000 American children. Pediatrics 118:2173–2186 25. World Health Organization. International Programme on Chemical Safety (2006) Principles for evaluating health risks in children
25
associated with exposure to chemicals. WHO Publications, Geneva 26. Dietert RR (2008) Developmental immunotoxicity (DIT) in drug safety testing: matching DIT testing to adverse outcomes and childhood disease risk. Curr Drug Saf 3:216–226 27. Holladay SD, Smialowicz RJ (2000) Develop ment of the murine and human immune system: differential effects of immunotoxicants depend on time of exposure. Environ Health Perspect 108(Suppl. 3):463–473 28. Dietert RR, Etzel RA, Chen D, Halonen M, Holladay SD, Jarabek AM, Landreth K, Peden DB, Pinkerton K, Smialowicz RJ, Zoetis T (2000) Workshop to identify critical windows of exposure for children’s health: immune and respiratory systems work group summary. Environ Health Perspect 108(Suppl. 3): 483–490 29. Luster MI, Dean JH, Germolec DR (2003) Consensus workshop on methods to evaluate developmental immunotoxicity. Environ Health Perspect 111:579–583 30. Holsapple MP, Paustenbach DJ, Charnley G, West LJ, Luster MI, Dietert RR, Burns-Naas L (2004) Symposium summary: children’s health risk-What’s so special about the developing immune system? Toxicol Appl Pharmacol 199:61–70 31. Luster MI, Johnson VJ, Yucesoy B, Simeonova PP (2005) Biomarkers to assess potential developmental immunotoxicity in children. Toxicol Appl Pharmacol 206:229–236 32. Dietert RR, Holsapple M (2007) Methodo logies for developmental immunotoxicity (DIT) testing. Methods. 41:123–131 33. Selgrade MK (2007) Immunotoxicity: the risk is real. Toxicol Sci 100:328–332 34. Burns-Naas LA, Hastings KL, Ladics GS, Makris SL, Parker GA, Holsapple MP (2008) What’s so special about the developing immune system? Int J Toxicol 27:223–254 35. Dietert RR (2009) Developmental immunotoxicology: focus on health risks. Chem Res Toxicol 22(1):17–23 36. Dietert RR, Zelikoff JT (2008) Early-life environment, developmental immunotoxicology, and the risk of pediatric allergic disease including asthma. Birth Defects Res B Develop Reprod Toxicol 83(6):547–560
Chapter 3 An In Vivo Tiered Approach to Test Immunosensitization by Low Molecular Weight Compounds Irene S. Ludwig, Lydia M. Kwast, Daniëlle Fiechter, and Raymond H.H. Pieters Abstract New chemical entities are tested in general toxicity assays during development before entering clinical trials. However, immunosensitization of these entities is not tested on a standard basis. There are no in vitro or in vivo standardized methods available for testing immunosensitization or immunostimulation. In this chapter, we describe a tiered strategy oral exposure model for assessing immunosensitization or immunostimulation capacity of low molecular weight compounds. The strategy starts from a set of data that may provide information on bioactivation, conjugation (hapten–protein conjugate formation), cytotoxicity and signs of inflammation in any of the animals in a 28 day-toxicity study. In case of concern, a reporter antigen–popliteal lymph node assay (RA–PLNA) and, subsequently, an oral exposure experiment with the reporter antigen can be performed. Based on the presence of RA-specific immune responses an indication for immunosensitization can be found. Key words: Drug-induced hypersensitivity, Reporter antigen, Mouse model, Oral, Relevant route, Antibodies
1. Introduction Many drugs are known to induce immune-mediated adverse effects in susceptible patients. The incidence of these reactions is usually low for a certain drug; however, the impact on the affected individuals can be very high. In some cases, a hypersensitivity response to a drug can lead to toxic epidermal necrosis with lethal effects. The background of susceptibility is not fully understood, yet. New drugs are tested in general toxicity assays during the development process before entering clinical trial. Toxicity based on pharmacological properties is assessed in these assays. However,
R.R. Dietert (ed.), Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, vol. 598 DOI 10.1007/978-1-60761-401-2_3, © Humana Press, a part of Springer Science + Business Media, LLC 2010
27
28
Ludwig et al.
idiosyncratic drug reactions, e.g., immunosensitization, cannot be predicted with these tests. There are also no standardized in vitro or in vivo methods available for testing immunosensitization or immunostimulation. The reporter antigen popliteal lymph node assay (RA–PLNA) is an in vivo assay that can be indicative of immuno-irritation or immunosensitization of low molecular weight compounds (1). Two well-defined antigens, Trinitrophenyl– Ovalbumin (TNP–OVA), which is a “regular” T cell-dependent antigen, and TNP–Ficoll, which is a so called T cell-independent type 2 antigen, are used in the RA-approach in the PLNA. In this assay, the immuno-enhancing capacity of low molecular weight compounds is measured by increased antibody responses to the reporter antigen that is co-injected in a low non-sensitizing dose. Although this assay is indicative of possible effects of the low molecular weight compound on the immune system, it also has its disadvantages. First, the effect of biotransformation of the low molecular weight compound is neglected since it is injected s.c.. Second, only local responses are measured. Since most drugs are administered orally in humans, there is the need for an oral exposure model. In this chapter, we describe a tiered approach to test for immunosensitization by a low molecular weight compound (2) with the combination of RA–PLNA and a mouse model with repeated oral exposure to a low molecular weight drug which offers the possibility to measure systemic responses. In the oral exposure model, similar to the RA–PLNA assay, a reporter antigen is used for detection of a response. Mice are exposed to drugs once daily for several consecutive days, and on the first day co-exposed to the RA (3). Systemic responses as delayed type hypersensitivity (DTH) and serum antibody levels can be determined as well as local secondary responses in the draining lymph node. A DTH response to the RA is indicative of a T-cell-mediated response. RA-specific antibody secreting cells (ASC) and RA-antibodies are indicative of B-cell responses. Furthermore, a distinction between Th1 and Th2 responses can be made based on the type of antibody induced by the low molecular weight compound; in the mouse, Th1 responses are characterized by IgG2a and Th2 responses by IgG1 induction. The cytokine profile of in vitro restimulated lymphocytes can give an indication of T cell skewing to Th1 or Th2 response with the induction of IFNg and IL-4 respectively. Altogether, these series of experiments can give an indication of induction of an immune response and the type of response by low molecular weight drugs.
An In Vivo Tiered Approach to Test Immunosensitization by Low Molecular
29
2. Materials 2.1. Subcutaneous Exposure
1. Female mice (weighing ~20 g), 5–6 weeks old at the time of arrival. 2. Test compound(s) and vehicle. 3. TNP–OVA (Biosearch Technology, Inc. Novato CA, USA). Prepare stock solution of 20 mg/mL TNP–OVA in NaCl and store in aliquots at −20°C until use. 4. 1 mL syringe and 25 G 16 mm needle. 5. Forceps and scissors. 6. Petri dish. 7. RPMI supplemented with penicillin/streptomycin and FCS (2 and 10%).
2.2. Oral Exposure
1. Female mice (weighing ~20 g), 5–6 weeks old at the time of arrival. 2. Test compound(s) and vehicle. 3. Gavage needle (21 G, 34 mm) with a rounded bulb at the end and 1 mL syringes. 4. TNP–OVA (Biosearch Technology, Inc. Novato CA, USA). Prepare stock solution of 20 mg/mL TNP–OVA in NaCl and store in aliquots at −20°C until use. 5. 18 G needle and minicollect tubes (Greiner) for blood collection. 6. Euthanasate (Pentobarbital or CO2). 7. Forceps and scissors. 8. Petri dish. 9. RPMI supplemented with penicillin/streptomycin and FCS (2 and 10%).
2.3. Delayed Type Hypersensitivity Assay
1. TNP–OVA 10 mg/20 mL NaCl and sterile NaCl. 2. Insulin needle with syringe (29 G, 12 mm, Terumo Europe N.V., Leuven, Belgium). 3. Digital microcalliper. 4. Anesthetic (e.g., ketamine/xylamzine mixture or isoflurane).
2.4. Preparation of Single Cell Suspension of Lymph Nodes
1. RPMI supplemented with penicillin/streptomycin and FCS (2 and 10%). 2. Glass slides with frosted ends. 3. 25 G 16 mm needles and 1 mL syringes. 4. Conic tubes (4 mL). 5. 25 G needles and 1 mL syringes.
30
Ludwig et al.
2.5. Serum Ig ELISA
1. Carbonate buffer 0.05 M pH 9.6: 318 mg Na2CO3, 586 mg NaHCO3. (a) Dissolve in 200 mL bidest. (b) Adjust pH to 9.6 with 6 N NaOH. (c) Store at 4°C. 2. Diethanol amine buffer pH 9.8: 97 mL diethanol amine, 0.2 g MgCl2⋅6H2O, (a) Dissolve in ±800 mL bidest. (b) Adjust pH with 1 N HCl to 9.8. (c) Complete up to a liter. (d) Store at 4°C. (e) Protect from light. 3. Substrate solution: 1 mg/mL 4-nitrophenylphosphate in diethanol amine buffer. Prepare just before use. 4. PBS 10×: 80 g NaCl, 2 g KCl, 17.4 g Na2HPO4⋅7H2O, 2 g KH2PO4. (a) Dissolve ±800 mL bidest. (b) Complete up to a liter with bidest. (c) Store at room temperature. (d) Dilute PBS 10× before use 10 times with bidest, and adjust pH (7.2–7.4) to get PBS 1×. 5. PBS/Tween 10×: 80 g NaCl, 2 g KCl, 17.4 g Na2HPO4·7H2O, 2 g KH2PO4. (a) Dissolve ± 800 mL bidest. (b) Add 5 mL Tween-20. (c) Complete up to a liter with bidest. (d) Autoclave and store at room temperature. (e) Dilute PBS/Tween 10× before use 10 times with bidest, and adjust pH (7.2–7.4) to get PBS/Tween 1×. 6. PBS/Tween/BSA (1%): add 1 g BSA (Sigma A-4503) to 100 mL PBS/Tween. 7. Automated reader ELX800 (Bio-Tek Instruments, Winooski, VT).
2.6. ELISpot
1. PBS/Tween/1%BSA: add 1 g BSA (Sigma A-4503) to 100 mL PBS/Tween. 2. Alkaline–phosphatase (AP) conjugated anti mouse-IgG1 or IgG2a (goat-anti-mouse IgG1-AP (SBA 1070-04) and goatanti-mouse IgG2a-AP (SBA 1080-04) from Southern Biotechnology Associates (SBA), Inc., Birmingham, AL). 3. AP-buffer (500 mL): 6.05 g Trizma base (100 mM) (Sigma T1503), 2.92 g NaCl (100 mM), 5.08 mg MgCl2⋅6H2O (5 mM).
An In Vivo Tiered Approach to Test Immunosensitization by Low Molecular
31
(a) Dissolve in 400 mL MiliQ water. (b) Adjust pH to 9.5 with HCl. (c) Add MiliQ water until a volume of 500 mL. (d) Store at room temperature. 4. Substrate solution; prepare this solution just before use. (a) Dissolve 1 tablet of Nitro Blue Tetrazolium (NBT, Sigma N5514) in 30 mL of AP-buffer. (b) Filter solution over filter paper when tablet is dissolved. (c) Prepare BCIP (5-Bromo-4-chloro-3-indolyl phosphate p-toluidine salt, Sigma B8503) solution just before use (35 mg/mL in dimethylformamide). (d) Add 142 mL of BCIP solution to 30 mL AP buffer with NBT. Be careful: compounds are toxic: wear gloves, and prepare solutions in fume cab. 5. ELISpot blocks (made in house) and protein blot membranes (Immobilon PVDF Transfer, Millipore, Etten-Leur, Netherlands) or commercial ELISpot plates with a well surface of approximately 2 cm2.
3. Methods 3.1. Subcutane Exposure and Experimental Setup RA–PLNA
1. Acclimate female mice (5–6 weeks old at arrival) for 1 week before starting the experiment. 2. Randomize the mice into 6–8 animals per treatment group. 3. House the animals in solid-bottom cages with woodchip bedding. Provide drinking water and standard laboratory food pellets ad libitum. House the animals according to the guidelines of The Association for Assessment of Laboratory Animal Care. 4. Administer the low molecular weight compound in combination with 10 mg reporter antigen in a total of 50 mL vehicle (see Note 1). 5. Prepare at least three different doses and one vehicle as control (see Note 2). 6. Inject the compound and reporter antigen solution subcutaneously in the footpad toe-to-heel with a 1 mL syringe with a 25 G 16 mm needle. 7. Check animals daily for irritation of the paw and general health state. 8. Sacrifice the mice 7 days after the s.c. injection by cervical dislocation. 9. Wet the hind leg with 70% ethanol.
32
Ludwig et al.
10. Make an incision in the skin from the heel without cutting the tendon. 11. Tear the skin slowly from the leg until the knee joint is exposed. 12. Stretch the leg and use a forceps to isolate the PLN. 13. Place lymph nodes in a small Petri dish with RPMI supplemented with 2% fetal calf serum (FCS) on ice until further use. The PLNs can be used for immunohistology, or for the preparation of single cell suspensions to be used in functional assays. Several assays can be performed with the single cell suspensions, e.g., an Enzyme Linked Immunosorbent Spot (ELISpot) Assay (see Subheading 3.3.5) to determine the formation of RA-specific ASC, ex vivo restimulation (see Subheading 3.3.7) to detect cytokine production profile, and flow cytometry (see Subheading 3.3.6) to detect changes in cell populations or activation status of cells (4). 3.2. Oral Exposure and Experimental Setup
1. Acclimate female C3H/HeOuJ mice (5–6 weeks old upon arrival) for a week before starting the experiment.
2. Randomize the mice in 6–8 animals per treatment group and house the animals in solid-bottom cages with woodchip bedding. 3. Provide drinking water and standard laboratory food pellets ad libitum. 4. House the animals according to the guidelines of The Association for Assessment of Laboratory Animal Care. 5. Give the mice a daily dose of low molecular weight drugs for several days orally using a gavage needle (21 G, 3.4 cm long) (see Notes 1 and 3) 6. Preferably, dilute the test compound in 200 mL sterile H2O or PBS. 7. On the first day, give a low dose of reporter antigen (TNP– OVA) (10 mg/mouse) i.p. in 100 mL sterile NaCl simultaneously with the first oral dose of drugs. 8. Check the mice daily for general health state. 3.2.1. Collecting Blood
1. Collect blood one day before the first drug administration, 10 days after the first drug administration and at the final day of the experiment, before euthanizing the animals. 2. Collect blood in minicollect tubes (Greiner Bio-One, Alphen a/d Rijn, Netherlands) with serum separation gel by a puncture with an 18 G needle in the submandibular vein. This vein is localized in the cheek of the mice.
An In Vivo Tiered Approach to Test Immunosensitization by Low Molecular
33
3. Centrifuge the blood at 2,000 × g for 7 min at 4°C to obtain serum. 4. Store serum samples at −20°C until analysis. 5. Determine reporter antigen specific antibodies in the serum using a sandwich ELISA (see Subheading 3.3.4). 3.2.2. Delayed Type Hypersensitivity Response
1. On day 15 after the start of the experiment, determine the DTH response to the RA. 2. Measure ear thickness of both left and right ear of the mice with a digital microcalliper before injection. 3. Inject one ear of each mouse with a low dose of RA (10 mg TNP–OVA in 20 mL sterile NaCl). To control the effect of injection liquid in the ear, inject one ear per mouse with 20 mL sterile NaCl only as a reference. (a) Use an insulin syringe (29 G, 12 mm) because of the fine needle and small scale on the syringe. (b) Apply the needle from the top of the ear to the base. (c) Inject the 20 mL very carefully avoiding disruption of the ear. (d) All the operations are performed under isoflurane anesthetics. 4. After 24 h, determine the thickness of both ears again with the digital caliper. 5. Calculate the DTH response as the difference in ear thickness of TNP–OVA injected ear minus the difference in ear thickness of the vehicle injected ear. 6. The DTH response can also be performed in the hind foot pad (see Note 4).
3.2.3. Isolation of the Auricular Lymph Node
1. At day 21, 6 days after DTH measurement, take blood from the submandibular vein. 2. Euthanize the mice. Cervical dislocation is not preferable since this method could disrupt the structure around the auricular lymph node (ALN). 3. Moisten the neck and facial area with 70% ethanol. 4. Isolate the ALN at the side of the TNP–OVA injected ear by making a cut from the ear down the cheek. 5. Carefully remove the skin from the underlying tissue by gently tearing the skin with two forceps. The ALN is localized at the bifurcation of the jugular vein posterior of the masseter muscle. 6. Carefully remove the ALN with a pair of forceps. 7. Place lymph nodes in a small Petri dish with RPMI supplemented with 2% fetal calf serum (FCS) on ice until further isolation of cells.
34
Ludwig et al.
3.3. Preparation of Cell Suspensions
1. For the preparation of a single cell suspension, place the individual lymph nodes between two glass slides at the frosted sides and carefully crush the lymph nodes. Keep the glass slides wet with RPMI all the time. 2. Take the suspension from the dish with a syringe with an orange needle and place in a conic 4 mL tube. 3. Spin down the cell suspension at 230 × g for 10 min and resuspend in RPMI 10% FCS. 4. Count the cell numbers. 5. Dilute the cell suspensions to the desired concentration. A concentration of 10e6 cells/mL is sufficient for ELISpot.
3.4. RA-IgG1 and IgG2a ELISA for Serum Samples
1. Coat hibond 96 wells plates (costar 3590) with TNP–BSA in carbonate buffer (20 mg/mL) 100 mL/well overnight at 4°C. 2. Wash wells three times with PBS/Tween (200 mL/well). 3. Block the plates with PBS/Tween/1% BSA (150 mL/well) for 1 h at RT (see Note 5). 4. Make serial dilutions of the serum samples starting with an 8× dilution of the sample in PBS/Tween/1%BSA. 5. Prepare for the detection of IgG1 8 two-step dilutions and for IgG2a 6 two-step dilutions. Also include wells with only PBS/Tween/1%BSA as blanks to determine the background staining. 6. Add 100 mL of the sample to each well. 7. Incubate for 2 h at room temperature. 8. Wash the plates subsequently 3 times with PBS/Tween. 9. Prepare just before use alkaline–phosphatase conjugated anti mouse-IgG1 or IgG2a (goat-anti-mouse IgG1-AP (SBA 1070-04) and goat-anti-mouse IgG2a-AP (SBA 1080-04) in PBS/Tween/1%BSA. Add 100 mL of AP-conjugated antibody per well and incubate for 1 h at room temperature. 10. Wash wells three times with PBS/Tween and once with diethanolamine buffer. 11. Do not discard diethanolamine buffer in the sink but in a special vessel for halogen poor waste. 12. Add diethanolamine buffer with 1 mg/mL 4-nitrophenylphosphate (100 mL/well). 13. Incubate in the dark at room temperature until a color change is observed (about 30 min). 14. Stop substrate conversion with 50 mL 10% EDTA in bidistilled water per well. 15. Measure the optical density at 405 nm using an automated reader ELX800.
An In Vivo Tiered Approach to Test Immunosensitization by Low Molecular
35
16. Plot data as optical density per dilution or as maximal dilution at which OD is above background. 3.5. ELISPOT Assay
1. Determine the induction of RA-specific ASC by the treatment of the mice by means of ELISpot assay (5). 2. Prewet the protein blot membranes (Immobilon PVDF Transfer) with methanol in a fume cab (see Notes 6 and 7). 3. Wash the membranes with filtered PBS/Tween (22 mm). 4. Coat the membranes with TNP–BSA (10 mg/mL, 15 mL per blot) in PBS/Tween over night on a shaking table at 4°C. 5. Wash the membranes 2 times with PBS/Tween. 6. Incubate for 1 h at room temperature with PBS/Tween/1%BSA while shaking to block the membrane for a specific protein binding (see Note 8). 7. Wash membranes 2 times with PBS. 8. Place in a special holder and add PBS to the wells (see Note 9). 9. When cell suspensions are ready, discard the PBS from the wells and add 500 mL of cell suspension (500 × 10e3 cells is usually sufficient). 10. Centrifuge the blocks at 230 × g for 7 min without the brake. 11. Incubate the blocks for 4 h at 37°C, 5%CO2. 12. Discard the cells and wash the wells once with PBS. 13. Release the membranes from the holders and wash once more with PBS and twice with PBS/Tween. 14. Incubate the blots with 15 mL AP-conjugated goat anti mouse-IgG1, IgG2a or other isotype (goat-anti-mouse IgG1-AP (SBA 1070-04) and goat-anti-mouse IgG2a-AP (SBA 1080-04), 1/2,000 in PBS/Tween) over night on a shaking table at 4°C. 15. Wash the membranes 4 times with PBS/Tween and once with AP buffer. 16. Incubate the membranes with substrate solution for approximately 15 min while shaking. 17. Do not discard substrate buffer in the sink but in a special vessel for halogen poor waste. 18. Stop the color reaction by rinsing the blots for 15 min with slow running tap water. 19. Dry the membranes between filter paper for about 2 h. 20. Count the spots with a microscope. Spots appear as dark purple spots with a diffuse halo.
36
Ludwig et al.
3.6. Flow Cytometry
1. Analyze cell suspensions using flow cytometry for changes in cell subset distribution. This assay gives more clear results for RA–PLNA than for LN cells isolated from oral exposed animals. 2. Plate 150,000 cells per sample in round bottom 96 wells plates in PBS/0.05%BSA/0.1%NaN3. 3. Keep cells at 4°C all the time. 4. Incubate the cells with anti-CD3-, CD8-, and CD4fluorescence labeled mAbs for 30 min at 4°C in order to detect CD4+ (T helper) or CD8+ (cytotoxic) T cells. 5. Wash cells twice in PBS/0.05%BSA/0.1%NaN3 at 230 × g for 5 min at 4°C. Samples can be analyzed immediately or after 3 days maximum. 6. When the samples are not analyzed immediately, fix samples in 100 mL 1% formalin. 7. Detect other cell subsets, like B-cells, macrophages and dendritic cells using the appropriate antibodies.
3.7. Cell Culture
1. Analyze polarization of the T-cell response in the draining lymph node. (a) Culture them with or without a stimulus. (b) Test for IFN-g and IL-4 secretion. 2. Incubate 250,000 per well in a round bottom 96 well plate in a total of 200 mL. 3. Use RPMI with 10% FCS in this assay. 4. Use LPS (2 mg/mL), con A (5 mg/mL), or anti-CD3/antiCD28 antibodies as general stimuli. 5. Incubate cells at 37°C, 5% CO2. 6. Collect the supernatant after 3 days. 7. Store supernatants at −20°C until analysis. 8. Measure IL-4 and IFN-g production using commercially available ELISA kits.
4. Notes 1. Use in both RA–PLNA and oral exposure assay at least three different doses of low molecular weight compound. Do not use solvents that have an intrinsic effect on the immune response, and therefore always include a control group that will receive solvent and RA only.
An In Vivo Tiered Approach to Test Immunosensitization by Low Molecular
37
2. Use a separate group of animals exposed to vehicle and RA only as negative control group instead of using the contralateral popliteal lymph node (PLN) of the chemical treated mice. 3. Be careful while applying the gavage needle. Harming the esophagus or the stomach can give a false positive test result. 4. The DTH response can also be performed in the hind foot pad. (a) Apply the needle from in-between the toes to the heel. (b) The s.c. injection in the footpad is easier. However, the readout of swelling is less sensitive than in the ear. 5. PBS/Tween with 3% milk powder will also sufficiently block the wells in this assay. 6. Never touch membranes with your fingers because the membranes will also bind proteins from your skin and this can give high background; wear gloves or use pair of forceps. 7. Never leave the membranes without buffer. If membranes are dry you have to prewet them with methanol before you can continue. 8. Coated (and blocked) membranes can be stored in a refrigerator (4°C) for about 2 weeks; dry them between filter paper (for ±2 h) before storage. Before use, prewet the membranes with methanol, wash them once with PBS, and put them in special holder with PBS. 9. There are complete prefab ELISpot plates commercially available. Well surface should be around 2 cm2.
References 1. Albers R, Broeders A, van der Pijl A, Seinen W, Pieters R (1997) The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Toxicol Appl Pharmacol 143:102–109 2. Pieters R (2007) Detection of autoimmunity by pharmaceuticals. Methods 41:112–117 3. Nierkens S, Aalbers M, Bol M, van Wijk F, Hassing I, Pieters R (2005) Development of an oral exposure mouse model to predict drug-induced hypersensitivity reactions by using reporter antigens. Toxicol Sci 83: 273–281
4. Nierkens S, van Helden P, Bol M, Bleumink R, van Kooten P, Ramdien-Murli S, Boon L, Pieters R (2002) Selective requirement for CD40-CD154 in drug-induced type 1 versus type 2 responses to trinitrophenyl–ovalbumin. J Immunol 168:3747–3754 5. Schielen P, van Rodijnen W, Tekstra J, Albers R, Seinen W (1995) Quantification of natural antibody producing B cells in rats by an improved ELISPOT technique using the polyvinylidene difluoride membrane as the solid support.J Immunol Methods 188: 33–41
Chapter 4 Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing Rodney R. Dietert, Janice M. Dietert, and Jerrie Gavalchin Abstract Autoimmunity represents a potentially diverse and complex category among the range of adverse outcomes for detection with immunotoxicity testing. For this reason, the risk of autoimmune disease is discussed in this overview chapter with additional mention among the later specific protocol chapters. Improvements in clinical diagnostic capabilities and disease recognition have led to a more accurate picture of the extent of autoimmune diseases across different human populations. While the risk of any single autoimmune disease remains modest when compared with that of lung or heart disease, the cumulative prevalence of autoimmune diseases is both significant and increasing. Autoimmune diseases are usually viewed in the context of the damaged tissue or organ (e.g., as a thyroid, gastrointestinal, cardiovascular or neurological disease). But improved recognition that underlying immune dysfunction can connect the risks for these as well as other diseases is critical for optimizing risk assessment. Since autoimmune diseases are chronic in nature with many first appearing in children or in young adults, these diseases exert a serious impact on both health care costs and quality of life. This chapter provides a discussion of the issues that should be considered with immunotoxicity testing for risk of autoimmunity. Key words: Autoimmunity, Autoimmune disease, Target organ, Systemic, T cell populations, Immune dysregulation, Chronic inflammation, Microbial triggers
1. Introduction Autoimmune diseases as a group are recognized as contri buting to a significant portion of chronic diseases in humans. As discussed in a recent review by Fairweather et al. (1), autoimmune diseases affect approximately 5–8% of the popu lation in the United States (2). Included among these are approximately 100 reported or proposed conditions that are either autoimmune or chronic inflammatory in nature (3). Given their prevalence in the human population, the role of toxicants in R.R. Dietert (ed.), Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, vol. 598 DOI 10.1007/978-1-60761-401-2_4, © Humana Press, a part of Springer Science + Business Media, LLC 2010
39
40
Dietert, Dietert, and Gavalchin
risk of disease and the prominent role of immune dysfunction in mediating the diseases, detection of potential autoimmune risk has become an increasing concern in immunotoxicity testing. These diseases can take the form of either systemic conditions (e.g., systemic lupus erythematosus, SLE), or they can target individual organs or tissues (e.g., autoimmune hepatitis). Many of these diseases are most notably identified, characterized and treated based primarily on the organ or tissue that suffers from inflammatory-mediated damage. This is despite the fact that most of these diseases involve some aspect of immune dysregulation. Autoimmune diseases can strike at any age, and a majority of the diseases exhibit an age-of-onset range spanning decades of life. However, most of the diseases first appear in the young adult. Figure 4.1 illustrates a timeline with the approximate age of onset
Fig. 4.1. The timeline illustrates the approximate average age of onset for 18 different autoimmune diseases. Of the diseases listed, most have established autoimmune associations. Hidradenitis suppurativa is a chronic inflammatory condition with a suspected autoimmune basis.
Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing
41
shown for several established and/or suspected autoimmune diseases and conditions. Note that some of the autoimmune diseases exist in both juvenile and adult forms (e.g., arthritis and celiac dis ease). Additionally, for some of the diseases, males and females differ in their average age of onset. Therefore, these should only be used as approximations. The lack of prior appreciation for the underlying immune dysfunction affecting autoimmunity has been an impediment, not only to a life-long approach to immune management (4, 5), but also to optimizing detection of autoimmune risk factors during immunotoxicity testing. This has happened for several reasons. Importantly, because of the ready organ association of many of these diseases, autoimmune thyroiditis has been viewed as a thyroid–endocrine problem, autoimmune hepatitis as a liver issue, autoimmune myocarditis as a heart disorder, celiac disease as a gastrointestinal disorder, rheumatoid arthritis as a problem of vascular and connective tissues, multiple sclerosis a neurological disorder, and type 1 diabetes mellitus as a pancreas-insulin issue. However, an additional factor is that the identification and understanding of immune cell regulators of autoimmunity have only occurred recently. The identification of specialized T cell populations such as T helper (Th) 17 cells, Th3 cells, and regula tory T cells (Tregs) (e.g., CD4+CD25+Foxp3+ Tregs) has pro vided useful biomarkers for identifying immunotoxic risk for autoimmunity. As will be discussed later in this chapter, a recent trend toward improved recognition of the underlying immune dysfunction that supports autoimmune disease is critical for effective health man agement. In part, this is because the same immune dysfunction (e.g., impaired Treg function) is very likely to alter the risk for other autoimmune and non-autoimmune diseases over the course of a lifetime.
2. The Multifactorial Nature of Autoimmune Disease
Multiple factors go into determining the overall risk for autoim mune disease. Certainly genetic background, age and gender are all significant factors influencing the overall risk. The female–male partitioning of autoimmunity is discussed later in this chapter. But apart from genetic and gender-based considerations, most autoimmune diseases are also under environmental influence. In fact, a recent study across numerous strains of mice found that mercury and silver can predispose for autoantibody production regardless of whether known susceptibility genes are carried within the strain (6). The author suggested that environmental determinants may be at least as important as genetic background in
42
Dietert, Dietert, and Gavalchin
the risk of autoimmune disease. For this reason, including the capability of evaluating the risk of autoimmune disease within immunotoxicity testing is a significant issue. Numerous chemicals and drugs have been shown to be capable of elevating the risk of autoimmune disease, and this was recently reviewed by Cooper and Miller (7). Examples of environmental factors reported to increase the risk of autoimmunity in animals and/or humans are: mercury (8–10), lead (11, 12), gold (13), trichloroethylene (14), hexachlorobenzene (15, 16), ethanol (17), silica (18, 19), 2,3,7,8-tetrachlorodibenzo-p-dioxin (20), hydralazine and other demethylating agents (21), cyclosporine A (22) and cigarette smoke (23). Table 4.1 provides examples of environmen tal factors that have been reported to increase the risk of lupus or lupus-like symptoms.
Table 4.1 Examples of environmental factors associated with lupus or lupus-like symptomsa Environmental factor
References
2,3,7,8-tetrachlorodibenzo-p-dioxin
(20)
Aniline
(64)
Asbestos
(65)
Bisphenol-A
(66)
Cigarette smoke
(67)
Diethylstilbesterol
(68, 69)
Estrogen
(70)
Infectious agents
(71, 72)
Lead
(12)
Mercury
(10, 73)
Organochlorine pesticides
(74)
Polychlorinated biphenyls
(75)
Prolactin
(76)
Silica
(18, 77)
Sunlight/UVB radiation
(78)
Trichloroethylene
(79)
L-Tryptophan
(80)
From studies in rodents and/or humans. In some studies, induction of lupus-like symptoms was the endpoint measured. In other studies, acceleration of symptom onset or exacerbation of symptoms was detected in autoimmune-prone strains of mice a
Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing
43
It should be noted that some autoimmune diseases have both juvenile and adult forms, which may differ slightly in presentation (e.g., celiac disease and rheumatoid arthritis). However, even adult forms generally arise no later than middle age. As a result, these diseases are likely to require extensive and expensive health care management over decades of life. This can place considerable strain on patients and the health care community and negatively impact patients’ quality of life. Since the periods of childhood, adolescence and young adulthood are particular focal points for disease onset, they have implications for immunotoxicity assessment. It means that the windows of greatest interest for exposure to potential toxicants occur before adulthood. As a result, exposure-assessment of the non-adult can be critical in assessing the risk for autoimmunity. This is also discussed in the chapter on developmental immuno toxicity (DIT).
3. Environmental Toxicant Exposure and Skewed Host Responses to Microbes as a Problem
Microbial exposure and host response to microbes have long been recognized as important considerations in the risk of autoimmu nity. Historically, much of the focus has been on molecular mim icry in which pathogen-associated molecules that have overlapping epitopes with self molecules elicit host immune responses of a specificity that damage tissues. Suggestions for the involvement of molecular mimicry can be seen with streptococcal infections, autoimmune responses in rheumatic fever (24) and trypanosome infection with chronic Chagas disease cardiomyopathy (25). While there are many avenues to get to autoimmune disease, recent research points toward one that involves skewed host responses to microbes that may trigger autoimmunity. This is dis cussed by Rose (26) and presented as an adjuvant effect in which immune co-factors can skew a response to an infectious agent resulting in tissue pathology that facilitates autoimmunity. But it is important to recognize that from an environmental/toxicant standpoint, the adjuvant component can just as easily be embedded in the dysfunctional host immune response present after earlier environmentally induced immune insult. So, excessive proinflam matory production by immune cells could be an outcome of prior heavy metal-, alcohol-or dioxin-induced immunotoxicity that caused skewed responses to: 1) bacteria contributing to thyroiditis or 2) viruses contributing to myocarditis (27–29). In fact, Vas et al. (30) recently described a model in which low-level mercury expo sure combined with exposure to natural killer T (NKT) cells and toll-like receptor (TLR) ligands from microbes combine to facili tate a break in tolerance and elevated the risk for autoimmunity.
44
Dietert, Dietert, and Gavalchin
Thus specific microbial activation of NKT cells could enhance the risk of mercury-induced autoimmunity. This has been discussed by Cooke (31) who noted the likely importance of dysfunctional host responses to microbes as trig gers for both autoimmunity and childhood leukemia. Infections are likely to serve as triggers for many autoimmune diseases, and the underlying inappropriate or dysfunctional host response to the microbe may trigger a critical step leading to autoimmunity. For example, Mattner et al. (32) found that an accumulation of a common bacterium, Novosphingobium aromaticivorans, in the liver and subsequent responses by NKT cells could lead to auto immune liver disease. Environmental modulation of Th17 cells vs. Tregs seems to be a prominent pathway to facilitate autoimmunity. Veldhoen et al. (33) discussed the opportunity for aryl-hydrocarbon (Ah) receptor agonists like 2,3,7,8 tetrachlorodibenzo-p-dioxin to alter Th17 activity and promote autoimmunity.
4. Sex-Specific Issues in Autoimmunity and Testing
Differences among women and men in risk of disease are only now beginning to be fully appreciated (34). While many immune dysfunction-associated diseases can show some evidence of sex bias, either in prevalence of the disease or timing of onset, autoimmune diseases are in a novel category of their own when it comes to the importance of gender. The vast majority of autoimmune diseases are not equally distributed among the sexes. In fact, greater than 75% of autoimmune disease occurs in women (1, 35). While a handful of specific autoimmune diseases are either of equal risk among sexes or slightly more common in men (36, 37), overall autoimmunity is a major women’s health issue (38, 39). The importance of age and sex in autoimmunity is also supported in animal models of these diseases (40–42). There are three main hypotheses for the bases of the female bias in autoimmunity: (1) the effects of sex steroids on environment-gene-immune cell interaction (42, 43), (2) microchimerism among lymphocytes (44, 45), (3) X chromosome monosomy (46), and/or sex chro mosome complement (47). It should be noted that while X chromosome monosomy has been seen with some female-pre dominant autoimmune diseases, it was not found in a recent study with SLE (48). Whatever toxicant-hormone-chromosome-gene interactions distinguish the sexes as per risk for a specific autoimmune disease, these interactions result in detectable differences in immune capacity and host responses to challenge that are connected to the
Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing
45
increased specific disease risk (49–51). For immunotoxicity test ing, it also means that the specific testing for autoimmunity needs to use relevant immune endpoints and evaluation in both sexes.
5. The Challenge of Identifying Immunotoxic Risk Factors for Autoimmune Disease
6. Role of Autoimmune-Prone Strains in Immunotoxicity Testing?
It should be noted that detection of risk factors for specific auto immune diseases has been a difficult challenge for immunotoxic ity testing until recently. Risk assessment of pharmaceuticals for autoimmunity was recently discussed (52) as were principles for evaluating chemicals in risk of autoimmunity (37). In many cases, identification of an immunotoxicant as con tributing to risk of autoimmunity resulted as either a secondary observation of other immunotoxic endpoints (enhanced immune responses) or was from the association of a specific autoimmune disease in humans with administration of a specific drug [e.g., minocycline and autoimmune hepatitis (53, 54)]. There are several reasons why detection of xenobiotic risk fac tors for autoimmune disease has proven to be a challenge. Most surround the fact that several different xenobiotic–host interac tion mechanisms can contribute to an elevated risk of autoimmu nity. First, some xenobiotics or their metabolites may be molecular mimics of tissue antigens eventually leading to a loss of tolerance against the self-antigen. Alternatively, the xenobiotic may be complex with self components and form new antigens where no prior tolerance has been established. Finally, exposure to a xeno biotic may alter the immune cell populations increasing the risk of loss of tolerance. The example of disruption of Tregs vs. Th17 balance was previously discussed. However, the actual problem atic immune responses may not occur until the immune system receives a relevant challenge (e.g., an infection). A further prob lem is that the disease-associated reactions may only arise among certain genetic backgrounds. The genetic background can influ ence both the metabolism and distribution of the xenobiotic as well as the susceptibility of the host immune system for a prob lematic response to a specific environmental insult. Obviously, it can be difficult to ensure that a routine immunotoxicity screening strategy can account for all of these possibilities.
There are several unresolved issues in approaching immunotoxicity testing for the risk of autoimmunity. However, among the more significant is whether the necessary information needed for
46
Dietert, Dietert, and Gavalchin
hazard characterization can be obtained using conventional animal strains (also used for other toxicity testing), or whether specialized strains of rodents or other test species must be used to fully assess the risk of xenobiotic-induced autoimmunity. While numerous scientific reviews have discussed this issue and presented options, there has yet to be a definitive answer relative to safety testing (37). The issue is connected to the role of genetic background and xenobiotic-associated epigenetic effects leading to autoimmunity. Since induction of autoimmunity can involve several different mechanisms, it is likely that a single test strain of a species will not effectively model all the chemical- or drug- induced routes to autoimmunity that may be relevant for a specific test compound. In contrast, strains with spontaneously occurring autoimmunity may be pertinent for only some autoimmune outcomes and mechanisms. There, it is usually autoimmune exacerbation that can be evaluated most effectively instead of disease induction. Some F1 hybrids between autoimmune prone and control strains have been used to ensure that a genetically permissible back ground is present in the test animals but to avoid the high level of spontaneous disease occurrences present in the parental strain. While this may help the modeling of risk for a single autoimmune disease (e.g., SLE) or a category of diseases, the question still remains whether a single test strain (specialized or not) can pro vide the needed information. Examples of autoimmune-prone experimental animal models frequently used for the study of xenobiotic-promoted autoimmu nity (37, 55–57) include: the Brown Norway, Lewis and biobreeding diabetes prone (BB-DP) strains of rats, the New Zealand Black – New Zealand White F1 hybrid (NZB X NZW F1), the MRL-lpr strain and non-obese diabetic (NOD) strain of mice and the Obese strain of chickens.
7. Tiered Approach As discussed in the World Health Organization Environmental Health Criteria Report titled “Principles and Methods for Assessing Autoimmunity”(37) and in the prior section of this chapter, there are numerous animal models available for examin ing the ability of chemicals and therapeutics to either induce or to exacerbate autoimmunity. However, the reality is that these highly specialized animal models are unlikely to be used in a first tier of screening for general hazard identification and characterization. Beyond research tools, their use in immunotoxicity testing would more likely come after some initial immune-related out come was obtained using more routine test animals or alternatives
Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing
47
(e.g., in vitro tests). Of course, the concern or limitation is whether a more general test animal or cell line will have a suffi ciently permissive genetic background to model the risk for auto immune reactions that may exist across all genotypes. Among screening tools more feasible to be employed in an initial tier, there are several biomarkers or indicators of immune alterations that should cause a heightened concern for risk of autoimmunity. These are also discussed in more detail in the chapters on sensitization, the local lymph node assay (LLNA) and inflammation. Test compound-induced enhancement of endpoints measured in the LLNAs, the delayed-type hypersen sitivity (DTH) response, and the T-dependent antibody response (TDAR) should be of potential concern. Additionally, inflammation is an important component of most autoimmune conditions, and test compound-induced promotion of inflam mation is also a possible indicator for a heightened concern of autoimmunity. Finally, significant changes in T lymphocyte populations involved in regulation, tolerance maintenance and inflammation are likely to play a role in risk of autoimmune responses. Additional endpoints that could be useful within a general screening assessment would be quantitation of anti-DNA and anti-histone antibodies and measures of immune complex formation (37). These could be added to more general screening protocols. But as is discussed in the other chapters, these may be more readily observed during the course of responses following challenge (e.g., infection or immunization) of the immune system. In fact, because microbial triggers are thought to be associated with a significant incidence of human autoimmune disease, there may be benefit in using a natural infection/antigen model in more general immunotoxicity testing. Infection challenge models are more likely to facilitate the inclusion of add-on indicators of autoimmune reactions (e.g., measures of inflammatory mediators, autoantibodies and immune complexes).
8. Conclusions Risk of autoimmune disease is multifactorial and includes not only genetic background, sex and age as factors, but also exposure to immunotoxic chemicals and therapeutic agents (58). Both sexes are affected although most autoimmune diseases are predominant in females (59, 60). However, toxicant-induced promotion of autoimmune disease may itself be sex-biased. Therefore, it is important to include both females and males in any screening.
48
Dietert, Dietert, and Gavalchin
Since autoimmune diseases can be either systemic or organspecific, can be mediated by different immune-related responses and can take many forms, reliable detection of autoimmunepromoting environmental exposures is a formidable challenge. While numerous specialized animal models are available to study the environmental-autoimmune interactions, autoimmune-prone strains are unlikely to be used in more generalized safety testing screening. Therefore, biomarkers that may be useful toward the identification of autoimmune responses should be included in the more general screens. These include enhanced antibody, cellmediated and inflammatory responses as well as misregulated or misdirected inflammatory responses. Added measures of autoan tibodies (61), immune complexes and specialized T cell popula tions may be useful. But these may be best assessed using a challenged immune system including exposure to infectious agents (62, 63). The development of new tools to apply to screen ing for risk of autoimmunity is needed and should be a goal of future immunotoxicity testing. References 1. Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600–609 2. The Autoimmune Disease Coordinating Committee of the National Institutes of Health (2005) Report to Congress, March. NIH Publication No. 05–5140 3. Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepide miology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325–330 4. Dietert RD, Piepenbrink MS (2008) The man aged immune system: protecting the womb to delay the tomb. Hum Exp Toxicol 27:129–134 5. Dietert RR, Zelikoff JT (2009) Pediatric immune dysfunction and health risks following early-life immune insult. Curr Pediatr Rev 5(1):36–51 6. Abedi-Valugerdi M (2009) Mercury and silver induce B cell activation and anti-nucleolar autoantibody production in outbred mouse stocks: are environmental factors more impor tant than the susceptibility genes in connection with autoimmunity? Clin Exp Immunol 155:117–124 7. Cooper GS, Miller FW (2008) Environmental influences on autoimmunity and autoimmune disease. In: Luebke R, House R, Kimber I (eds) Immunotoxicology and immunopharmacol ogy, 3rd edn. CRC Press, Boca Raton, FL, pp 437–453
8. Silbergeld EK, Silva IA, Nyland JF (2005) Mercury and autoimmunity: implications for occupational and environmental health. Toxicol Appl Pharmacol 207:282–292 9. Havarinasab S, Bjorn E, Ekstrand J, Hultman P (2007) Dose and Hg species determine the T-helper cell activation in murine autoimmu nity. Toxicology 229:23–32 10. Pilones K, Lai ZW, Gavalchan J (2007) Prenatal HgCl(2) exposure alters fetal cell phenotypes. J Immunotoxicol 4:295–301 11. Bunn TL, Marsh JA, Dietert RR (2000) Gender differences in developmental immu notoxicity to lead in the chicken: analysis fol lowing a single early low-level exposure in ovo. J Toxicol Environ Health A 61:677–693 12. Hudson CA, Cao L, Kasten-Jolly J, Kirkwood JN, Lawrence DA (2003) Susceptibility of lupus-prone NZM mouse strains to lead exac erbation of systemic lupus erythematosus symptoms. J Toxicol Environ Health A 66: 895–918 13. Havarinasab S, Johansson U, Pollard KM, Hultman P (2007) Gold causes genetically determined autoimmune and immunostimu latory responses in mice. Clin Exp Immunol 150:179–188 14. Blossom SJ, Doss JC (2007) Trichloroethylene alters central and peripheral immune function in autoimmune-prone MRL(+/+) mice fol lowing continuous developmental and early life exposure. J Immunotoxicol 4:129–141
Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing 1 5. Cripps DH, Peters HA, Gocman A, Dogramici I (1984) Porphyria turcica due to hexachlorobenzene: a 20 to 30 year followup study on 204 patients. Br J Dermatol 111:412–422 16. Michielsen CC, van Loveren H, Vos JG (1999) The role of the immune system in hexachlo robenzene-induced toxicity. Environ Health Perspect 107:783–792 17. Vidali M, Stewart SF, Rolla R, Daly AK, Chen Y, Mottaran E, Jones DE, Leathart JB, Day CP, Albano E (2003) Genetic and epigenetic factors in autoimmune reactions toward cyto chrome P4502E1 in alcoholic liver disease. Hepatology 37:410–419 18. Brown JM, Pfau JC, Pershouse MA, Holian A (2005) Silica, apoptosis, and autoimmunity. J Immunotoxicol 1:177–187 19. Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, Nakano T, Fukuoka K, Kishimoto T, Hyodoh F, Ueki A, Nishimura Y (2007) Immunological effects of silica and asbestos. Cell Mol Immunol 4:261–268 20. Mustafa A, Holladay SD, Goff M, Witonsky SG, Kerr R, Reilly CM, Sponenberg DP, Roddick GT, Jr M (2008) An enhanced post natal autoimmune profile in 24 week-old C57BL/6 mice developmentally exposed to TCDD. Toxicol Appl Pharmacol 232:51–59 21. Zhou Y, Lu Q (2008) DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 7:376–383 22. Barendrecht MM, Tervaert JW, van Breda Vriesman PJ, Damoiseaux JG (2002) Susceptibility to cyclosporin A-induced auto immunity: strain differences in relation to auto regulatory T cells. J Autoimmun 18:39–48 23. Brix TH, Hansen PS, Kyvik KO, Hegedus L (2000) Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med 160:661–666 24. Guilherme L, Fae KC, Oshiro SE, Tanaka AC, Pomerantzeff PM, Kalil J (2007) T cell response in rheumatic fever: crossreactivity between streptococcal M protein peptides and heart tis sue proteins. Curr Protein Pept Sci 8:39–44 25. Cunha-Neto E, Bilate AM, Hyland KV, Fonseen SG, Kalil J, Museum ED, Galleries A (2006) Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39:41–54 26. Rose NR (2008) The adjuvant effect in infec tion and autoimmunity. Clin Rev Allergy Immunol 34:279–282 27. Croker BA, Lawson BR, Berger M, Rutschmann S, Berger M, Eidenschenk C,
49
Blasius AL, Moresco EM, Sovath S, Cengia L, Shultz LD, Theofilopoulos AN, Pettersson S, Beutler BA (2008) Inflammation and autoim munity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci USA 105:15028–15033 28. Rose NR (2008) Autoimmunity in coxsackie virus infection. Curr Top Microbiol Immunol 323:293–314 29. Larizza D, Calcaterra V, Martinetti M, Negini R, De Silvestri A, Cisternino M, Iannone AM, Solcia E (2006) Helicobacter pylori infection and autoimmune thyroid disease in young patients: the disadvantage of carrying the human leukocyte antigen-DRB1*0301 allele. Clin J Endocrinol Metab 91:176–179 30. Vas J, Mattner J, Richardson S, Ndonye R, Gaughan JP, Howell A, Monestier M (2008) Regulatory roles for NKT cell ligands in envi ronmentally induced autoimmunity. J Immunol 181:6779–6788 31. Cooke A (2009) Infection and autoimmunity. Blood Cells Mol Dis 42:105–107 32. Mattner J, Savage PB, Peung P, Oertelt SS, Wang V, Trivedi O, Scanlon ST, Pendem K, Teyton L, Hart J, Ridgway WM, Wicker LS, Gershwin ME, Bendelac A (2008) Liver auto immunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 3:304–315 33. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to envi ronmental toxins. Nature 453:106–109 34. Ober C, Loisel DA, Gilad Y (2008) Sexspecific genetic architecture of human disease. Nat Rev Genet 9:911–922 35. Fairweather D, Rose NR (2004) Women and autoimmune diseases. Emerg Infect Dis 10:2005–2011 36. Calin A, Brophy S, Blake D (1999) Impact of sex on inheritance of ankylosing spondylitis: a cohort study. Lancet 354:1687–1690 37. World Health Organization. Environmental Health Criteria 236 (2006) Principles and methods for assessing autoimmunity associ ated with exposure to chemicals. WHO Publications, Geneva, Switzerland 38. Gleicher N, Barad DH (2007) Gender as risk factor for autoimmune diseases. J Autoimmun 28:1–6 39. Zandman-Goddard G, Peeva E, Shoenfeld Y (2007) Gender and autoimmunity. Autoimmun Rev 6:366–372 40. Gause WC, Jackson JV, Dietert RR, Marsh JA (1985) Autoanti-thyroglobulin production in
50
Dietert, Dietert, and Gavalchin
obese chickens: influence of age and sex as measured by ELISA. Dev Comp Immunol 9:107–118 41. Sorg H, Lorch B, Jaster R, Fitzner B, Ibrahim S, Holzhueter SA, Nizze H, Vollmar B (2009) Early rise in inflammation and microcircula tory disorder determine the development of autoimmune pancreatitis in the MRL/ Mp-mouse. Am J Physiol Gastrointest Liver Physiol 295:G1274–G1280 42. Gubbels Bupp MR, Jorgensen TN, Kotzin B (2008) Identification of candidate genes that influence sex hormone-dependent disease phenotypes in mouse lupus. Genes Immun 9:47–56 43. Hughes GC, Clark EA (2007) Regulation of dendritic cells by female sex steroids: relevance to immunity and autoimmunity. Autoimmunity 40:470–481 44. Stevens AM (2006) Microchimeric cells in sys temic lupus erythematosus: targets or inno cent bystanders? Lupus 15:820–826 45. Rak JM, Maestroni L, Balandraud N, Guis S, Boudinet H, Guzian MC, Yan Z, Azzouz D, Auger I, Roudier C, Martin M, Didelot R, Roudier J, Lamber NC (2008) Transfer of the shared epitope through microchimerism in women with rheumatoid arthritis. Arthritis Rheum 60:73–80 46. Selmi C, Invernizzi P, Gershwin ME (2006) The X chromosome and systemic sclerosis. Curr Opin Rheumatol 18:601–605 47. Smith-Bouvier DL, Divekar AA, Sasidhar M, Du S, Tiwari-Woodruff SK, King JK, Arnold AP, Singh RR, Voskuhl RR (2008) A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 205:1099–1108 48. Invernuizzi P, Miozzo M, Oetelt-Prigione S, Meroni PL, Persani L, Selmi C, Battezzati PM, Zuin M, Lucchi S, Marasini B, Zeni S, Watnik M, Tabano S, Maitz S, Pasini S, Gershwin ME, Podda M (2007) X monosomy in female systemic lupus erythematosus. Ann N Y Acad Sci 1110:84–91 49. Nandula SR, Armarnath S, Molinolo A, Bandyopadhyay BC, Hall B, Goldsmith CM, Zheng C, Larsson J, Sreenath T, Chen W, Ambudkar IS, Karlsson S, Baum BJ, Kulkarni AB (2007) Female mice are more susceptible to developing inflammatory disorders due to impaired transforming growth factor beta sig naling in salivary glands. Arthritis Rheum 56:1798–1805 50. Jane-wit D, Altuntas CZ, Monti J, Johnson JM, Forsthuber TG, Tuohy VK (2008) Sexdefined T-cell responses to cardiac self deter mine differential outcomes of murine dilated cardiomyopathy. Am J Pathol 172:11–21
51. Sinha S, Kaler LT, Procter TM, Teuscher C, Vandenbark AA, Offner H (2008) IL-13mediated gender difference in susceptibility to autoimmune encephalomyelitis. J Immunol 180:2679–2685 52. Hastings KL (2006) Risk assessment in drug development: autoimmunity. J Toxicol Environ Health A 69:893–898 53. Goldstein NS, Bayati N, Silverman AL, Gordon SG (2000) Minocycline as a cause of drug-induced autoimmune hepatitis: report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 114:591–598 54. Chamberlain MC, Schwartzenberg SJ, Akin EU, Kurth MH (2006) Minocycline-induced autoimmune hepatitis with subsequent cirrho sis. J Pediatr Gastroenterol Nutr 42:232–235 55. Schuurs AH, Dietrich H, Gruber J, Wick G (1992) Effects of sex steroid analogs on spontaneous autoimmune thyroiditis in obese strain chickens. Int Arch Allergy Immunol 97: 337–344 56. Lam-Tse WK, Lernmark A, Drexhage HA (2002) Animal models of endocrine/organspecific autoimmune diseases: do they really help us to understand human autoimmunity? Springer Semin Immunopathol 24:297–321 57. Morrel L (2004) Mouse models of human autoimmune diseases: essential tools that require the proper controls. PloS Biol 2:e241 58. Cooper GS, Gilbert KM, Greidlinger EL, James JA, Pfau JC, Reinlib L, Richardson BC, Rose NR (2008) Recent advances and oppor tunities in research on lupus: environmental influences and mechanism of disease. Environ Health Perspect 116:695–702 59. Gerosa M, De Angeslis V, Roboldi P, Meroni PL (2008) Rheumatoid arthritis: a female challenge. Womens Health (Lond) 4:195–201 60. Lleo A, Battezzati PM, Selmi C, Selmi C, Gershwin ME, Podda M (2008) Is autoimmunity a matter of sex? Autoimmun Rev 7:626–630 61. Rose NR (2008) Predictors of autoimmune dis ease: autoantibodies and beyond. Autoimmunity 41:419–428 62. Plot L, Amiltal H (2009) Infectious associa tions of Celiac disease. Autoimmun Rev 8(4):316–319 63. Ercolini AM, Miller SD (2009) The role of infections in autoimmune disease. Clin Exp Immunol 155:1–15 64. Tabuenca JM (1981) Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 2:567–568 65. Noonan CW, Pfau JC, Larson TC, Spence MR (2006) Nested case-control study of autoimmune disease in an asbestos-exposed population. Environ Health Perspect 114:1243–1247
Risk of Autoimmune Disease: Challenges for Immunotoxicity Testing 66. Yurino H, Ishikawa S, Sato T, Akadegawa K, Ito T, Ueha S, Inadera H, Matsushima K (2004) Endocrine disruptors (environmental estrogens) enhance autoantibody production by B1 cells. Toxicol Sci 81:139–147 67. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, Karlson EW (2004) Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 50:849–857 68. Burke L, Segall-Blank M, Lorenzo C, Dynesius-Trentham R, Trentham D, Mortola JF (2001) Altered immune response in adult women exposed to diethylstilbestrol in utero. Am J Gynecol 185:78–81 69. Fenaux JB, Gogal RM Jr, Lindsay D, Hardy C, Ward DL, Saunders G, Ahmed SA (2005) Altered splenocyte function in aged C57BL/6 mice prenatally exposed to diethylstilbestrol. J Immunotoxicol 2:221–229 70. Grimaldi CM (2006) Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr Opin Rhematol 18:456–461 71. Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA (2009) Aberrant Epstein-Barr viral infection in sys temic lupus erythematosus. Autoimmun Rev 8:337–342 72. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A (2008) Human par vovirus B19 infection and autoimmunity. Autoimmun Rev 8:116–120 73. Vas J, Monestier M (2008) Immunology of mercury. Ann N Y Acad Sci 1143:240–267
51
74. Wang F, Roberts SM, Butfiloski EJ, Morel L, Sobel ES (2007) Acceleration of autoimmu nity by organochlorine pesticides: a compari son of splenic B-cell effects of chlordecone and estradiol in (NZBxNZW)F1 mice. Toxicol Sci 99:141–152 75. Tsai PC, Ko YC, Huang W, Liu HS, Guo YL (2007) Increased liver and lupus mortalities in 24-year follow-up of the Taiwanese people highly exposed to polychlorinated biphenyls and dibenzofurans. Sci Total Environ 374:216–222 76. Jara LJ, Benitez G, Medina G (2008) Prolactin, dendritic cells, and systemic lupus erythema tosus. Autoimmun Rev 7:251–255 77. Parks CG, Cooper GS, Nylander-French LA et al (2002) Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 46:1840–1850 78. Menke J, Hsu MY, Byrne KT, Lucas JA, Rabacal WA, Croker BP, Zong XH, Stanley ER, Kelley VR (2008) Sunlight triggers cuta neous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice. J Immunol 181:7367–7379 79. Cai P, König R, Boor PJ, Kondraganti S, Kaphalia BS, Khan MF, Ansari GA (2008) Chronic exposure to trichloroethylene causes early onset of SLE-like disease in female MRL +/+ mice. Toxicol Appl Pharmacol 228:68–75 80. Eidson M, Philen RM, Sewell CM, Voorhees R, Kilbourne EM (1990) L-Tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 335:645–648
Chapter 5 Markers of Inflammation Dori R. Germolec, Rachel P. Frawley, and Ellen Evans Abstract Inflammation is a complex and necessary component of an organism’s response to biological, chemical or physical stimuli. In the acute phase, cells of the immune system migrate to the site of injury in a care fully orchestrated sequence of events that is mediated by cytokines and acute phase proteins. Depending upon the degree of injury, this acute phase may be sufficient to resolve the damage and initiate healing. Persistent inflammation as a result of prolonged exposure to stimulus or an inappropriate reaction to self molecules can lead to the chronic phase, in which tissue damage and fibrosis can occur. Chronic inflam mation is reported to contribute to numerous diseases including allergy, arthritis, asthma, atherosclerosis, autoimmune diseases, diabetes, and cancer, and to conditions of aging. Hematology and clinical chemis try data from standard toxicology studies can provide an initial indication of the presence and sometimes location of inflammation in the absence of specific data on the immune tissues. These data may suggest more specific immune function assays are necessary to determine the existence or mechanism(s) of immunomodulation. Although changes in hematology dynamics, acute phase proteins, complement factors and cytokines are common to virtually all inflammatory conditions and can be measured by a variety of techniques, individual biomarkers have yet to be strongly associated with specific pathologic events. The specific profile in a given inflammatory condition is dependent upon species, mechanisms, severity, chronicity, and capacity of the immune system to respond and adapt. Key words: Acute phase proteins, Basophil, Chemokine, Clinical pathology, Complement, Cytokine, Eosinophil, Hematology, Inflammation, Lymphocyte, Macrophage, Monocyte, Neutrophil, Platelet
1. Introduction Inflammation is a complex and necessary component of an organism’s response to biological, chemical or physical stimuli. In the acute phase, leukocytes, primarily granulocytes, migrate along a chemo tactic gradient to the site of injury in a carefully orchestrated effort that is mediated by cytokines and acute phase proteins (APPs) to remove the stimulus (e.g., infectious agent, foreign material) or cells damaged by injury and to initiate healing. Depending upon R.R. Dietert (ed.), Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, vol. 598 DOI 10.1007/978-1-60761-401-2_5, © Humana Press, a part of Springer Science + Business Media, LLC 2010
53
54
Germolec, Frawley, and Evans
the degree of injury, this acute cellular phase may be sufficient to resolve any damage. Persistent inflammation as a result of prolonged exposure to stimulus or an inappropriate reaction to self molecules can lead to the chronic phase in which the active immune cell pop ulations shift to include a mononuclear phenotype, and tissue dam age and fibrosis can occur. Chronic inflammation is reported to contribute to numerous diseases including allergy, arthritis, asthma, atherosclerosis, autoimmune diseases, diabetes, and cancer, and to conditions of aging. The inflammatory process involves multiple physiological systems with the immune system playing a central role (1–3). Detailed information on the specific cells, cell surface molecules and soluble mediators of the inflammatory response is beyond the scope of this overview, and the reader is referred to chapters which cover specific aspects of the immune response or topic-specific reviews cited below for additional details.
2. General Considerations from Standard Toxicology Studies
Hematology data (including erythrocyte parameters, platelet count, total number of leukocytes, and leukocyte differentials and morphology), coagulation (clotting times, fibrinogen) and clini cal chemistry data (total protein, albumin and globulin, liver enzymes, renal parameters, electrolytes, bilirubin) are included in standard toxicology studies. These clinical pathology data can provide an initial indication of the presence and sometimes loca tion of inflammation in the absence of specific data on immune tissues. When possible, pretest samples should be collected for nonrodent studies so that the experimental data can be inter preted in comparison to a baseline; for all species, data should be compared with age-matched concurrent and historical controls. Hematology and serum chemistry may provide information on both innate and acquired immunity, and in addition to basic infor mation on immune cells, these endpoints provide baseline informa tion on other organ systems that may affect or be affected by the immune system. For example, changes in erythrocyte parameters or leukocyte counts may indicate altered bone marrow function and the potential for decreased production of immune cells or precur sors, and decreases in globulins may signal decreased antibody syn thesis, particularly if the albumin/globulin ratio is increased. Increased fibrinogen may suggest an inflammatory process, even in the absence of an inflammatory leukogram. It is important that these data be considered along with other available information such as clinical observations and histological changes when avail able, and to attempt to distinguish those changes that represent direct effects of a chemical agent on the immune system (such as a shift in leukocyte populations as a result of destruction of bone
Markers of Inflammation
55
marrow progenitors or lymphocytes) from those that may be a secondary consequence of immune system perturbation (such as a shift in leukocyte populations as a result of infection). The clinical pathology data may suggest more specific immune function assays that are necessary to determine the existence or mechanism(s) of immunomodulation. However, these data alone are not always reliable predictors of immunotoxicity; for example, circulating leukocyte numbers may be within normal values even when there are extreme changes in immune function, such as those observed in chronic, well established infection and in some children with primary immunodeficiencies. Conversely, effects on leukocyte trafficking unrelated to the immune system may affect circulating numbers of individual white blood cell types. 2.1. Cells of the Inflammatory Response
In the acute phase of inflammation, platelets and granulocytic cells such as basophils/mast cells, neutrophils and eosinophils are activated and in turn produce and release a number of soluble mediators that stimulate and regulate the inflammatory response.
2.1.1. Neutrophils
Neutrophils, which are sometimes referred to as polymorphonu clear neutrophils (PMNs), are the primary cellular mediators of the acute inflammatory response. Their granules contain a variety of enzymes, peptides, and proteins and also undergo a respiratory burst. The intent of their armamentarium is to destroy and digest organisms and foreign material following phagocytosis, but gran ule contents may also be released and damage tissues at the inflam matory site. Measurement of some neutrophil products, notably myeloperoxidase, may be used to assess severity of inflammation (4). Vasodilation and increased vascular permeability following basophil/mast cell degranulation, complement activation, or release of prostaglandins and leukotrienes allows neutrophils to migrate from the blood to the site of injury, and this mobilization usually results in an increase of circulating neutrophils (Fig. 5.1). However, there are numerous causes of increased numbers of circulating neutrophils (neutrophilia), and some of these may not directly relate to immune status, which underscores the need to integrate all of the data from a toxicology study rather than assessing individual components separately. Two examples of neutrophil trafficking effects that are not directly immune systemrelated include excitement and stress: excitement with epineph rine release results in demargination and an increased mobilization of neutrophils from bone marrow storage pools; stress and its resultant corticosteroid release results in increased release from bone marrow and decreased migration to tissues. In both cases, an increase in circulating mature neutrophils is seen. In contrast, neutrophilia as a consequence of inflammation is typically characterized by a shift toward immature cell types
56
Germolec, Frawley, and Evans
Fig. 5.1 Mediators in the process of inflammation. This figure summarizes the roles of the various mediators important in the process of inflammation from the acute to chronic phase. PGE prostaglandin E, VIP vasoactive intestinal polypeptide, LTB leukotriene B, LTD leukotriene D, PAF platelet activating factor, IFN interferon, IL interleukin.
(called a “left shift”) with increased numbers of bands or earlier neutrophil stages (myelocytes, promyelocytes, ring forms in rodents) as the bone marrow depletes its reserve of mature neu trophils to meet the demand. It should be noted that immature forms are less likely to be seen in chronic, established infections. Specific morphologic changes such as Döhle bodies, basophilia, toxic granulation or vacuolation (known collectively as “toxic change”) may be seen in any situation of accelerated myelopoiesis in the bone marrow. The term “toxic change” is somewhat of a misnomer in that “toxicity” (either from a drug, chemical, or bac terial toxin) is not necessary to bring about these morphologic changes. 2.1.2. Basophils
Basophils and mast cells contain cytoplasmic granules that serve as reservoirs for soluble mediators that function in many aspects of the inflammatory response. Early phase reactants released from mast cells such as histamine and serotonin, and prostaglandin and leukotriene products of arachidonic acid metabolism mediate the vasodilation and increased vascular permeability characteristic of the acute vascular response. The secretion of platelet activating factor (PAF) by mast cells also increases vascular permeability and stimulates the release of inflammatory mediators from platelets and the activation of neutrophils. Enzymes such as B-glucoronidase, amylosidase and chymase released from mast cells play significant roles in tissue damage and repair. While basophil counts are routinely included in leukocyte differentials, their low numbers (<1% of the total leukocytes in
Markers of Inflammation
57
health) make them the most difficult of the leukocytes to enumerate accurately by manual differential. Unfortunately, the determina tion of basophil counts by automated differential instruments is challenging as well. The size and staining characteristics of baso phils make them difficult for instruments to categorize them, and basophils may overlap with other cell types. It has been dem onstrated that automated instruments tend to underestimate the counts during true basophilia (5). Furthermore, increases in baso phils are rarely significant enough to appreciably affect the total leukocyte count. Manually scanning peripheral blood smears may be useful to identify cases in which the instrument underestimates basophil numbers. It has been suggested that circulating numbers of basophils may be reduced in conditions of chronic inflamma tion due to active recruitment of the cells to the site of injury (6). However, since reference intervals for basophils generally start at 0 cells/mL, basopenia is usually not a practical entity for diagnos tic purposes. 2.1.3. Eosinophils
Eosinophils predominate in inflammatory sites associated with hypersensitivity responses and clearance of parasitic infections. Eosinophils are recruited to the site of inflammation by a number of factors including interleukin (IL)-5, IL-2, IL-16, histamine, neutrophil peptides and some complement proteins. Activation of eosinophils results in the release of eosinophil peroxidase, major basic protein (MBP), eosinophil-derived neurotoxin and eosinophil cationic proteins (ECP). In respiratory hypersensitivity responses, these mediators induce rapid vasoconstriction followed by increased vascular permeability and pulmonary edema. MBP and ECP are highly basic proteins that degrade nearby cells such as the tracheal epithelium. Automated hematology analyzers may vary in ability to accurately identify eosinophils across species due to variability in granulation. However, changes in eosinophil numbers are easy to identify in manual leukocyte differentials, as their cytoplasmic granules have a high affinity for acidic dyes that result in a characteristic pink/red staining. In certain allergic con ditions such as asthma and rhinitis, the numbers of circulating eosinophils may be correlated to disease severity (7). However, eosinophilic inflammatory responses may not always result in increased numbers in peripheral blood (8). MBP and ECP are becoming important clinical markers for eosinophil activation and allergic disease, and can be evaluated in serum, sputum and pulmonary lavage fluid.
2.1.4. Platelets
Platelets are anucleate circulating cell fragments consisting of membrane-bound cytoplasm derived from megakaryocytes, which in turn are derived from the common myeloid progenitor cells in the bone marrow. They are rapidly deployed to sites of vascular compromise, injury and infection and are locally activated.
58
Germolec, Frawley, and Evans
Although they are highly differentiated for hemostasis, platelets also have inflammatory and antimicrobial functions, linking clotting and immune events (9). Platelets release reactive oxygen species, which may contrib ute to tissue damage, and mediators such as heparin and sero tonin, which promote the acute vascular response. However, the primary function of platelets is to facilitate clot formation and prevent leakage from damaged blood vessels. Platelets work in concert with APPs of the coagulation system such as fibrinogen and vitronectin at sites of vascular damage. While peripheral blood platelet counts and morphology may be affected by or part of inflammatory processes, assessment of platelet parameters alone is not helpful in identifying inflammation. A number of therapeutic agents (e.g., procainamide, sulfame thoxaxole, gold salts) can induce immune-mediated thrombo cytopenias and/or aplastic anemias that may result in reduced platelet counts. Immune-mediated thrombocytopenias are gener ally regenerative in nature. That is, mean platelet volume (MPV) is increased and large platelets are noted on blood smears, indicating accelerated release of platelets by megakaryocytes, and megakaryocytes in bone marrow are increased in number. However, if the target of toxicity or an immune-mediated process is an earlier progenitor cell, MPV’s may be normal and mega karyocytes reduced in number. Thrombocytosis (an increased number of platelets in periph eral blood) may be manifested during hemorrhage, acute inflam mation or infections, or develop as a secondary result of some chronic inflammatory conditions such as rheumatoid arthritis, or during liver regeneration following hepatotoxicity or hepatec tomy (10). It has also been suggested that the increased cardio vascular mortality associated with high levels of air pollution may be linked to toxicant-induced thrombocytosis that initiates embo lism formation (11). 2.1.5. Lymphocytes
Lymphocytic infiltration is often a prominent feature in chronic inflammation. Lymphocytes may act as specific effectors of cyto toxicity, or they may secrete antibodies or cytokines that partici pate in tissue damage or inflammatory cell recruitment. Lymphocytes can also participate in nonspecific inflammatory reactions, recruited as a consequence of elevated cytokine and adhesion molecule levels. However, lymphocyte responses, both systemic and local, may have no impact on the numbers of circu lating total lymphocytes or subsets. Conversely, changes in the numbers of circulating lymphocytes are not necessarily reflective of immune stimulation or inflammation and may be the result of physiologic responses mediated by epinephrine (lymphocytosis likely due to diminished homing to peripheral lymphoid tissue), changes in cytokine secretion, or modulation of lymphocyte homing
Markers of Inflammation
59
and trafficking, such as occurs in stress responses mediated by corticosteroids (lymphopenia due to increased homing to lymphoid tissues or lysis). Peripheral blood lymphocytosis is seen with lymphocytic neoplasia and occasionally occurs with chronic infections (e.g., Rickettsial diseases, fungal infections, etc.) or other chronic antigenic stimulation. For most species, peripheral blood lymphocytosis is not a typical component of the inflammatory leukogram; lymphocytes tend to be more concentrated in lymph nodes or sites of inflammation. In fact, stress-induced lym phopenia is a more typical component of inflammation. However, lymphocytosis is not uncommon in inflammatory responses of rats. In inflammatory conditions or chronic antigenic stimu lation, morphologically reactive lymphocytes may be seen in peripheral blood. 2.1.6. Macrophages
Macrophages tend to accumulate at the site of injury following lymphocytic infiltration and may also be the primary response to chronic diseases such as mycobacterial infections. They serve as antigen presenting cells (APCs) and help drive and perpetuate the immune response, releasing a variety of inflammatory cytok ines and cytokines that stimulate lymphocytes. However, they play a predominant role in the regulation and resolution of the inflammatory response. The lysozomal enzymes contained within the macrophage break down inflammatory mediators and participate in the phago cytic degradation of foreign materials. In addition to resident macrophages in such tissues as lung and liver, which are capable of reproducing, macrophages may be recruited to inflammatory sites from the bone marrow as monocytes, which then continue to differentiate into macrophages (Fig. 5.1). Monocytes and macrophages play a major role in the removal of dead or abnormal cells, and thus, increased numbers of these cells may be indicative of inflammation or tissue necrosis. Macrophages are only rarely seen in peripheral blood, but mono cytes on their way to inflammatory sites may appear activated. Increases of monocytes in peripheral blood can occur with both acute and chronic inflammation. Monocytosis may also be seen as part of a corticosteroid-mediated stress response, but this is a less consistent finding than lymphopenia.
2.1.7. Red Blood Cells
While not considered mediators or primary participants in inflam mation, red blood cells can be affected by and reflective of inflam matory processes. Red blood cells are very susceptible to immune-mediated and other processes that accelerate red blood cell destruction. The immune-mediated process and potentially the red blood cell destruction itself may trigger an inflamma tory response. Therefore, inflammatory leukograms are very
60
Germolec, Frawley, and Evans
c ommon in immune-mediated anemias and are sometimes seen in other hemolytic anemias. Hemolytic anemias are typically very regenerative in nature, as indicated by increased reticulocytes, polychromasia and anisocytosis. Inflammation can also cause red blood cell loss if significant hemorrhage occurs, either as part of the inflammatory process or if disseminated intravascular coagulation (DIC) is a sequela of the inflammation. This anemia may or may not appear regenerative, depending upon whether or not the bone marrow has had time (usually 2–5 days) to respond. The most common red blood cell finding with inflammation is a nonregenerative, mild-to-moderate decrease in red blood cells termed “anemia of chronic disease (ACD)” or sometimes “ane mia of inflammatory disease.” Multiple inflammatory cytokines are involved in the pathogenesis of ACD (12). The major purpose of ACD seems to be limiting iron availability, which is beneficial in inflammation by reducing the potential for oxidation and free radical formation and limiting iron-dependent bacterial growth. The cytokines thought to play a role in ACD include IL-1b and Tumor Necrosis Factor (TNF)-a, which cause reduction of eryth ropoietin release by the kidneys. TNF-a is also thought to enhance erythrophagocytosis by macrophages and, along with IL-1b and interferon (IFN)-g, it directly decreases erythroid progenitor pro liferation. In addition, IL-6 increases hepcidin production by the liver. Hepcidin in turn inhibits ferroportin-mediated release of iron stores from macrophages and absorption of iron into circula tion from the intestine, resulting in diminished erythropoiesis due to the lack of iron availability (13, 14). Because ACD can mimic iron deficiency anemias, serum ferritin may be measured. With iron deficiency, serum ferritin (a protein involved in the storage of iron and considered an APP) concentration is typically decreased. In ACD, serum ferritin concentration is normal or increased. 2.1.8. Summary of Inflammatory Cell Evaluation
In summary, the classic peripheral blood hematology profile that suggests inflammation is dominated by neutrophilia or neutrope nia with a left shift, and monocytosis is frequently present (15). Decreases in lymphocytes are a common finding in inflammation in nonrodent species primarily due to secondary stress, but lym phocytosis is frequently seen in rodents. In addition, a nonregen erative, mild-to-moderate decrease in red blood cell parameters may be seen. Serum chemistry information such as increased globulins due to increased immunoglobulin and/or APPs (dis cussed in greater detail in Section 2.3.4), or coagulation informa tion such as fibrinogen may provide additional evidence of the presence of inflammation. The hematology profile represents a snapshot of a very dynamic process, therefore, the classic profile is not always seen. The specific profile in a given situation is dependent
Markers of Inflammation
61
upon the species, mechanisms, severity, chronicity, and capacity of the immune system to respond and adapt. 2.2. Cell Surface Receptors and Adhesion Molecules
Adhesion molecules control the interactions between leukocytes and endothelial cells during the inflammatory response. These cell-to-cell interactions are the result of a cascade of events stimu lated by the upregulation of cell surface ligands early in inflamma tion. Once inflammatory cells have arrived at the site of injury, further interactions with the endothelium, other parenchymal cells, immune cells and extracellular matrix proteins perpetuate the response leading to resolution or chronic inflammation. Several families of adhesion molecules participate in this cascade of events including the integrins, selectins, vascular addressins and lymphocyte homing receptors (16, 17).
2.2.1. Selectins
Selectins are cell surface molecules that are expressed on leuko cytes (L-selectin), endothelial cells (P-selectin, E-selectin) and platelets (P-selectin). L-selectin initiates the interaction between leukocytes and endothelial cells via binding to mucin-like mole cules called addressins on the vascular endothelium and functions as a homing receptor for lymphocytes. P-selectin is localized to membrane-bound granules in endothelial cells and alpha granules in platelets and is rapidly expressed following mast cell degranula tion. P-selectin facilitates the interactions between PMNs, plate lets and endothelial cells and is important in both clot formation and degradation. E-selectin expression promotes the adhesion of PMNs and is upregulated in the acute phase of the inflammatory response by cytokines and bacterial cell wall products such as lipopolysaccharide (LPS). Expression of selectins on cells changes as the acute phase resolves or progresses into chronic inflammation and can be quan titated using antibody-based labeling techniques for immunohis tochemistry, flow cytometry or microscopy. Soluble forms of the selectins are present in serum and can be measured via ELISA or other immunoassays.
2.2.2. Integrins
The integrins are a widely expressed family of molecules that mediate cell–cell interaction and interactions between cells and the extracellular matrix. Integrins contain an extracellular domain that engages other cell adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1) or adhesive ligands such as fibrin ogen and LPS, and a cytoplasmic domain that interacts with intracellular proteins. The leukocyte integrin lymphocyte func tion-associated antigen-1 (LFA-1) binds to ICAM-1 on endothe lial cells and directs lymphocytes to target tissues during inflammation and promotes cell–cell interactions during Natural Killer cell (NK)- or Cytotoxic T Lymphocyte (CTL)-mediated cytotoxicity. Similarly, Mac-1 binding is important in the adherence
62
Germolec, Frawley, and Evans
of monocytes to endothelial cells and also serves as a complement receptor to enhance the phagocytosis of opsonized cells or bacteria. Very late antigens of activation (VLA) are integrins that function during inflammation to bind immune cells to extracel lular matrix proteins such as fibronectin, collagen and laminin and to attract nonimmune cells such as fibroblasts and endothelial cells. Inflammatory cytokines upregulate the expression of cell adhesion molecules that serve as ligands for the integrins ICAM1, ICAM-2 and vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells in a coordinated fashion, so inflammatory cells can be selectively recruited during the various phases of the inflammatory response. As discussed for the selectins above, expression of integrins and their ligands can be quantitated using antibody-based techniques for immunohistochemistry, flow cytometry or microscopy. In addi tion, there are a number of antibody- and ligand-based functional assays that have been used as research tools to assess integrin medi ated cell signaling and the efficiency of cell adhesion (18). 2.3. Soluble Mediators of the Inflammatory Response 2.3.1. Cytokines
Cytokines exhibit a number of general biological effects that are important to understand when considering their utility as markers of inflammation. A single cytokine may affect a number of different cell types or targets and may have both autocrine and paracrine effects. Cytokines also exhibit multiple effects on different cell types, often with synergistic or opposing results. This frequently means that cytokines act as molecular messengers to coordinate the interplay between, and control of, different component cell types in the immune response – an action that is of great importance in the amplification of immune and inflammatory responses. During innate immune responses cytokines are primarily secreted by phagocytic cells and NK cells, but in adaptive immune responses they are mainly produced by APCs and lymphocytes. Although often described separately, crosstalk between the innate and adaptive immune systems is frequent, and cytokines represent a major means of communication between the various arms of the immune system. The balance between production of an effec tive immune response and tissue damage depends on careful regulation of the cytokine network. The short half-life of cytokines suggests that under normal conditions most of these soluble mediators are rapidly eliminated thereby ensuring their limited bioactivity. However, during acute and/or chronic inflammatory conditions, cytokines may be released in sufficient quantity that systemic effects are observed, and toxicants that act on either the mediators themselves or the cells that produce these mediators may alter the mechanisms that regulate cytokine production leading to inflammation and disease.
Markers of Inflammation
63
This section provides general information on the cytokines that contribute to inflammatory processes. For a more detailed discus sion of the production and function of the various cytokines the reader should consult Chapter 20. Many cytokines and chemokines (see below) contribute to inflammation; some facilitate leukocyte chemotaxis to the site of injury, while others modulate immune cell function (Table 5.1). The cytokines that are best known for stimulating and perpetuat ing inflammatory responses are IL-6, IL-1, IL-2, TNF-a, IFN-g, and transforming growth factor (TGF)-b. 1. IL-6 was originally identified as a B-cell differentiation factor, and increased levels of this cytokine have been associated with polyclonal B cell activation and chronic inflammation. In the initial phases of acute inflammation, IL-6 mediates the acute phase response. IL-6 levels remain high in chronic inflammatory processes leading to enhanced survival and growth of lymphocytes and macrophages that perpetuate inflammation. 2. IL-1 has a number of direct and indirect activities that pro mote inflammation including the stimulation of the produc tion of other cytokines and the release of prostaglandins. These promote the generation of cytotoxic effector cells and synergize with colony stimulating factors to increase the pro duction of inflammatory cells in the bone marrow. 3. IL-2 augments NK cell activity, stimulates the production of inflammatory cytokines such as IL-1 and IFN-g and enhances macrophage cytotoxicity. It also contributes to chronic inflam mation by stimulating the proliferation of antigen specific T- and B-lymphocytes. 4. TNF-a enhances inflammation and is important in the pro cess of removing dead and dying cells through apoptosis. TNF-a has been shown to upregulate the expression of Class I and II major histocompatibility complex (MHC) molecules on certain cell types resulting in cell activation and cytokine release. 5. IFN-g is a potent activator of macrophages. It stimulates the production of IL-1 and TNF-a and enhances the expression of Class II MHC molecules on immune cells and vascular endothelium. The latter is of particular importance in allow ing inflammatory cells to move through the vasculature into tissues or a site of injury. 6. TGF-b is important in the regulation of tissue repair and regeneration following injury. It is produced by a number of immune and nonimmune cell types and is important in the regulation of the inflammatory response by inhibiting the production of proinflammatory cytokines such as IL-2, IFN-g
Table 5.1 Cytokines and chemokines important in inflammation Mediator
Source
Function
Cytokines Interleukin-1 (IL-1)
Macrophages, dendritic cells, Activates T and B lymphocytes T and B cells Increases production of other cytokines and acute phase proteins Induces adhesion molecules
Interleukin-2 (IL-2)
Activated T cells, B cells
Growth and activation of T and B cells Growth and activation of NK cells and macrophages Induces production of proinflammatory cytokines
Interleukin-6 (IL-6)
Macrophages, dendritic cells, Multiple effects on T cells B cells, activated T cells Myeloid cell development Regulation of acute phase proteins
Interferon gamma (IFN-g)
T cells, NK cells, epithelial cells, fibroblasts
Increases MHC expression Enhances CTL, NK and macrophage activity Stimulates production of IL-1 and TNF-a
Transforming growth factor Macrophages, megakaryo beta (TGF-b) cytes, chondrocytes
Inhibits cytokine production and activity Inhibits B cell proliferation Stimulates wound healing
Tumor necrosis factor alpha Macrophages, dendritic cells, Increases MHC expression (TNF-a) lymphocytes, mast cells Activates macrophages Enhances tumor cell killing Chemokines Macrophage Endothelial cells, epithelial chemoattractant protein-1 cells, fibroblasts, (MCP-1) (CC family) monocytes
Attracts monocytes Activates macrophages and T cells Stimulates histamine release
RANTES (CC family)
T cells, endothelial cells, platelets
Attracts macrophages
Gro (a, b, g MSGA) (CXC family)
Macrophages, fibroblasts
Attracts PMNs, angiogenesis
Interleukin-8 (IL-8) (CXC family)
Macrophages, lymphocytes
Mobilizes PMNs from bone marrow
Fractalkine (CX3C family)
Endothelial cells, microglia macrophages
Attracts T cells, monocytes and PMNs in the brain
Markers of Inflammation
65
and TNF-a. TGF-b is released by platelets following tissue injury. It plays an essential role in wound healing by attracting inflammatory cells, inducing angiogenesis and enhancing the deposition of proteins that make up the extracellular matrix. 2.3.2. Nuclear Factor-kB
2.3.3. Chemokines
The relative importance of any individual soluble mediator in a specific inflammatory condition varies. Because cytokines operate in cascades and networks, target cells may be influenced by mul tiple cytokines. While these molecules regulate production of APPs and other inflammatory mediators, they in turn may be modulated by transcription factors such as Nuclear Factor-kB (NF-kB) (19, 20). NF-kB, which has been called a “master tran scriptional switch in inflammation,” regulates dozens of targets involved in inflammation and other biochemical processes, and changes in NF-kB expression have also been used as a biomarker of inflammation (21). Inflammatory chemokines control the recruitment of effector leukocytes in infection, inflammation, tissue injury and tumors. As part of the inflammatory process, chemokines direct cellular migration, activate macrophages and PMNs, and modulate wound healing through their effects on angiogenesis and the generation of fibrosis (16). Cell migration often occurs along chemokine gradients and changes in chemokine receptor levels on leukocytes and endothelial cells regulate localization of leukocytes to sites of inflammation (22). Chemokines are defined based on their amino acid composi tion, specifically on the presence of a conserved tetra-cysteine motif, and not by their function as chemotactic cytokines. The relative position of the first two consensus cysteines (either sepa rated by a nonconserved amino acid or next to each other) provides the basis for division of chemokines into the two major subclasses, CXC and CC chemokines, respectively (23). (a) In general, CC chemokines serve as chemoattractants for monocytes (RANTES, monocyte chemoattractant proteins (MCP) 1–5), eosinophils (eotaxins 1–3), basophils (MCP 4–5) and lymphocytes (Macrophage inflammatory protein (MIP)-1a and b). (b) Members of the CXC family, which includes IL-8, Platelet factor 4 and Gro a and b, attract PMNs and modulate angio genesis and wound healing. Several homologous molecules are also regarded as chemok ines and fall into two additional subclasses. These are typified by CX3C (Fractalkine or neurotaxin), which has three intervening amino acids between the first cysteines, and XCL1 and XCL2 from the C family of chemokines, which have only a single terminal cysteine.
66
Germolec, Frawley, and Evans
Chemokines also induce astrocytic migration and microglial cell proliferation, which promote the transmission of nociceptive pain signals that serve as a warning sign in response to acute tissue damage (24). Chemokines share receptors with other chemo tactic molecules such as PAF, C5a (see below) and Leukotriene B4. Activated effector or memory T cells are the source of mul tiple inflammatory chemokines and, by sustaining effector T cell and macrophage recruitment, inflammatory chemokines control the local production of proinflammatory cytokines (25). Thus, locally produced chemokines influence disease progression and pathogenesis. Increased levels of chemokines have been associated with a number of chronic inflammatory diseases including atherosclero sis and glomerulonephritis. Numerous tools are available for eval uating the role and function of chemokines and their receptors in inflammation and disease. As indicated above, for many localized mediators a frequently used method to define the composition of inflammatory infiltrates is immunohistochemical staining of relevant tissue sections. There are a number of monoclonal antibodies available for the characterization and measurement of chemokines and their receptors. In addition, chemokine function can be measured in cell-based assays that assess the migration of cells across filters or membranes in response to chemoattractants (26). 2.3.4. Acute Phase Proteins
The APPs, notably C-reactive protein (CRP), complement fac tors, and the coagulation factor fibrinogen, are considered classi cal biomarkers of inflammation. Other APPs involved in inflammation include amyloid A, ceruloplasmin, haptoglobin, and alpha 2-macroglobulin. These proteins are regulated in response to inflammatory signals and change rapidly as the condi tion changes, making them good markers of inflammation. APPs are produced primarily by hepatocytes in response to cytokine signals from the site of inflammation. They alter homeostasis and initiate or support defensive or adaptive processes that contribute to healing in the short term, but can lead to chronic inflammation, metabolic disturbances and tissue damage with prolonged stimula tion. Traditionally, these proteins are measured directly in plasma or serum and are used clinically to evaluate the presence, intensity and course of an inflammatory process or disease. For individual APPs, basal levels and the degree of participation in the acute phase response varies across species, so the most relevant marker for one species may not have relevance in another (27, 28). In addition, some available assays are species-specific and reagents may not be available for a given APP in the species of interest. To increase sensitivity, it is best to determine the most appropriate APP for the species in question, or to assess a panel of APPs.
Markers of Inflammation
67
(a) C-Reactive Protein The most sensitive and commonly recognized diagnostic tool for the acute phase response in humans is CRP. However, CRP is of variable importance in species commonly used for toxi cology studies (27). CRP levels can increase as much as 1,000-fold in response to cell damage (16). Hepatic CRP synthesis is regu lated by proinflammatory cytokines including IL-6, IL-1 and TNF-a so that almost any form of tissue injury, infection, inflam mation or stress can be associated with increased circulating CRP values (29). CRP shares several functions with Ig molecules in that it can opsonize microorganisms such as bacteria and fungi through binding to cell wall polysaccharides as well as facilitate phagocyto sis through its ability to activate and fix complement. Conventional CRP immunoassays have been shown to be more reliable indica tors of acute inflammation than leukocyte counts as blood levels rise and fall rapidly in a reflection of the disease process (30). Although somewhat controversial, CRP has been shown to be a good predictor of cardiovascular disease risk, hypertension and diabetes (31–34). (b) The complement system is a complex network of proteins that participate in the acute inflammatory response through their enzymatic activity, effects on mediator release, chemotaxis and vascular permeability, and the ability to enhance phagocytosis through opsonization of microbes. A highly simplified sum mary of the complement system is presented in Fig. 5.2, and the reader is referred to basic texts such as Janeway’s Immunobiology (35) for a more comprehensive discussion. (i) The classical arm of the complement system is activated by antigen–antibody interactions, which trigger a cascade of reactions, each of which results in the activation of another complement component. There are two antibodyindependent pathways that can trigger complement acti vation. Several lectins, including mannose-binding lectin and ficolin, are structurally similar to the C1 proteins that initiate the classical complement cascade (36). These lec tins can activate complement by cleaving the C2 and C4 proteins in a manner similar to that of C1. This leads to the cleavage of C3, which is a common step in all three path ways of the complement network. (ii) Microbial cell wall proteins such as LPS and zymosan (from yeast) activate the alternate complement pathway by interacting with three triggering factors (initiating fac tor, factor B and factor D) that combine to cleave C3. C3 is the most abundant of the complement proteins and plays a central role in the complement pathway (37). Cleavage of C3 releases a small peptide, C3a, which, along
68
Germolec, Frawley, and Evans
Fig. 5.2. Overview of complement activation. This figure summarizes the three major pathways of complement activation and formation of the membrane attack complex. MBL mannose binding lectin, MASP MBL-associated serine protease.
with C5a, increases vascular permeability allowing the influx of inflammatory cells and proteins. The larger cleav age product, C3b, binds to the surface of pathogens as well as to complement receptors on inflammatory cells and enhances cell adhesion and phagocytosis. C3b also binds to the activated products from earlier steps in the classical/ lectin (C4b2a) or alternate (Bb) pathways to form the C3 convertase. The C3 convertase cleaves the C5 protein into C5a, the most potent of the peptide mediators of local inflammation, and C5b, which triggers the terminal events in the complement cascade resulting in the formation of the cytolytic membrane attack complex. The formation of immune complexes in autoimmune diseases activates com plement resulting in chronic inflammation and tissue dam age. Deposition of complement is frequently used as an immunohistochemical marker of inflammation, and the levels of individual complement factors can be quantitated in serum. The activity of serum complement can be deter mined in the laboratory by evaluating its ability to lyse cells in vitro. Assessment of the activity of individual comple ment components is not routinely used as a marker of inflammation but is more commonly used as a diagnostic tool for complement deficiencies.
Markers of Inflammation
69
(c) Fibrinogen Fibrinogen is an APP that has significant cross-species rele vance and is easily incorporated into standard preclinical toxicity studies. It must be measured in plasma, not serum, as it is con sumed in the formation of the blood clot. Fibrinogen provides an interface between inflammation and coagulation (38). The coag ulation process is similar to that of the complement system in that it operates as a series of transformations of proenzymes to acti vated enzymes. This process culminates in the formation of thrombin, which converts soluble fibrinogen into insoluble fibrin. These enzymatic reactions normally occur on the surface of acti vated endothelial cells and platelets. Cross talk between proteins in the complement and clotting cascades occurs at a number of points, either through interactions with target cells or through processes involving inflammatory mediators other than comple ment effectors (39). Receptors for fibrinogen have been identified on monocytes/macrophages, neutrophils, platelets and NK cells, and the binding of fibrinogen activates signaling pathways that upregulate NF-kB expression and the release of proinflammatory cytokines (40). Peptides formed during the cleavage of fibrinogen increase vasodilation and serve as chemoattractants, allowing fibrinogen to act as a bridging molecule between leukocytes and endothelial cells facilitating the recruitment of these cells to the site of inflammation. Along with CRP, serum levels of fibrinogen have been used as a predictor of cardiovascular disease risk, hypertension and diabetes in humans (34, 41). It should be noted that fibrinogen is utilized at an accelerated rate in situations of DIC, which may occur during severe inflammatory processes. In the face of DIC, plasma fibrinogen decreases. This may mask the increase seen in inflammation and vice versa. The measurement of fibrin degradation products (FDP) or D-dimer, breakdown products of fibrin, along with the assessment of other parameters suggesting inflammation (leukogram, other APPs) or DIC (throm bocytopenia, prolonged clotting times) are useful in interpreting fibrinogen data. (d) “Omics” Recently “omics” technologies have been used to detect APP associated with inflammation in human and animal studies. Consistent with conventional measures of APP, serum and plasma are commonly used matrices for detection of circulating proteins by two-dimensional electrophoresis (2DE) and mass spectrome try (MS). These techniques can provide a more complete picture of the inflammatory process, since they can separate and measure active proteins, precursors, metabolites and degradation products (42, 43). Upregulation of a number of APP, including CRP (42, 44), a-2-macroglobulin (45), complement C3 (45), serum amy loid A (46), and plasminogen (42) have been identified through
70
Germolec, Frawley, and Evans
2DE and/or MS in association with inflammatory diseases. Ironically, several of the most abundant APP, including fibrino gen, haptoglobin and a-1-antitrypsin, are often removed prior to proteomic analysis because their strong signals mask that of other proteins (42, 47, 48).
3. Conclusions Although changes in hematology dynamics, APP, complement factors and cytokines are common to virtually all inflammatory conditions, reliable, individual biomarkers associated with specific pathologic events are not yet available. High-content technolo gies, such as gene and protein microarrays, are necessary for gene/protein screening and model development. Using DNA microarrays, Ezendam et al. (49) conducted a multi-organ, multipathway study into the toxic effects of hexachlorobenzene (HCB) in rats. They identified increased transcript levels of markers for granulocytes and macrophages that were consistent with histo pathological findings, as well as upregulation of genes encoding proinflammatory cytokines and chemokines, APPs, and comple ment components, suggesting that HCB induces a strong, sys temic inflammatory response. In addition to the immune response genes, this study also identified altered functions and pathways associated with metabolism, oxidative stress, and reproductive toxicity, and it enabled the relative comparison of effects in spleen, liver, kidney, blood, mesenteric lymph nodes and thymus. Since most APP and complement factors are produced in the liver, rather than directly in the affected tissue, they do not help to identify the specific target tissue(s) or provide an accurate reflec tion of the extent of damage. If damage to target tissue is easily assessed by clinical pathology data (e.g., leakage enzymes in the case of hepatitis), the damaged tissue may be identified. However, blood chemistry is generally unrewarding in identifying sites of inflammation. The protein and gene profiles of inflammation vary with each disease or condition, and several studies indicate that multiple molecules representing different biochemical pathways and pathophysiologic processes offer the best strategy for identifying gene signatures representative of inflammatory changes (50–52). Using protein arrays and a support vector machine algorithm, Tabibiazar et al. (50) identified an inflammatory signature expression pattern, consisting primarily of cytokines and chemok ines, that was successfully used to predict the stage of atheroscle rosis in an independent data set. The investigators evaluated proteins found in serum and validated potential markers using
Markers of Inflammation
71
uantitative real-time reverse transcriptase polymerase chain reac q tion (RT-PCR) of RNA from aortic vascular wall to discover a profile that is specific to atherosclerosis. The primary members of the biomarker panel were Ccl9, Ccl2, Ccl21, Ccl19, Cxcl1, IL5, Tnfsf11, and Vegfa. More common cytokines, such as IL-6, pro duced in other tissues and promoting general inflammation, were not sufficiently specific in this model (50). Proteomic and genomic technologies allow simultaneous analysis of the complement factors, cytokines and chemokines, apolipoproteins, and other APP, as well as tissue-specific pro teins and proteins associated with other physiological functions to provide a more integrated picture of inflammation, mecha nisms of action and the disease process (48). Transcriptome profiles offer the possibility of unifying traditional diagnostic markers of inflammation with regulatory and immune-related molecules to provide temporal, mechanistic and predictive information.
Acknowledgments This work was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health References 1. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–455 2. NIA workshop on inflammation, inflammatory mediators, and aging. Sept. 1–2, 2004. Sponsored by National Institute on Aging, National Institutes of Health, Department of Health and Human Services. Workshop sum mary. Available at http://www.nia.nih.gov/ NR/rdonlyres/A8B847EC-8E2B-418DAD39-62D56E8CEAB2/2083/ NIAWorkshoponInflammationMtgRpt61805_ Ed.pdf. Accessed 9 Jan 2009 3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867 4. Alegre J, Jufresa J, Segura R et al (2002) Pleural-fluid myeloperoxidase in complicated and noncomplicated parapneumonic pleural effusions. Eur Respir J 19:320–325 5. Buttarello M, Plebani M (2008) Automated blood cell counts: state of the art. Am J Clin Pathol 130:104–116
6. Grattan CE, Dawn G, Gibbs S, Francis DM (2003) Blood basophil numbers in chronic ordinary urticaria and healthy controls: diur nal variation, influence of loratadine and pred nisolone and relationship to disease activity. Clin Exp Allergy 33:337–341 7. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME (2003) Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 111:227–242 8. Latimer KS, Mahaffey EA, Prasse KW (eds) (2003) Duncan & Prasse’s veterinary labora tory medicine: clinical pathology, 4th edn. Iowa State Press, Ames, IA 9. Weyrich AS, Zimmerman GA (2004) Platelets: signaling cells in the immune continuum. Trends Immunol 25:489–495 10. Kosone T, Takagi H, Horiguchi N et al (2007) Hepatocyte growth factor accelerates throm bopoiesis in transgenic mice. Lab Invest 87:284–291
72
Germolec, Frawley, and Evans
11. González-Villalva A, Fortoul TI, Avila-Costa MR et al (2006) Thrombocytosis induced in mice after subacute and subchronic V2O5 inhalation. Toxicol Ind Health 22:113–116 12. Means RT, Krantz SB (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80:1639–1647 13. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1012–1023 14. Zarychanski R, Houston DS (2008) Anemia of chronic disease: a harmful disorder or an adap tive, beneficial response? CMAJ 179:333–337 15. Evans EW (2008) Clinical pathology as cru cial insight into immunotoxicity testing. In: Bussiere JL, Herzyk D (eds) Immunotoxicology strategies for pharmaceutical safety assess ment. Wiley, Hoboken, NJ, pp 13–26 16. Sell S (2001) Inflammation and wound heal ing. In: Sell S (ed) Immunology, immunopa thology and immunity, 6th edn. ASM press, Washington, DC, pp 33–100 17. Kelly M, Hwang JM, Kubes P (2007) Modulating leukocyte recruitment in inflam mation. J Allergy Clin Immunol 120:3–10 18. Mousa SA (2002) Cell adhesion molecules: potential therapeutic and diagnostic implica tions. In: Rose NR, Hamilton RG, Detrick B (eds) Manual of clinical laboratory immunol ogy, 6th edn. ASM press, Washington, DC, pp 368–375 19. Sarada S, Himadri P, Mishra C, Geetail P, Ram MS, Ilavazhagan G (2008) Role of oxi dative stress and NFKB in hypoxia-induced pulmonary edema. Exp Biol Med (Maywood) 233:1088–1098 20. Bashir MM, Sharma MR, Werth VP (2009) TNF-alpha production in the skin. Arch Dermatol Res 301:87–91 21. Schmid H, Boucherot A, Yasuda Y et al (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993–3003 22. Bachmann MF, Kopf M, Marsland BJ (2006) Chemokines: more than just road signs. Nat Rev Immunol 6:159–164 23. Rot A, von Andrian UH (2004) Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22:891–928 24. Abbadie C (2005) Chemokines, chemokine receptors and pain. Trends Immunol 26:529–534 25. Moser B, Wolf M, Walz A, Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25:75–84 26. Poznansky MC, Scadden DT, Luster AD (2002) Chemokine and chemokine receptor
27.
28.
29. 30. 31.
32.
33.
34.
35. 36.
37.
38.
analysis. In: Rose NR, Hamilton RG, Detrick B (eds) Manual of clinical laboratory immu nology, 6th edn. ASM press, Washington, DC, pp 357–367 Gentry PA (1999) Acute phase proteins. In: Loeb WF, Quimby FW (eds) The clinical chem istry of laboratory animals, 2nd edn. Taylor and Francis, Philadelphia, PA, pp 336–398 Evans EW, Duncan JR (2003) Proteins, lipids and carbohydrates. In: Latimer KS, Mahaffey EA, Prasse KW (eds) Duncan & Prasse’s veteri nary laboratory medicine: clinical pathology, 4th edn. Iowa State Press, Ames, IA, pp 162–192 Kushner I, Rzewnicki D, Samols D (2006) What does minor elevation of C-reactive pro tein signify? Am J Med 119:166e.17–166e.28 Kind CRH, Pepys MB (1984) The role of C-reactive protein (CRP) measurement in clinical practice. Int Med 5:112–151 Acevedo M, Corbalán R, Braun S, Pereira J, Navarrete C, Gonzalez I (2006) C-reactive protein and atrial fibrillation: “evidence for the presence of inflammation in the perpetuation of the arrhythmia”. Int J Cardiol 108:326–331 Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK (2002) C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 144:233–238 Nesto R (2004) C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovas cular disease, and the effects of insulin-sensi tizing treatment with thiazolidinediones. Diabet Med 21:810–817 Corrado E, Rizzo M, Muratori I, Coppola G, Novo S (2006) Association of elevated fibrin ogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes. Arch Med Res 37:1004–1009 Murphy KM, Travers P, Walport M (2007) Janeway’s immunobiology, 7th edn. Garland Science Textbooks, New York Giclas P (2002) Choosing complement tests: differentiating between hereditary and acquired deficiency. In: Rose NR, Hamilton RG, Detrick B (eds) Manual of clinical labora tory immunology, 6th edn. ASM press, Washington, DC, pp 111–116 Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM (2005) Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 97:171–179 Altieri D (2001) Interface between inflamma tion and coagulation. In: Ley K (ed) Physiology of inflammation. Oxford University Press, Oxford, England, pp 402–422
Markers of Inflammation 39. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD (2007) Complement and coagulation: strangers or partners in crime? Trends Immunol 28:184–192 40. Sitrin RG, Pan PM, Srikanth S, Todd RF 3rd (1998) Fibrinogen activates NF-kappa B tran scription factors in mononuclear phagocytes. J Immunol 161:1462–1470 41. Paraskevas KI, Baker DM, Vrentzos GE, Mikhailidis DP (2008) The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thromb Res 122:1–12 42. Shen Z, Want EJ, Chen W et al (2006) Sepsis plasma protein profiling with immu nodepletion, three-dimensional liquid chro matography tandem mass spectrometry, and spectrum counting. J Proteome Res 5:3154–3160 43. He QY, Yang H, Wong BC, Chiu JF (2008) Serological proteomics of gastritis: degrada tion of apolipoprotein A-1 and alpha-1-antit rypsin is a common response to inflammation irrespective of Helicobacter pylori infection. Dig Dis Sci 53:3112–3118 44. Cho WC, Yip TT, Chung WS, Leung AW, Cheng CH, Yue KK (2006) Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J Cell Biochem 99:256–268 45. Hanas JS, Hocker JR, Cheung JY et al (2008) Biomarker identification in human pancreatic cancer sera. Pancreas 36:61–69
73
46. Kristiansson MH, Bhat VB, Babu IR, Wishnok JS, Tannenbaum SR (2007) Comparative time-dependent analysis of potential inflam mation biomarkers in lymphoma-bearing SJL mice. J Proteome Res 6:1735–1744 47. Lull ME, Carkaci-Salli N, Freeman WM et al (2008) Plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Pediatr Res 63:638–644 48. Wu J, Kobayashi M, Sousa EA et al (2005) Differential proteomic analysis of bronchoal veolar lavage fluid in asthmatics following seg mental antigen challenge. Mol Cell Proteomics 4:1251–1264 49. Ezendam J, Staedtler F, Pennings J et al (2004) Toxicogenomics of subchronic hexachlo robenzene exposure in Brown Norway rats. Environ Health Perspect 112:782–791 50. Tabibiazar R, Wagner RA, Deng A, Tsao PS, Quertermous T (2006) Proteomic profiles of serum inflammatory markers accurately pre dict atherosclerosis in mice. Physiol Genomics 25:194–202 51. Parikh SV, de Lemos JA (2006) Biomarkers in cardiovascular disease: integrating pathophys iology into clinical practice. Am J Med Sci 332:186–197 52. Mehra MR, Feller E, Rosenberg S (2006) The promise of protein-based and gene-based clinical markers in heart transplantation: from bench to bedside. Nat Clin Pract Cardiovasc Med 3:136–143
Chapter 6 Evaluating Macrophages in Immunotoxicity Testing John B. Barnett and Kathleen M. Brundage Abstract Macrophages are the heterogeneous grouping of cells that are derived from monocytes. They have a multitude of functions depending on their final differentiated state. These functions range from phagocy tosis to antigen presentation to bone destruction, to name a few. Their importance in both the innate and acquired immune functions is undeniable. Xenobiotics that degrade their functional status can have grave consequences. In this chapter, we provide an overview of the types of macrophages, their hematopoietic origin and a general discussion of the many different assays that are used to assess their functional status. Key words: Macrophage, Monocyte, Phagocytosis, Reactive oxygen species, Reactive nitrogen species, Osteoclast, Autophagy, Apoptosis, Confocal microscopy, ELISA
1. Introduction The purpose of this chapter is to review the basic biology of the group of cells collectively referred to as “macrophages”. Rather than pro viding detailed methods on how to perform the assays to measure the number and functional status of these cells, we provide a reference(s) to particularly instructive literature or in some instances reference to the techniques manual where detailed methods can be found. This allows us to stretch the boundaries of macrophage functional assess ments into areas of molecular biology that we would not have space for in this chapter if we were to provide detailed protocols.
2. Hematopoietic Origin of Macrophages
Like all immune cells, macrophages originate from the hema topoietic stem cells (HSC) and arrive at their final configuration through a series of maturation steps. Each of the known maturation
R.R. Dietert (ed.), Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, vol. 598 DOI 10.1007/978-1-60761-401-2_6, © Humana Press, a part of Springer Science + Business Media, LLC 2010
75
76
Barnett and Brundage
steps can be identified by surface markers. However, it is important to note that there appears to be much that we do not know about this maturation process. In this section, we provide a summary of the known steps as primarily discussed in a review by Weissman and Shizuru (1). As shown in Fig. 6.1, the HSC pro gresses through several intermediate stages of multipotent progenitor cells (MPC) that are progressively triggered by growth and differentiation factors. To make the figure more manageable, only one of these stages is diagrammed. The last stage of this series of progenitor cells provides an important decision point in the hematopoietic process. At this point, depending on the influ ence of known growth/differentiation factors, the cells follow the route to become common lymphoid progenitors (CLP) or common myeloid progenitors (CMP). The surface markers that are unique for each progenitor cell population are listed on Fig. 6.1. CMP cells can become granulocyte–macrophage progenitor (GMP) cells or megakaryote–erythroid progenitor (MEP) cells. Again, each of these progenitors possesses a unique set of surface markers and involves a unique combination of transcription factors. For example, GMP, which are also called granulocyte– macrophage colony forming units (GM-CFU), have PU.1high, GATA-1−, c/EMPahigh phenotype, as shown in Fig. 6.1. Under the influence of macrophage-colony stimulating factor (M-CSF), the GMP cells proceed through a semifinal series of maturation steps that ultimately results in the production of monocytes. Monocytes are circulating blood cells, whereas, macrophages are further differentiated end-cells derived from monocytes that are found in tissues. As previously described, under further influence of specific growth and differentiation factors, the monocytes develop into mature tissue-resident cells. Some of these cells have very special ized activities and names. For example, osteoclasts are respon sible for maintaining normal bone homeostasis, in balance with another cell type, the osteoblast. Osteoclasts differentiate from monocytes under the influence of receptor activator of Nuclear Factor (NF)-kB ligand (RANKL) and macrophage-colony stim ulating factor (M-CSF) (2, 3). As outlined below, several other types of macrophages are formed and are often named for the tissue in which they finally reside (e.g., alveolar macrophages are found in the lung). The maturation pathway that leads to the formation of termi nal (mature) “macrophages” presents the first area suitable for testing in the area of immunotoxicology. Agents that interfere with the maturation process can skew the number of mature cells and in some cases, the anatomical location of the hematopoi etic maturation (4), and this may have detrimental effects on the health of the animal. We will discuss this further in a later section.
Evaluating Macrophages in Immunotoxicity Testing
HSC PU.1low GATA-1− C/EBPαlow
PU.1+ GATA-1low
Mu=Lin-c-Kit+Sca1+Flk2-CD34-Slamf1+ Hu=Lin-CD34+CD38-CD90+CD45RA-
MPC (multiple stages) CLP CMP
PU.1+ GATA-1+ C/EBPα+
Mu=Lin−c-Kit+Sca1−CD34+FCγRlow Hu=Lin−CD34+CD38+IL3RαlowCD45RA−
MEP PU.1high GATA-1− C/EBPαhigh
PU.1− GATA-1high
GMP (GM-CFU) Mu=Lin − c-Kit+Sca1− CD34−FCγR+ Hu=Lin− CD34+CD38+IL3Rα+CD45RA+
M-CFU → Monoblast → Promonocyte PBM
tissue macrophage • spleen • histocyte • alveolar • Kupffer cell • microglial
osteoclast
KEY: CELLS: CLP, common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor; GM-CFU, granulocyte-macrophage colony forming unit; HSC, hematopoietic stem cell; MEP, megakaryocyte-erythroid progenitor; M-CFU, macrophage coloy forming unit; PBM, peripheral blood monocyte; MPC, multipotent progenitor cell. Transcription factors known to affect cell differentiation are listed in the boxes REFN: Bryder et al., Am J. Path 169:338 (06); Weissman & Shizuru, Blood 112:3543 (07); Iwasaki & Akashi, Immunity 26:726 (07); Mosser & Edwards, Nature Reviews Immunol 8:958 (08)
Fig. 6.1. Hematopoetic maturation scheme for the production of macrophages [see also (1,5,44,45)].
77
78
Barnett and Brundage
3. Types of Macrophages As is common among the immune cells, there are several types of macrophages. Classifying these types primarily by tissue or organ of residence provides the following list: peritoneal, splenic, histo cyte, Kupffer cells, alveolar, osteoclast and microglial. Some inves tigators further divide some of these cells, e.g., within in the spleen there appear to be differences depending on whether they reside in the white pulp, red pulp or marginal zone (5). A potentially more important subdivision of macrophage populations has been extensively reported by Mosser and others (reviewed in (5)). Briefly, resident macrophage populations have been divided into three distinct populations based on the charac teristics and criteria discussed below. The first of these popula tions is the “classically-activated” (CA) macrophage. This population is generated in response to either interferon-gamma (IFNg) in combination with tumor necrosis factor-alpha (TNF-a) or to stimuli that induce TNF-a (5, 6). These macrophages pro duce reactive oxygen and nitrogen species, secrete the prototypi cal group of cytokines that are either proinflammatory or affect Th1 cell responses and have antimicrobial activities (5, 6). A second population of macrophages is referred to as “woundhealing” (WH) macrophages (also called “alternatively activated” macrophages). These cells are induced by interleukin (IL)-4 and/ or IL-13 (Th2 cytokines) and do not produce nitric oxide (NO). However, they do have an abundance of mannose receptors (6)as well as uniquely expressing the genes for FIZZ1, a resistin-like secreted protein up-regulated during pulmonary inflammation, and Ym, which is a chitnase-like secretory lectin that is also upregulated during the development of allergy (7). WH mac rophages have been reported in bone marrow (6), lung (8), peritoneal cavity (9) and spleen (10). The third population is generated by the macrophage being activated in the presence of immune complexes (6, 11). These macrophages are referred to as “regulatory” macrophages (previ ously referred to as “Type II-activated” macrophages). Cross link ing of Fcg receptors (FcgR) by the immune complexes results in strong down regulation of IL-12 with a concominant up-regula tion of IL-10 (6). Careful dissection of the biochemical and func tional differences between these three populations has revealed a number of different surface markers, biochemical functions as well as biological activities (6). The review by Mosser and Edwards (5) provides a convenient table of the characteristics of the three dif ferent populations of macrophages. The potential effect of differ ent xenobiotic compounds specifically on any of these three different macrophage populations has not been reported.
Evaluating Macrophages in Immunotoxicity Testing
79
4. Macrophage Functional Assays Figure 6.2 provides a schematic of the many functions that have been described for macrophages or other monocyte-derived cells (e.g., osteoclasts). In many cases, there is a known link between
Confocal microscopy APC×T cell cytokine prod’n
Specialized stains (TRAP)
ELISA
Colony-forming assays Antigen Presentation
Autophagy
Extracellular Protein Expression
Differentiation Immunofluorescence
Killing Surface Molecule Expression
Antimicrobial
Phagocytosis
Flow cytometry Gene Expression
Pathology
Pharmacologic Mediators
Histology
Whole genome sequencing
Apoptosis
mRNA quantn
ELISA ELISA Biochemical assays
TUNEL
Intracellular Signaling
Annexin V
Intracellular relocalization Target gene protein expression Protein phosphorylation Ca2+ influx Enzyme analysis
Fig. 6.2. Macrophages functions that are suitable for testing.
80
Barnett and Brundage
the function described in a particular outer circle, e.g., the expression of a cell surface receptor that is necessary for initiating antimi crobial activity, which in turn requires a cascade of intracellular signaling. However, for the purposes of this chapter, we will describe (in alphabetical order) assays available to measure each of these characteristics individually with the assumption that each assay is interpreted in the context of the function of the whole cell. Before discussing each assay, a brief discussion of the methods used to isolate macrophages from tissues is provided. Because macrophages reside in tissues, a number of laboratory procedures have been developed to enrich the cell harvest for macrophages (i.e., reduce the number of nonmacrophage cells in the prepara tion). An excellent detailed description of a number of methods is provided by Zhang et al. (12). A key feature and problem with macrophages is their “stickiness”. They can (and do) adhere to glass and plastic surfaces, which is useful in the procedures needed to enrich the population for macrophages, however, in doing so, this initiates a number of intracellular signals. Thus, quiescent, unstimulated primary macrophages are difficult to isolate. Many published reports on the effect of xenobiotics on macrophage function make comparisons between treated versus untreated macrophages isolated in an identical manner to control for this problem. A commonly used source of mouse and rat macrophages is the peritoneal cavity. Two types of macrophages from the perito neal cavity are used, resident and elicited. Resident macrophages are those that are residing in the peritoneal cavity normally and have the advantage of being less biochemically stimulated but are fewer in number than if the cells were elicited. Often, to increase the number of macrophages, a sterile irritant, such as thioglycol late, is injected several days prior to harvesting the cells. The resulting peritoneal cells are referred to as elicited macrophages. While this procedure substantially increases the number of perito neal macrophages, it also has its drawbacks. That is, the irritant can be phagocytosed and, thus, upset the normal baseline physi ology of the cells. Thus, an informed choice must be made in the design of the experiment. A hint that is often overlooked by new comers who wish to elicit the peritoneal macrophages is that the thioglycollate must be aged, that is stored in the dark for several weeks after sterilization prior to use. Isolation procedures for the other macrophage populations are obviously organ dependent. Zhang et al. (12) provide detailed methods for the isolation of murine bone marrow and alveolar macrophages. Others have published some detailed methods of isolating human monocytes and macrophages mainly from either peripheral blood or cord blood (13, 14).
Evaluating Macrophages in Immunotoxicity Testing
4.1. Antimicrobial Killing/Phagocytosis
81
A hallmark characteristic of macrophages is their ability to kill the engulfed microorganisms. Because of the requirement that the cell actually phagocytose the microorganism, these assays can be combined with assays that assess the phagocytosis of the organ ism. These assays are often the foundation of an immunotoxico logical assessment of the effect of a xenobiotic. Various bacterial species are used to assess the killing efficiency of isolated mac rophages. Care must be exercised to be certain that the assay excludes those bacteria that are bound to the surface of the cell as opposed to bacteria that have been engulfed and are in the phagosome or phagolysosome. To control this potentiality, after an initial incubation period to allow the cells to engulf the bacte ria, the macrophages are washed with a bactericidal antibiotic solution and then reincubated to determine the level of killing over time. As with many macrophage assays, the cells often must be activated in order to stimulate their phagocytic and antimicro bial functions. This activation step is dependent on the method used to obtain the macrophages. That is, if the primary mac rophages are from animals elicited with thioglycollate, then they are partially activated at the time of harvest, and the addition of interferon-gamma (IFNg) completes the activation processes leading to antimicrobial killing. Other methods of macrophage harvest (e.g., using resident macrophages) require an initial activation step with lipopolysaccharide (LPS). These stimuli can be used either sequentially (LPS then IFNg) or simultaneously. There are a number of methods that are suitable for measuring the microbial killing by primary macrophages as well as macrophage-like cell lines. A procedure used by Ustyugova et al., (15) to measure the effects of the herbicide, propanil, on mac rophage function was an adaptation of a technique published by Ouadrhiri et al. (16). THP-1 or peritoneal exudate cells (PEC) were activated with IFNg for 24 h in RPMI 1640 media containing 10% FBS (no antibiotics). This activation does not cause adhesion of THP-1 cells, which continued to grow in loose suspension as described (16). THP-1 cells were washed with PBS, resuspended in PBS containing 1% fetal calf serum (FCA), and infected with 2.5 × 106 Listeria monocytogenes, strain EGD/ml. Activated PEC were trypsinized, washed in PBS, resuspended in PBS containing 1% FCS, and also infected with 2.5 × 106 L. monocytogenes, strain EGD/ml. LPS stimulation and vehicle and DCPA treatments were initiated at the same time as initial infection. Cells were transferred to 5-ml snap-cap tubes and incubated at 37°C in 5% CO2 on a rocker for 1 h to allow for infection. Cells were then washed twice with PBS. The final pellet was resuspended in PBS containing 25 mg/ml gentamicin. Initial infection levels (1 h) were obtained by lysing cells in ice-cold, sterile, distilled water and plating an aliquot of the lysate. Remaining treatment groups were
82
Barnett and Brundage
returned to incubation conditions in the gentamicin solution. Cell lysates were prepared at 3 and 5 h after infection. Lysates were plated on Trypticase soy agar plates (Difco Laboratories, Detroit, MI) using an Autoplate 4000 (Spiral Biotech, Bethesda, MD) in triplicate. Plates were incubated at 37°C for 24 h, and colonies were counted using a CASBA 4 plate scanner and CIABEN colony imaging and analysis software (Spiral Biotech). Resulting L. monocytogenes colony-forming units (CFU) per 1 ml were calculated and compared across treatments. In these studies, we were able to determine that propanil inhibited the ability of primary macrophages and THP-1 (human monocytic cell line) cells to kill L. monocytogenes. 4.2. Autophagy
Autophagy is one of two methods by which cells degrade pro teins. Degradation by proteosomes (the alternative form) targets polyubiquitinated substrates, however, autophagy targets cell organelles and aggregates of long-lived proteins (17). It is fitting that this technique follows the “antimicrobial killing” section because in macrophages, autophagy is known to play a vital role in restricting viral infections and inhibiting replication of intracel lular bacteria and parasites (18). Of course, this is not its only role; it also functions in morphogenesis, cellular differentiation and tissue remodeling (19). Thus, assays for possible effects of xenobiotics on autophagy would also be an appropriate assay. The number of reports on the role of autophagy in macrophage function have increased slowly over the past few years (84 cita tions in 2008 versus 1 in 2000). However, the small number of citations also means that ways for assessing autophagy are also relatively new and untested by time. Nonetheless, the most recent methodology articles discuss the use of the expression of LC3, which is a mammalian homolog of the yeast autophagy-related protein-8 (Atg8), as a measure of autophagy (19). In macrophages, autophagosomes increase in number as a result of appropriate stimulation (e.g., by a microbe). The microbe is phagocytosed into an autophagosome after which it fuses with a lysosome to form an autophagolysosome (19). The merging of these two structures allows for the contents (e.g., microbe) and the LC3 protein to be degraded. Stimulation of the macrophages also causes an increase in autophagosome numbers in the cell and this increase can also be monitored by assaying LC3 protein levels (19). Swanson et al. (19) discuss the various methods of measuring intracellular LC3 levels in bone marrow macrophages after appropriate stimulation using either fluorescence microscopy to visually detect a LC3GFP signal or by western blotting techniques using an antiLC3 antibody. Given the current hypothesis that autophagy consti tutes an important macrophage antimicrobial function, assays of the effects of various xenobiotics on autophagy would seem to be
Evaluating Macrophages in Immunotoxicity Testing
83
an important measure. Similarly, even without the antimicrobial function, it is conceivable that induction or interference with the normal autophagy functions could affect the operative status of the macrophage. 4.3. Antigen Presentation Assays
Given that macrophages were the first antigen-presenting cell (APC) identified, there is no shortage of methods to measure this function. In spite of the longstanding knowledge of the APC capabilities of macrophages, there are few references that actually measure the effect of a xenobiotic on the APC capabilities of macrophages. In addition, some of the early work may need updating because of our new knowledge of dendritic cells. Macro phages can differentiate into dendritic cells and dendritic cells are superb APC (20). One area with some literature on the effects of xenobiotic insult on a macrophage population’s APC capacity is on alveolar cells (21) and Kupffer cells (22), and in both of these reports the outcome was an up-regulation of the immune (allergic) response. Appropriate methods to measure macrophage APC capacity are provided in Harding (23, 24). In this detailed procedure, either peritoneal macrophages elicited with L. monocytogenes pro teose peptone or Concanavalin A (ConA) or bone marrow mac rophages are used as the APC (23). In a companion chapter, Harding (24) provides a detailed protocol for using these mac rophages in an antigen-presenting assay in which the production of IL-2 by the T cells is the read out for the assay.
4.4. Biochemical Assays
Macrophages produce a number of biochemical substrates that are important to their function. Among these are the reactive oxygen species (ROS), reactive nitrogen species (RNS), prostaglandins (PG), inducible nitric oxide synthetase (iNOS), cyclooxygenase (COX)-1 and COX-2. These assays are so important to assess the function of macrophages, that commercial kits to measure their production are readily available. Using our own work as an exam ple, we have measured concentration-dependent changes in respi ratory burst using a luminol assay, intracellular ROS assessed by the fluorescent dye oxidation using confocal microscopic intensity measurements, iNOS production by western blotting, and NO production using the biochemical test called the Greiss test in elic ited PEC (15). In companion analyses (manuscript in prepara tion), we further measured COX-2 protein production by western blot and COX-2 enzymatic activity by assaying the conversion of arachidonic acid (its substrate) to PGE2. PGE2, as well as the other prostaglandin production, can be measured using any one of a number of commercial ELISA assays that are available. Respiratory burst activity can be effectively measured using Luminol, 5-amino-2-3dihydro-1,4 phthalazinedione (Sigma) to amplify the chemiluminescence (CL) signals generated by activation
84
Barnett and Brundage
of the NADPH-oxidase (25). The CL signal generated by luminol occurs as the compound accepts an electron from free radical species as they return to ground state. The actual experimental configuration is dependent on the instrument used to measure the fluorescence produced by the respiratory burst. In our work, cells were plated in 35 mm tissue culture dishes, and the respiratory burst activity was elicited by addition of PMA and LPS simultane ously with the luminol plus either vehicle or xenobiotic (15). CL readings were taken every minute for 20 min using a luminometer (Berthold, Co., Wilbad, Germany). CL curves are generated from these readings over time to peak values. Control experiments to determine if the xenobiotic or vehicle alone quenched the CL signal are also included (15). Intracellular ROS can be measured using 5-(and 6)-chloromethyl2¢,7¢-dichlorodihydro-fluorescein diacetate, acetyl ester (CMH2DCFDA, Invitrogen, Carlsbad, CA). CM-H2DCFDA is a nonfluorescent dye which enters the cells by passive diffusion. It becomes fluorescent only when it is oxidized by ROS, particularly by hydrogen peroxide (H2O2), hydroxyl radicals (•OH), or their downstream free radical products. After incubation with the dye, cells are typically washed and the cells are treated with the xeno biotic or vehicle control and simultaneously stimulated with LPS and PMA. In our studies, cultures are examined with a Zeiss Axiovert 100 M microscope equipped with a laser-scanning confocal attachment (model LSM 510; Zeiss) to locate the cells and analyze their images overtime (15). CM-H2DCFDA is excited with the 488-nm line of an argon/krypton mixed-gas laser; emis sion was collected with a 505 nm long-pass filter and images were collected every 2 min for up to 20–30 min (15). Fluorescence emission from 25–30 cells per experiment is analyzed by LPS 510 software (15). NO release from macrophages is typically measured using the Greiss reagent (0.1% naphthylethylenediamine chloride (Sigma) in 60% acetic acid and 1% sulfanilamide (Sigma) in 30% acetic acid. The cells are stimulated with LPS, simultaneously treated with the xenobiotic and incubated for 12, 24 and 48 h for NO induction by monitoring color development at 540 nm with a mQuant plate reader (BioTek Instruments, Inc. Winooski, VT). A standard curve is generated with a serial dilution of sodium nitrite dissolved in culture medium. 4.5. Calcium Influx
The quintessential method of measuring calcium (Ca2+) influx into cells is via patch clamping. This requires very specialized equipment that may not be readily available to many immuno toxicologists but, nonetheless, excellent indications of Ca2+ influx can be obtained using one of several Ca2+-specific indicator dyes, such as Fluo-3 and Fura-2. These dyes have been used with a variety of cell types to monitor Ca2+ influx, frequently using a
Evaluating Macrophages in Immunotoxicity Testing
85
spectrofluorometer with a stirring cuvette to keep the cells in suspension. This method works very well for nonadherent cells (e.g., T cells) (26). Use of these dyes requires that the cells remain in suspension, hence the stir-bar equipped cuvette. Thus, mac rophages with their inherent “stickiness” are not generally amenable to these technique if a spectrofluorometer is the instrument used to measure the fluorescent output. We have adapted a technique that uses a fluorescence-recording inverted microscope with appropriate software to measure the quantity of light. Macrophages are allowed to adhere for 2 h at 37°C in a tissue culture incubator to coverslip bottomed culture chambers specifically designed for fluorescence microscopy (LabTek #1 Borosilicate chambers, Nalge Nunc Intl.). The cells are then loaded with the esterified form of the appropriate dye, which enters the cell and is trapped by intracellular esterases that cleave the dye into an active form. For Fura-2, cells are loaded with Fura-2AM with the addition of pluronic, a detergent which aids in the uptake of the dye for 30 min at 37°C in the dark. A group of control cells is treated with the dye diluent alone to act as a background fluorescent measure during the experiment. The cells are then washed with tissue culture media without phenol red to reduce the autofluoresence of the media. Fields of cells can then be monitored for changes in cytosolic Ca2+ due to increased influx or the release of Ca2+ from the internal stores over several minutes. The effect of a xenobiotic on the Ca2+ influx can be measured in comparison to agents known to cause Ca2+ influx, e.g., thapsi gargin, as well as known channel/pump-specific inhibitors. For calculation of the actual intracellular concentration of cal cium, calibration measurements are taken at the end of the exper iment. These typically consist of permeabilizing the cells with ionomycin and driving intracellular calcium to saturating levels (Rmax) and then lowering it to sub nanomolar levels through the addition of EGTA (Rmin). Detergent treatment can also be used to monitor the uptake of the dye into intracellular compartments which can confound the cytosolic signals. Digitonin is typically used to lyse the plasma membrane to release cytosolic dye while maintaining organelle integrity so that the fluorescent signal from these compartments can be detected. 4.6. Colony Forming Assays
As shown in Fig. 6.1, each of the progenitor cell populations beginning with the HSC has a unique combination of cell surface markers. The relative numbers of each of these cell types varies as the hematopoietic maturation process proceeds. The number of HSC is reported to be 0.05% of bone marrow cells (27). Thus, while it is possible to measure each of these progenitor and HSC populations via flow cytometry, this is not always practical because of the limited availability of reagents to measure each of the pro genitors as well as their low total numbers in the specimen.
86
Barnett and Brundage
Therefore, to determine the myelo-toxicity of xenobiotics, the ability of specific progenitor populations can be determined using the colony-forming assays. Colony forming units (CFU) are induced with recombinant colony stimulating factors (rCSF) in culture conditions described by Metacalf (28) or similar. CFU-IL-3 (multipotent progenitor cells), CFU-GM (granulocyte/macrophage progenitors) and CFU-M (macrophage [monocyte] progenitors) can be enumer ated after 6 days in culture in semisolid agar cultures. The semi solid agar cultures are prepared using Dulbecco’s minimal essential medium containing 20% prescreened fetal calf serum and 0.3% agarose or 2% methyl cellulose. Colonies of greater than 50 cells are counted using an inverted or dissecting microscopy. Control cultures without rCSF are also prepared and evaluated. This method has been useful in determining the myelo-toxicity of two pesticides (4, 29). 4.7. Confocal Microscopy/ Immunofluorescence
Confocal microscopy has become an indispensable tool for cell biology. There are many different types of confocal microscopes, but the most commonly available is the laser-scanning confocal microscope (30). The basic design of this microscopy involves exciting the specimen in the microscopy with a narrow band laser and capturing the emitted fluorescent image that is returned. The availability of many different dyes (stains) that emit light at different wavelengths provides the ability for multiple staining of a specimen. From this, it is possible to detect the intracellular location of a particular organelle or molecule and compare this to the location of a separate molecule by merging the images to produce a separate color. The combinations of fluorochromes with different antibodies attached are large, and the further use of secondary fluorescent-tagged antibodies make this instrument extremely versatile. Newer models can image living cells making it possible to study the effects of different stimuli on on-going biochemical processes (31). These microscopes have the further ability to “focus” on different planes in the specimen (frequently called the Z-stack), thus, providing a complete picture of the loca tion of molecules throughout the entire cell. Examples of the use of confocal microscopy in immunotoxicology include the work of Henjakovic et al. (32), who reported on the use of precision lung slices for ex vivo immune response testing. Similarly, Neumann et al. (33) reviewed the courses of L. monocytogenes within the macrophage using confocal microscopic techniques. Excellent protocols are available in comprehensive methods manuals, such as Current Protocols in Cell Biology. A general tech nique that has been reported specifically for the immunotoxico logical studies used IC-21 macrophages that were grown on coverslips overnight to approximately 70–90% confluence (34). The following day, cells were either not stimulated or stimulated
Evaluating Macrophages in Immunotoxicity Testing
87
with LPS in the presence of either vehicle, or propanil for 1–4 h. Coverslips were rinsed in phosphate buffered saline (PBS), then the cells were fixed in a 1:1 methanol:acetone solution, followed by blocking in PBS + 5% bovine serum albumin (BSA). Rabbitanti-p65 (Santa Cruz Biotechnology, Santa Cruz, CA) was added to the cells at 100 mg/ml in PBS and incubated at room tempera ture for 1 h. Coverslips were washed 3× in PBS for 5 min each with gentle rotation. Goat-anti rabbit FITC was added at 50 mg/ml in PBS for 1 h at room temperature and kept in the dark. Coverslips were washed 3× in PBS for 5 min each, then mounted to glass slides with Fluormount-G (Southern Biotechnology Associates, Inc, Birmingham, AL). Slides were kept in the dark until visua lized by confocal microscopy (Zeiss LSM 510, Thornwood, NY, equipped with an argon laser). This technique allowed us to follow the translocation of NF-kB p65 into the nucleus of these macrophages (34). In summary, the potential uses of confocal microscopy is vast, progress on the newer types of instruments and software is so rapid, that a comprehensive review of this field is not practical within the limitations of this chapter. 4.8. Enzyme-Linked Immunosorbent Assay (ELISA)
4.9. Flow Cytometry
ELISA methods are commonly used to quantitatively measure the protein levels, and there are many variations on the basic prin cipal of this assay. In its simplest form, the protein to be assayed (analyte) is captured (usually in a 96 well tissue culture plate) by its binding to either its specific antigen (if the analyte is an antibody) or using a specific antibody to the analyte for other proteins. A blocking agent, often an unrelated protein such as bovine serum albumin, to prevent nonspecific binding of the next reagent, is then added. The captured analyte is then detected using a second antibody to which an enzyme, such as horse radish peroxidase (HRP), is conjugated. The last step is to add a sub strate for the HRP enzyme that changes color in direct propor tion to the amount of enzyme present. There are extensive wash steps between each step in the assay to eliminate any nonspecific reactions. Thus, the amount of substrate color developed is directly proportional to the amount of the analyte in the sample. This method works well for a variety of fluids, including culture supernatants and serum. This technique is very specific, quantita tive, reproducible and amiable to high throughput analyses. The ELISA technique has become a standard for measuring a vast array of proteins and there are a huge number of commerciallyavailable ELISA kits available to measure these proteins. However, if it is necessary to develop an ELISA for a specific protein, an excellent protocol is described by Hornbeck et al. (35, 36). Flow cytometry is the measurement of the physical and/or the chemical characteristics of single cells or particles as they pass
88
Barnett and Brundage
through the measuring apparatus in a fluid stream. It utilizes laser beams that hit the cells or particles in the flow cell. A fluorescent objective lens collects and focuses the fluorescent light emitted onto the individual collection fibers. Fiber optic cables transfer the light to the detector arrays. It has been around for many years and is a valuable tool for not only phenotyping cells but also assaying their metabolic activity, viability, DNA integrity and pro liferative capacity. In order to identify cells of the macrophage lineage in the bone marrow, a series of antibodies are used that are conjugated to different fluorochromes and specific for different surface markers. Figure 6.1 shows the combination of the surface proteins that allow for the identification of HSC, MPC, CMP and GMPs. In addition, M-CFU can be identified by the surface markers c-Kitlo, CD13+, CD45RA+, CD33+, MHC Class II+, CD2+/−, CD7+/− and CD34− and monocytes can be identified by the surface markers CD11b+, CD14+, CD33+, CD2−, CD40−, CD80−, CD86−, CD45RA−, TLR2+, TLR4+, TLR5+ and TLR8+. There are a number of surface markers that can identify monocytes/macrophages in the periphery. In mice, CD11b, CD14 and CD115 are the key markers while in humans CD11b and CD14 are used to identify these cell populations. There are other surface markers that can be used to determine the activation state of the cells such as MHC Class II, CD80 and CD86. Apoptosis or programmed cell death is one process that can be analyzed by flow cytometry using the interaction of annexin V and the membrane phospholipid phosphatidylserine (PS) in the presence of calcium. PSs are not normally exposed on the surface of a cell unless the cell is in the process of apoptosis. It is one of the earliest indicators that the cell is undergoing apoptosis. In this assay annexin V conjugated to a fluorochrome, usually fluorescein isothiocyanate (FITC), is incubated with the cells for several min utes (37–39). Excess annexin V is washed away, and propidium iodide is added to discriminate between cells dying via apoptosis from those dying by necrosis (37–39). There are other flow cytometry based assays that can be used to assess if a cell is undergoing apoptosis including measuring a decrease in mitochondrial membrane potential. This is done using the fluorescent probe 3,3′-dihexyloxacarbocyanine (DiOC2(3)). DiOC2(3) is a cell permeant green fluorescent lipophilic dye that is selective for mitochondria at low levels. Cells are incubated with this dye for a short period of time at 37°C and assayed by flow cytometry. A decrease in green fluorescence is indicative of a decrease in mitochondria membrane potential and thus a cell undergoing apoptosis (38). Another important assay of macrophages that uses flow cytometry is one that looks for the generation of reactive oxygen species (ROS). This is usually performed using the nonpolar
Evaluating Macrophages in Immunotoxicity Testing
89
compound 2,7-dichlorodihydrofluorescein diacetate H2DCFDA. This compound diffuses easily into cells. Once in the cell the acetate group is removed by endogenous intracellular esterases. Thus, H2DCFDA is converted to H2DCF and becomes trapped in the cell. When cells loaded with the indicator dye produce hydrogen peroxide and other peroxidases, these compounds oxidize the H2DCF to DCF (2,7¢-dichlorofluorescein), which is highly fluorescent. The standard protocol is to incubate the cells with 1–30 mM of dye for 5–60 min at 37°C then the unincorpo rated dye is removed (38). The more ROS produced by the cell the higher the fluorescence in the cell. 4.10. Protein Phosphorylation
The process of phosphorylation and dephosphorylation is a common mechanism used by many signaling molecules to switch between the active and inactive states. The process of phosphory lation changes the quaternary configuration of the signaling molecule revealing the active site, and the molecule then has phos phokinase activity with specificity for the next molecule in the cascade. This triggers a signaling pathway. Each signaling molecule can then be, in turn, switched off by a specific phosphatase that removes the phosphate returning the molecule to its inactive state. The technique is frequently used to detect the effects of xenobiot ics on specific signaling molecules by assaying cell extracts for the phosphorylated form versus nonphosphorylated form. Basically the phosphorylated form is detected by developing western blots using antibody specific for the phosphorylated form. For example, primary antibody specific for total c-jun (non phosphorylated form) versus phospho c-jun ser 73 (phosphoryla tion of serine 73) will provide an indication of the effect of a xenobiotic on this signaling molecule (40). If the molecule has multiple phosphorylation sites, then specific antibody for these molecules when phosphorylated on a specific site can also be very informative about the upstream problems that a xenobiotic may have caused because different phosphorylation sites may be phos phorylated by different upstream phosphokinases (40).
4.11. Transcriptional Activation/RNA Quantification
Activation of cells often involves de novo protein production with the accompanying transcription of their genes. Thus, quantifying the action of a xenobiotic on transcription is an excellent place to begin to determine the mechanism of the effects of a xenobiotic. This is done by monitoring the mobilization of transcription fac tors to the nucleus, the binding of transcription factors to pro moter targets or the initiation or rate of transcription (mRNA production). Often more than one assay is performed to obtain a more complete picture of what is happening to the cell, e.g., translocation of a transcription factor to the nucleus, its binding to the promoter and the subsequent mRNA generation. This combination can indicate roughly where an alteration has occurred
90
Barnett and Brundage
in the signal transduction pathway. A brief description of some standard assays is provided below. Nuclear translocation can be ascertained visually (see Subheading 6.4.7) or by measuring protein levels in specific cellular subcompartments. For example, NF-AT a common tran scription factor for many cytokines is translocated to the nucleus after Ca2+-dependent activation. To monitor this phenomenon, cytoplasmic and nuclear cellular fractions can be prepared after appropriate activation using IFNg and LPS (41). The purity or lack of cross contamination of each of the fractions must be con firmed by measuring the organelle- or compartment-specific markers (e.g., Oct1 for nuclear contents and GAPDH for cyto plasm). Usually this is done by western blot. Similarly, the protein of interest, in this case NF-AT, can be measured using western blotting techniques. This technique is especially informative when there are “qualitative” differences between the two states, (i.e., the transcription factor is absent in the nucleus prior to activation and present in the nucleus after activation). Similar methods can be used to measure the other transcription factors when different forms of the transcription factor are present pre- and postactiva tion (e.g., we have used this approach to measure activation of NF-kB in stimulated IC-21 cells) (34). Use of a gene reporter assay is an excellent way to monitor the transcriptional activation. As an example, to monitor NF-kB acti vation, macrophages can be transiently transfected with a NF-kBdependent plasmid (PBIIX) using a transfection agent such as FuGene6 (Boehringer Manneheim, Indianapolis, IN) (34). This reporter plasmid contains two kB sites from the Ig-k enhancer upstream of a luciferase reporter gene (42). Cells were stimulated with LPS in the presence or absence of the xenobiotic for the appropriate times. Whole cell lysates were made using luciferase assay lysis buffer (Promega, Madison, WS), and luciferase activity was measured using luciferase assay reagent (Promega, Madison, WS) in a luminometer. Protein concentration of the lysates must be determined to normalize luciferase activity. The relative luciferase activity is a direct indicator of NF-kB activation (42). Two methods to monitor binding of a transcription factor to its promoter target are available. The first method is the electro phoretic mobility shift assay (EMSA) which monitors the shift in migration of the transcription factor in a gel with and without binding to the DNA. The use of this assay for macrophages is described in Frost et al (34) and Klinke et al. (41). To perform this assay, NF-kB consensus oligonucleotides (e.g., sc-2505, Santa Cruz Biotechnology, Santa Cruz, CA) are labeled with g-32P-ATP using a Ready-To-Go T4 polynucleotide kinase kit (Amersham Pharmacia Biotech, Piscataway, NJ). Nuclear extracts are incubated with the labeled probe for 30 min at room tem perature in binding buffer to allow formation of complexes.
Evaluating Macrophages in Immunotoxicity Testing
91
Additional complexes (called supershift complexes) are obtained by preincubating nuclear extracts in binding buffer with NF-kB p65 specific antibody (Rockland Immunochemicals, Gilbertsville, PA) or p50 specific antibody (Santa Cruz Biotechnology) before addition of the labeled probe for an additional 30 min at room temperature. Complexes are resolved from free probe in poly acrylamide gels, dried on Whatman 3MM paper and placed on PhosphorImage screens for analysis with a Molecular Dynamics PhosphorImager (Sunnyvale, CA) and/or X-Ray film (Eastman Kodak Company). Typically in this assay (as described above), at least three bands are shown on the gel, one for the free probe (unbound), a shifted band that is the probe bound to the DNA promoter and a supershifted band of the probe bound to the DNA promoter with the addition of the antibody (34). Another method to measure DNA binding of transcription factors has been developed called the Chemicon Nonradioactive Transcription Factor Assay (NTFA) (Millipore, Billerica, MA). This assay avoids the use of radioactive probes and in our labora tory it has been proven to be more reproducible than EMSA for measuring DNA-binding of NF-kB (41). Briefly, nuclear extracts are incubated with biotinylated NF-kB consensus DNA sequences in a transcription assay buffer containing sonicated salmon sperm DNA to allow the formation of protein/DNA complexes. Next, NF-kB protein in the nuclear extracts bound to biotinylated consensus sequences are immobilized to a streptavidin-coated plate and any unbound material washed away. NF-kB protein is detected with a specific rabbit anti-p65 antibody, followed by incubation with anti-rabbit HRP-conjugated antibody plus the HRB substrate, TMB/E (3,3′,5,5′-tetramethybenzidine). Absorbance of the samples is measured with a microplate spec trophotometer. The NTFA experimental results are reported as the ratio of the absorbance measured for a particular condition (i.e., time > 0) relative to the absorbance before treatment (i.e., time = 0). 4.12. Transcriptome Expression Analysis
There have been a number of reviews on the use of gene arrays to determine changes to cells after stimulation. One particularly pertinent study is the gene expression profiling during differen tiation from monocyte to macrophage by Lehtonen et al. (43). During this process, human monocytes were induced to differ entiate into macrophages using GM-CSF and IL-4 (43). Using an Affymetrix oligonucleotide microarray system which queries ~13,000 genes, they found that 340 and 190 genes were upregulated and down-regulated, respectively, during this differentiation process (43). The numbers changed over time after the stimulus to differentiate was added (43). At least some of these genes can be understood from a biological perspective (e.g., up-regulation of the transcription factor C/EBPb) (43).
92
Barnett and Brundage
The real challenge for these studies is how to assemble all of the data into a coherent story of how the choreography of activa tion occurs (i.e., what gene products control which down-stream genes, what inhibitor genes must be down regulated and when, etc). Although the study by Lehtonen et al. (43) was well designed and controlled, it left many questions unanswered. Part of the reason for this is that the bioinformatics software has lagged behind the technology and chemistry of collecting the raw data and the biology of understanding these relationships. Performing the actual RNA extractions as well as the other steps, needed to do these studies is aided by the very detailed protocols provided by the array chip manufacturer. In some cases, there must be concomitant instrumentation purchased to “read” the chips (e.g., the Affymetrix system). These instruments often include the software for the basic analysis of the data (i.e., which “genes” are up- or down-regulated and by how much). However, further analysis of the data usually is performed using either com mercial software specifically designed for this purpose or open source software, such as Bioconductor, that runs under the R-scripting computer language platform. Bioconductor is avail able free at www.bioconductor.org and includes several modules specifically designed for array analysis, including several specifi cally designed modules to read and analyze the data obtained using the Affymetrix system. Detailed instructions are included on the site on how to install and use this software. R can also be obtained free at http://cran.r-project.org. This technique is further hampered by the lack of agreement on how to best analyze the data. There is an attempt to “ware house” the huge amount of data collected so that it can be used (or mined) by other investigators. Many scientific journals require that array data by stored using the MIAME (minimum informa tion about a microarray experiment) standard. More detailed information on this can be found on the MGED Society web page (http://mged.org). Although not readily possible at the time of this writing, the prediction is that whole genome sequencing will soon be fast and inexpensive enough, that this approach will be used to either sup plement or replace the array chips. References 1. Weissman IL, Shizuru JA (2008) The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation toler ance and treat autoimmune diseases. Blood 112:3543–3553 2. Xing L, Schwarz EM, Boyce BF (2005) Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 208:19–29
3. Blair HC, Zaidi M (2006) Osteoclastic differen tiation and function regulated by old and new pathways. Rev Endocr Metab Disord 7:23–32 4. Blyler G, Landreth KS, Lillis T et al (1994) Selective myelotoxicity of propanil. Fundam Appl Toxicol 22:505–510 5. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958–969
Evaluating Macrophages in Immunotoxicity Testing 6. Edwards JP, Zhang X, Frauwirth KA, Mosser DM (2006) Biochemical and functional char acterization of three activated macrophage populations. J Leukoc Biol 80:1298–1307 7. Raes G (2002) FIZZ1 and Ym as tools to dis criminate between differentially activated macrophages. Dev Immunol 9:151–159 8. Siracusa MC, Reece JJ, Urban JF Jr, Scott AL (2008) Dynamics of lung macrophage activa tion in response to helminth infection. J Leukoc Biol 84:1422–1433 9. MacKinnon AC, Farnworth SL, Hodkinson PS et al (2008) Regulation of alternative mac rophage activation by galectin-3. J Immunol 180:2650–2658 10. Gangadharan B, Hoeve MA, Allen JE et al (2008) Murine gammaherpesvirus-induced fibrosis is associated with the development of alternatively activated macrophages. J Leukoc Biol 84:50–58 11. Anderson CF, Gerber JS, Mosser DM (2002) Modulating macrophage function with IgG immune complexes. J Endotoxin Res 8:477–481 12. Zhang X, Goncalves R, Mosser DM (2008) The isolation and characterization of murine macrophages. Curr Protoc Immunol Chapter 14:Unit 14.1.:14.1.1–14.1.14 13. Riedy MC, Stewart CC (2001) Characterization of human monocytes/macrophages. Curr Protoc Immunol Chapter 14:Unit 14.3.: 14.3.1–14.3.8 14. Wahl LM, Wahl SM, Smythies LE, Smith PD (2006) Isolation of human monocyte popula tions. Curr Protoc Immunol Chapter 7:Unit 7.6A.:7.6A.1–7.6A.10 15. Ustyugova IV, Frost LL, VanDyke K, Brundage KM, Schafer R, Barnett JB (2007) 3,4-Dichloropropionaniline suppresses nor mal macrophage function. Toxicol Sci 97:364–374 16. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PM (1999) Mechanism of the intracellular kill ing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 mac rophages activated by gamma interferon. Antimicrob Agents Chemother 43:1242–1251 17. Vieira P, O’Garra A (2007) Regula‘ten’ the gut. Nat Immunol 8:905–907 18. Schmid D, Munz C (2007) Innate and adap tive immunity through autophagy. Immunity 27:11–21 19. Swanson MS, Byrne BG, Dubuisson JF (2009) Kinetic analysis of autophagosome formation and turnover in primary mouse macrophages. Methods Enzymol 452:383–402 20. Geissmann F (2007) The origin of dendritic cells. Nat Immunol 8:558–560
93
21. Don Porto Carero A, Hoet PH, Nemery B, Schoeters G (2002) Increased HLA-DR expression after exposure of human mono cytic cells to air particulates. Clin Exp Allergy 32:296–300 22. Furst SM, Luedke D, Gandolfi AJ (1997) Kupffer cells from halothane-exposed guinea pigs carry trifluoroacetylated protein adducts. Toxicology 120:119–132 23. Harding CV (2001) Choosing and preparing antigen-presenting cells. Curr Protoc Immunol Chapter 16:Unit 16.1.:16.1.1–16.1.14 24. Harding CV (2001) Presenting exogenous antigen to T cells. Curr Protoc Immunol Chapter 16:Unit 16.2.:16.2.1–16.2.15 25. Dahlgren C, Karlsson A (1999) Respiratory burst in human neutrophils. J Immunol Methods 232:3–14 26. Lewis TL, Brundage KM, Brundage RA, Barnett JB (2008) 3,4-Dichloropropionanilide (DCPA) inhibits T cell activation by altering the intracellular calcium concentration follow ing store depletion. Toxicol Sci 103:97–107 27. Uchida N, Weissman IL (1992) Searching for hematopoietic stem cells: evidence that Thy1.1lo Lin- Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J Exp Med 175:175–184 28. Metcalf D (1971) Antigen-induced prolifera tion of bone marrow precusors of granulocytes and macrophages. Immunology 20:727–738 29. Blyler G, Landreth KS, Barnett JB (1994) Gender-specific effects of prenatal chlordane exposure on myeloid cell development. Fundam Appl Toxicol 23:188–193 30. Smith CL (2001) Basic confocal microscopy. Curr Protoc Cell Biol Chapter 4:Unit 4.5.: 4.5.1–4.5.12 31. Jedeszko C, Sameni M, Olive MB, Moin K, Sloane BF (2008) Visualizing protease activ ity in living cells: from two dimensions to four dimensions. Curr Protoc Cell Biol Chapter 4:Unit 4.20.:4.20.1–4.20.15 32. Henjakovic M, Sewald K, Switalla S et al (2008) Ex vivo testing of immune responses in precision-cut lung slices. Toxicol Appl Pharmacol 231:68–76 33. Neumann K, Eppler E, Filgueira L et al (2003) Listeria species escape from the phagosomes of interleukin-4-deactivated human mac rophages independent of listeriolysin. Immunol Cell Biol 81:431–439 34. Frost LW, Neeley YX, Schafer R, Gibson LF, Barnett JB (2001) Propanil inhibits tumor necrosis factor-alpha production by reducing nuclear levels of the transcription factor NF-kB in the macrophage cell line IC-21. Toxicol Appl Pharmacol 172:186–193
94
Barnett and Brundage
35. Hornbeck P (2001) Enzyme-linked immuno sorbent assays. Curr Protoc Immunol Chapter 2:Unit 2.1.:Unit 36. Hornbeck P, Winston SE, Fuller SA (2001) Enzyme-linked immunosorbent assays (ELISA). Curr Protoc Mol Biol Chapter 11:Unit11.2.: Unit11 37. Lee EO, Lee JR, Kim KH et al (2006) The methylene chloride fraction of Trichosanthis Fructus induces apoptosis in U937 cells through the mitochondrial pathway. Biol Pharm Bull 29:21–25 38. Pan MH, Liang YC, Lin-Shiau SY, Zhu NQ, Ho CT, Lin JK (2000) Induction of apoptosis by the oolong tea polyphenol theasinensin A through cytochrome c release and activation of caspase-9 and caspase-3 in human U937 cells. J Agric Food Chem 48:6337–6346 39. Nakadai A, Li Q, Kawada T (2006) Chlorpyrifos induces apoptosis in human monocyte cell line U937. Toxicology 224: 202–209 40. Brundage KM, Schafer R, Barnett JB (2003) Altered AP-1 (activating protein-1) activity
41.
42. 43.
44. 45.
and c-jun activation in T cells exposed to the amide class herbicide 3,4-dichloro propionanilide (DCPA). Toxicol Sci 79:98–105 Klinke DJI, Ustyugova IV, Brundage KM, Barnett JB (2008) Modulating temporal control of NF-kappaB activation: implications for therapeutic and assay selection. Biophys J 94:4249–4259 Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956–959 Lehtonen A, Ahlfors H, Veckman V, Miettinen M, Lahesmaa R, Julkunen I (2007) Gene expression profiling during differentiation of human monocytes to macrophages or dendritic cells. J Leukoc Biol 82:710–720 Iwaskai H, Akashi K (2007) Myeloid lineage commitment from the hematopoietic stem cell. Immunity 26:726–740 Bryder D, Rossi DJ Weissman IL (2006) Hematopoietic stem cells: the pradigmatic tissue-specific stem cell. Am J Pathol 169: 338–346
Part III Immunotoxicity and Host Resistance Models
Chapter 7 Host Resistance Assays Including Bacterial Challenge Models Florence G. Burleson and Gary R. Burleson Abstract Immunotoxicity testing is used to provide safety assessment with the major objective being the avoidance of unacceptable risk of infectious or neoplastic disease. To this end, immunotoxicity testing has employed a variety of host resistance challenge models for measuring both host resistance to disease as well as immune function. This chapter provides an overview of those viral, bacterial, fungal, and parasitic host resistance models that are most commonly used in safety assessment. It also describes in more detail the bacterial challenge models that are employed to address specific host resistance and immune function issues. Key words: Host resistance (HR) assays, Bacterial models, Immune challenge, Marginal zone B lymphocytes, Streptococcus, Listeria, Pseudomonas, Immune biomarkers, T-Independent antibody response, T-dependent antibody response
1. Introduction The purpose of immunotoxicity testing is to obtain data that are meaningful for safety assessment. For immunosuppression the major objective is to determine the significance with respect to increased susceptibility to infectious or neoplastic disease. Host resistance (HR) assays provide the only sure method of examining the influence of test articles on the functional integrity of the immune system and its ability to eliminate pathogenic microorganisms or tumor cells. HR assays are used to evaluate the effect of a test article on clearance of an infectious microorganism in order to assess functional immunocompetence. Immunotoxicity caused by a test compound may result in an impaired clearance of an infectious agent, increased susceptibility to opportunistic
R.R. Dietert (ed.), Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, vol. 598 DOI 10.1007/978-1-60761-401-2_7, © Humana Press, a part of Springer Science + Business Media, LLC 2010
97
98
Burleson and Burleson
infections, prevention or ineffective immunization, exacerbation of latent viral infections, or unintended immunostimulation. HR assays provide a means to directly assess the functional reserve of the immune system and the opportunity to measure immune biomarkers (all categories of immunoglobulins as well as inflammatory mediators) that have implications beyond infectious diseases and cancer. HR assays may be classified into either comprehensive HR assays or targeted HR assays. Clearance of an infectious microorganism allows an assessment of immunocompetence and serves as a biomarker of net immunological health. Immunological clearance of the infectious challenge agent is a more sensitive and meaningful measure of immunological function (1–3) than mortality. The number of infectious particles per organ or per gram of organ is quantified. Challenging the immune system with an extremely virulent or with an extremely high titer of infectious agent may overwhelm the immune system, with death occurring before development of the cascade of immunological responses required for clearance. Challenge with a highly virulent agent or with a high titer of infectious agent may reflect a model of sepsis or result in a “cytokine storm.” Titer does not necessarily correlate with mortality; that is, similar titers of virus were reported in the lungs of mice infected with either the mouse-adapted lethal influenza A/ Hong Kong/8/68 virus or the mouse-adapted nonlethal influenza A/Port Chalmers/1/73 virus (3). Viral titers also did not correlate with mortality in studies evaluating the immunotoxicity of TCDD (4). Screening assays to detect immunosuppression are surrogates for functional assays that are surrogates for host resistance assays. Luster and colleagues initiated a series of studies that form the basis of risk assessment in immunotoxicology evaluations. Luster et al. (5–9) evaluated immunological assays that predicted immunotoxicity and reported concordance values using host resistance as the comparator, since host resistance assays are considered to be the ultimate predictor of adverse effects (10). HR assays are the gold standard for immunotoxicological evaluation and there are numerous models available. The major function of the immune system is protection from infectious or neoplastic disease and most immunotoxicologists regard host resistance assays to be the most relevant for: (1) validating the usefulness of other detection methods and (2) extrapolating the potential of a substance, drug, or chemical to alter host susceptibility in the human population (10). In summary, HR assays provide information to determine if a test agent results in an adverse effect (decreased clearance) as well as information concerning the mechanism(s) of the adverse effect (cytokines, innate immune function, or adaptive immunity).
Host Resistance Assays Including Bacterial Challenge Models
99
2. Host Resistance Assays 2.1. Comprehensive Host Resistance Assay 2.1.1. Influenza Virus Host Resistance Assay
The influenza model in mice or rats is used to evaluate the overall health of the immune system, i.e., how the numerous components (Table 7.1) of the functional immune system work together to clear an infection while targeted host resistance assays are available to evaluate specific immunotoxicity questions (Table 7.2). The influenza host resistance assay is discussed in Chapter 8. Clearance of influenza virus requires an intact and functional immune system that incorporates a cascade of immune responses. HR assays serve as biomarkers of net immunological health or immunological well-being. Viral clearance requires all aspects of the immune system to work together and is the ultimate measure of the health of the immune system. Mechanistic immune functions may be included while measuring viral clearance and include: cytokines, macrophage activity, natural killer (NK) cell activity, cytotoxic T lymphocyte (CTL) activity, and influenza-specific IgM and IgG. Measurement of these immunological functions provides an evaluation of innate immunity (macrophage or NK activity), an evaluation of cell-mediated immunity (CMI) (CTL activity), and an evaluation of humoral-mediated immunity
Table 7.1 Comprehensive host resistance model to test the overall health of the immune system Influenza virus host resistance model: Viral clearance – Primary endpoint Mechanistic endpoints: • Cytokines • Interferon activity • Macrophage activity • NK cell activity • CTL activity • Influenza-specific IgM, IgG (IgG1 and IgG2a) – TDAR • Immunophenotyping • Histopathology Mechanistic endpoints may or may not be included
100
Burleson and Burleson
Table 7.2 Targeted host resistance models for evaluation of immunotoxicity Targeted host resistance models: 1. Evaluation of innate immunity: • Streptococcus pneumoniae pulmonary host resistance model 2. Evaluation of therapeutics affecting neutrophils and/or macrophages: • S. pneumoniae pulmonary host resistance model 3. Evaluation of anti-inflammatory therapeutics: • S. pneumoniae pulmonary host resistance model 4. Evaluation of therapeutics targeting TNFa: • S. pneumoniae pulmonary host resistance model 5. Marginal zone B (MZB) cell evaluation: • Systemic S. pneumoniae host resistance model to evaluate MZB cells 6. Neutrophil defect/Gram negative bacterial model: • Pseudomonas aeruginosa pulmonary host resistance model 7. Intracellular bacterial model for evaluation of liver and splenic macrophages and neutrophils: • Listeria monocytogenes systemic host resistance model 8. Fungal host resistance model: • Candida albicans host resistance model 9. Latent viral reactivation host resistance model: • Murine cytomegalovirus (MCMV) host resistance model 10. Tumor host resistance model: • B16F10 Tumor Model • PYB6 Tumor Model 11. Parasite host resistance model: • Trichinella spiralis • Malaria
(HMI) (influenza-specific IgM or IgG). Measurement of influenzaspecific IgM or IgG also provides a measurement of T-dependent antibody response (TDAR) since influenza is a T-dependent antigen (1, 4, 11–14).
Host Resistance Assays Including Bacterial Challenge Models
101
2.2. Targeted Host Resistance Assays
While the influenza host resistance assay is used to assess the overall health of the immune system, targeted host resistance models are available to answer specific questions concerning the immune system. Targeted host resistance assays may be used if a specific defect has been shown to occur or is of concern. Targeted HR assays will determine whether the decreased immune function is adverse (i.e., does the percent decrease in immunological function translate to a decreased clearance of the infectious agent). Targeted HR models are available to evaluate specific immunotoxicity questions (Table 7.2). These HR models answer specific questions concerning status of the immune system.
2.2.1. Latent Virus Reactivation Model
The murine cytomegalovirus (MCMV) latent viral model is a model to assess reactivation of latent viral disease as a result of immunosuppression. There are many similarities between the viruses responsible for latent/reactivated viral disease. CMV (cytomegalovirus), EBV (Epstein-Barr Virus), and HSV (Herpes Simplex Virus) belong to the Herpesviridae virus family, while BK virus and JC virus belong to the Papovaviridae virus family. All these viruses have double stranded DNA (the human polyoma viruses are circular), are ubiquitous in the human population, and cause mild primary infections followed by a latent viral infection. Additionally, immunosuppression, especially suppressed CMI, results in reactivation of latent viral infection (15). The MCMV reactivation model may be used to evaluate a pharmaceutical agent to determine if suppression of CMI or HMI results in reactivation of latent virus. Reactivation of latent virus may result in a fatal disease such as progressive multifocal leukoencephalopathy (PML).
2.2.2. Fungal HR Model
Candida albicans is a well-characterized fungal host resistance model (16, Burleson personal communication). Candida is administered intravenously and mortality or clearance monitored. Candida-specific IgG and cytokines may also be quantified.
2.2.3. Parasite HR Models
Parasite HR models have also been used for immunotoxicity testing. These include malaria (17) and Trichinella spiralis (18). Parasite models are discussed in Chapter 9.
2.2.4. Tumor HR Models
Tumor HR models have been used for immunotoxicity testing using the syngeneic tumor cell models B16F10 and PYB6 (19). Examples of tumor challenge protocols are presented in Chapter 10.
2.3. Bacterial HR Assays
There are several targeted host resistance models that may be used to answer specific questions concerning immune system status.
102
Burleson and Burleson
2.3.1. Evaluation of Innate Immunity
The Streptococcus pneumoniae pulmonary HR model has been used in Balb/c and C57BL/6 mice and Fischer (CDF), Lewis, and Sprague Dawley (CD) rats. Animals are infected intranasally and bacterial clearance measured. Bacterial clearance is quantified before the specific, acquired adaptive immune system is operative, and bacterial clearance is evaluated by determining the number of colony forming units (CFU) per gram of lung tissue. Dexamethasone or cyclophosphamide is used as a positive immunomodulatory control that has an immunosuppressive effect on innate immunity and decreases bacterial clearance. Cytokines may also be measured in the streptococcal model. The S. pneumoniae host resistance model in mice has been used in numerous immunotoxicity evaluations and was reported as one of a battery of three host resistance assays to evaluate a small molecule therapeutic targeted for splenic tyrosine kinase (Syk) (20). Likewise, the Streptococcal host resistance model in rat has been used in numerous immunotoxicity evaluations (21). One advantageous feature of the model is that cytokines may be measured in the lung as well as in the serum. Bacterial titers and bacterial clearance are quantified as the number of colony forming units (CFU) per organ or per gram of tissue. Additionally, macrophage and/or neutrophil function assays can be measured as a mechanistic probe if an effect on bacterial clearance is observed. However, the most conclusive single endpoint is bacterial clearance.
2.3.2. Evaluation of Therapeutics Affecting Neutrophils and/or Macrophages
Rodent models for bacterial pneumonia can be used to evaluate immunotoxicity that may predispose to bacterial pneumonia. Macrophages were demonstrated to be important in the clearance of streptococci from the lungs of mice (22) and rats (23). Further studies by Gilmour and Selgrade (23) demonstrated the importance of neutrophils in pulmonary streptococcal disease in rats by pretreatment with an antibody to neutrophils. S. pneumoniae has been used in mice and rats as a pulmonary infection following intranasal infection (22, 23; Burleson and Burleson personal communication) and has been used to evaluate whether pharmaceutical agents have either neutrophil and/or macrophage immunotoxicity.
2.3.3. Evaluation of Inflammatory Therapeutics
The S. pneumoniae host resistance model has been well characterized in mice and rats. Animals are infected intranasally and bacterial clearance measured. Bacterial clearance is evaluated by determining the number of CFU per gram of lung tissue or per lung. Dexamethasone is used as a positive immunomodulatory control as it has a suppressive effect on innate immunity and delays bacterial clearance. Komocsar et al. (24) used the S. pneumoniae pulmonary host resistance model in Lewis rats to assess the effects of anti-inflammatory agents on innate immunity. The
Host Resistance Assays Including Bacterial Challenge Models
103
model was able to predict suppression of the innate immune response to S. pneumoniae after administration of anti-inflammatory test articles. The ability to rank order the severity of innate immune suppression with multiple test articles in the same study enhances the utility of this model for screening potential drug candidates. 2.3.4. Evaluation of Therapeutics Targeting TNF-a
The S. pneumoniae host resistance model is also valuable for evaluating the importance of macrophage cytokines on bacterial host resistance. Human biological therapeutics targeting inhibition of TNF-a have been used to treat inflammatory autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Decreased TNF-a as a result of treatment with monoclonal antibodies (mAb) to TNF-a has an effect on several biomarkers of infection (25–28). These studies have reported that treatment of mice with a mAb to TNF-a results in altered levels of TNF-a in the lungs and serum, decreased neutrophils and increased numbers of bacteria (impaired bacterial clearance) with decreased survival in mice infected intranasally with S. pneumoniae. The Streptococcal pulmonary host resistance model is thus an important means to assess the functional immunological capacity of macrophages and neutrophils as well as macrophage cytokines. Therapeutic agents that target TNF-a may be tested using the S. pneumoniae pulmonary host resistance model, and this host resistance assay may be used to choose a lead compound among compounds with equivalent therapeutic efficacy based on immunosuppression. Monoclonal antibody to TNF-a has a dramatic effect on bacterial clearance in this model. Pseudomonas aeruginosa can also be used as a pulmonary bacterial host resistance assay to evaluate the immunotoxicity of therapeutics when immunotoxicity is suspected in neutrophils, macrophages, and/ or TNF-a (29; Burleson and Burleson personal communication). TNF-a also plays an essential role in preventing reactivation of latent tuberculosis (30).
2.3.5. Marginal Zone B Cell HR Evaluation
Bacteria encapsulated with a polysaccharide capsule such as S. pneumoniae or Haemophilus influenzae are blood-borne pathogens that present a different challenge to the immune system. Capsular polysaccharide antigens are thymus-independent type 2 antigens (TI-2) (31) and effective immune responses are dependent on the presence of a functional marginal zone (32–34). Capsular antigens stimulate a T-independent antibody response (TIAR). The marginal zone B (MZB) cell model in mice or rats measures bacterial clearance, hematology, cytokine production, and antibody production in a kinetic fashion over a 14-day period after intravenous infection to create a blood-borne infection. MZB cells in both humans and rodents are considered a critical host defense mechanism directed against encapsulated blood-borne pathogenic
104
Burleson and Burleson
microorganisms. Immunotoxicity directed against MZB cells not only decreases protection against blood-borne pathogens but also results in a depletion of immunological memory. In summary, T-independent antibody responses (TIAR) are decreased or ablated as a result of MZB cell immunotoxicity (35). Histopathology will detect defects in the splenic marginal zone and special immunophenotyping markers can be included to detect alteration in the number of MZB cells. Should an effect on MZB cells be observed, the pharmaceutical agent may be evaluated in the S. pneumoniae systemic MZB host resistance model for encapsulated bacteria to determine if the effect is adverse. The S. pneumoniae marginal zone B cell model has been characterized in mice and Sprague Dawley rats with a systemic blood-borne infection by intravenous inoculation. Bacteria are quantified by determining the number of CFU in the spleen, liver, lungs, and blood over a 2 week period. Cytokines, hematology, immunophenotyping, and anti-streptococcal antibody (TIAR) are also quantified in this model (Burleson and Burleson personal communication). 2.3.6. Neutrophil/Gram Negative Bacterial HR Model
P. aeruginosa is a Gram negative bacillus that is a human pathogen and primarily causes diseases of the urinary tract, burn patients, septicemia, abscesses, corneal infections, meningitis, bronchopneumonia, and subacute bacterial endocarditis. Treatment often fails and the mortality rate in Pseudomonas septicemia has been reported to be greater than 80%. P. aeruginosa is used as a pulmonary bacterial host resistance model to evaluate the immunotoxicity of therapeutics when an immunotoxic effect is suspected in neutrophils, macrophages, and/or TNF-a (29). TNF-a also is important in bacterial clearance of S. pneumoniae and plays an essential role in preventing reactivation of persistent tuberculosis (30).
2.3.7. Intracellular Bacterial HR Model for Evaluation of Liver and Splenic Macrophages and Neutrophils
The Listeria monocytogenes host resistance model is controlled primarily in the liver and spleen. The L. monocytogenes systemic infection assay is used primarily to evaluate adverse effects on neutrophils and Kupfer cells of the liver and splenic macrophages and neutrophils. NK cells and T lymphocytes also play a role in bacterial clearance. The L. monocytogenes host resistance model has been used to evaluate monoclonal antibodies (mAbs) directed against CD11b to determine whether inhibition of this adhesion molecule would enhance disease susceptibility to listeria and predict whether this anti-inflammatory therapeutic approach would enhance susceptibility to opportunistic infections in humans. CD11b/CD18 (Mac-1) is a leukocyte integrin that plays a critical role in neutrophil adhesion and the initiation of acute inflammatory processes and is therefore a therapeutic anti-inflammatory target. CD11b (alpha M integrin) complexes with CD18 (beta 2 integrin) to form complement receptor type 3 (CR3) heterodimer. Treatment with
Host Resistance Assays Including Bacterial Challenge Models
105
either monoclonal antibody NIMP-R10 or 5C6, both directed against CD11b resulted in decreased clearance of listeria in the liver and spleen with increased mortality (36), Burleson and Burleson personal communication). Neutrophils and monocytes were decreased and mice were unable to control the infectious intracellular bacterial disease. Treatment of mice with a surrogate biological mAb designated NIMP-R10 directed against the CD11b polypeptide of the CD18/CD11b heterodimer exacerbated listeriosis by preventing myelomonocytic cells from focusing at sites of infected hepatocytes in the liver. Under these conditions, an otherwise sublethal listeria inoculum grew unrestricted within hepatocytes and caused death in 3 days (36). The results obtained with NIMP-R10 are similar to those reported with a different anti-CD11b mAb (5C6) (37, 38).
3. Summary The influenza comprehensive HR assay is able to evaluate the overall health of the immune system as well as to evaluate mechanistic immunological function of the innate, CMI, and HMI of the immune system. HR assays measure the functional integrity of the immune system and are able to evaluate functional immunological reserve. The immunotoxicity safety assessment is difficult to assess when the biological significance of “X” percent change in a particular immune function is not known. Functional immune assessment must evaluate all facets of the total immune system and include innate immunity, CMI, and HMI. Targeted host resistance assays are available to evaluate specific immunotoxicity concerns including: therapeutics affecting neutrophils and/or macrophages, anti-inflammatory therapeutics, as well as therapeutics targeting TNF-a in the treatment of autoimmune disorders such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Targeted host resistance assays also include evaluations of therapeutics affecting splenic marginal zone B (MZB) cells. Immunotoxicity of MZB cells may result in an increase in the number of infections with encapsulated bacteria, blood–borne infections, and bacterial pneumonias. A number of bacterial infections is possible if the antibody response to T-independent antigens is depleted or suppressed. The L. monocytogenes targeted host resistance assay can be used to evaluate systemic immunotoxicity involving Kupffer cells and neutrophils of the liver and splenic neutrophils and macrophages. Therapeutics that suppress CMI or HMI should be further evaluated with a latent virus reactivation model. Suppression of CMI can result in recrudescence of latent viral disease with resultant serious herpes virus disease, cytomegalovirus disease or
106
Burleson and Burleson
reactivation of JC virus causing PML. Suppression of antibody production may result in a lower threshold with an increased susceptibility to the reactivated virus disease if concomitant suppression of CMI has resulted in reactivation of latent virus. Suppression of the humoral arm of the immune system may not only affect susceptibility to opportunistic infections, but may also result in ineffective immunizations, which can also be tested in HR models. There are several strategies to evaluate the potential immunotoxicity of therapeutic compounds. HR assays allow the evaluation of the overall health of the immune system, allow specific questions to be evaluated by the use of targeted HR assays, allow the use of sufficient numbers of animals to assure the statistical power to detect immunotoxicity, and allow the inclusion of positive controls necessary to confirm negative findings. It is crucial to evaluate all arms of the functional immune response in order to derive data that are useful in performing a meaningful immunotoxicity safety assessment.
Acknowledgment The authors thank Janice Dietert for her editorial suggestions. References 1. Burleson GR (1995) Influenza virus host resistance model for assessment of immunotoxicity, immunostimulation, and antiviral compounds, Chapter 14. In: Burleson GR, Dean JH, Munson AE (eds) Methods in immunotoxicology, vol 2. Wiley, New York, pp 181–202 2. Selgrade MJK, Daniels MJ (1995) Host resistance models: murine cytomegalovirus, Chapter 15. In: Burleson GR, Dean JH, Munson AE (eds) Methods in immunotoxicology, vol 2. Wiley, New York, pp 203–219 3. Lebrec H, Burleson GR (1994) Influenza virus host resistance models in mice and rats: utilization for immune function assessment and immunotoxicology. Toxicology 91:179–188 4. Burleson GR (1996) Pulmonary immunocompetence and pulmonary immunotoxicology, Chapter 7. In: Smialowicz R, Holsapple MP (eds) Experimental immunotoxicology. CRC, Boca Raton, FL, pp 113–135 5. Luster MI, Munson AE, Thomas PT, Holsapple MP, Fenters JD, White KL Jr, Lauer LD, Germolec DR, Rosenthal GJ, Dean JH (1988) Development of a testing battery
6.
7.
8.
9.
to assess chemical-induced immunotoxicity: National Toxicology Program’s guidelines for immunotoxicity evaluation in mice. Fundam Appl Toxicol 10(1):2–19 Luster MI, Pait DG, Portier C, Rosenthal GJ, Germolec DR, Comment CE, Munson AE, White K, Pollock P (1992) Qualitative and quantitative experimental models to aid in risk assessment for immunotoxicology. Toxicol Lett 64–65:71–78 Luster MI, Portier C, Pait DG, White KL, Gennings C, Munson AE, Rosenthal GJ (1992) Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fundam Appl Toxicol 18(2):200–210 Luster MI, Portier C, Pait DG, Rosenthal GJ, Germolec DR, Corsini E, Blalock BL, Pollock P, Kouchi Y, Craig W, White KL, Munson AE, Comment CE (1993) Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fundam Appl Toxicol 21(1):71–82 Luster MI, Portier C, Pait DG, Rosenthal GJ, Germolec DR (1995) Immunotoxicology and risk assessment, Chapter 5. In: Burleson GR,
Host Resistance Assays Including Bacterial Challenge Models
10.
11. 12. 13. 14.
15. 16.
17.
18.
19.
20.
21. 22.
Dean JH, Munson AE (eds) Methods in immunotoxicology, vol 1. Wiley, New York, pp 51–68 Germolec DR (2004) Sensitivity and predictivity in immunotoxicity testing: immune endpoints and disease resistance. Toxicol Lett 149:109–114 Burleson GR (2000) Models of respiratory immunotoxicology and host resistance. Immunopharmacology 48:315–318 Burleson GR, Burleson FG (2007) Testing human biologicals in animal host resistance models. J Immunotoxicol 5:1–9 Burleson GR, Burleson FG (2007) Influenza virus host resistance model. Methods 41: 31–37 Burleson GR, Burleson FG (2008) In: Herzyk DJ, Bussiere JL (eds), Immunotoxicology strategies for pharmaceutical safety assessment. Wiley, Hoboken, NJ, pp 163–177, Chapter 5.1 Burleson GR (2008) MCMV host resistance model to detect latent viral reactivation immunotoxicity. Int J Toxicol 27(6):417 Herzyk DJ, Gore ER, Polsky R, Nadwodny KL, Maier CC, Liu S, Hart TK, Harmsen AG, Bugelski PJ (2001) Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice. Infect Immun 69(2): 1032–1043 Luebke RW (1995) Assessment of host resistance to infection with rodent malaria. In: Burleson GR, Dean JH, Munson AE (eds). Wiley, New York, pp 221–242, vol 2, Chapter 16 Van Loveren H, Luebke RW, Vos JG (1995) Assessment of immunotoxicity with the parasitic infection model Trichinella spiralis. In: Burleson GR, Dean JH, Munson AE (eds), Wiley, New York, pp 243–271, vol 2, Chapter 17 McCay JA (1995) Syngeneic tumor cell models: B16F10 and PYB6. In: Burleson GR, Dean JH, Munson, AE (eds), Methods in immunotoxicology, vol 2. Wiley, New York, pp 143–157, Chapter 11 Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, Clemens GR (2007) Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol 221:268–277 Steele TD, Geng W, Burleson F, Burleson G (2005) Enfuvirtide does not impair host resistance to infection in rats. Toxicologist 84:178 Gilmour MI, Park P, Selgrade MK (1993) Ozone-enhanced pulmonary infection with Streptococcus zooepidemicus in mice. Am Rev Respir Dis 147:753–760
107
23. Gilmour MI, Selgrade MK (1993) A comparison of the pulmonary defenses against streptococcal infection in rats and mice following O3 exposure: differences in disease susceptibility and neutrophil recruitment. Toxicol Appl Pharmacol 123:211–218 24. Komocsar W, Burleson G, Wierda D (2007) The optimization of an acute rat model to evaluate effects on innate immunity induced by anti-inflammatory agents. Toxicologist 96:357 25. Van der Poll T, Keogh CV, Buurman WA, Lowry SF (1997) Passive immunization against tumor necrosis factor-a impairs host defense during pneumococcal pneumonia in mice. Am J Crit Care Med 155:603–608 26. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K (1997) Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 65:257–260 27. Benton KA, VanCott JL, Briles DE (1998) Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae. Infect Immun 66(2):839–842 28. O’Brien DP, Briles DE, Szalai AJ, Tu A-H, Sanz I, Nahm MH (1999) Tumor necrosis factor alpha I is important for survival from Streptococcus pneumoniae infections. Infect Immun 67(2):595–601 29. G